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Despite significant advances in cancer treatment, clinical response remains 
suboptimal and there is a continued requirement for improved 
chemotherapeutics. The attrition rate for new therapies is high, due principally 
to lack of in vivo efficacy and poor pharmacodynamics. Consequently better 
systems are required to determine in vivo preclinical efficiency and drug-target 
interactions. Engineering of cancer cells to express fluorescent or 
bioluminescent proteins, either endogenously or under the control of specific 
gene promoters, and their detection by noninvasive optical imaging has the 
potential to improve preclinical drug development.  
 
In this study, a panel of colorectal cancer cell lines were engineered to express 
fluorescent and luminescent proteins either constitutively or under control of 
gene-promoters for the DNA damage response gene p53 or the cell cycle 
regulator p21, both important pharmacodynamic sensors. These cell lines were 
characterised for their potential as in vivo models of primary and metastatic 
tumour therapy response, several showing significant potential. In addition to 
the development of these models, this study also addressed the 
pharmacokinetics of different luciferase substrates and identified optimal 
temporal and dose characteristics for each. Furthermore, a new application for 
bioluminescent imaging was developed and validated for use in preclinical 
evaluation of vascular disrupting agents, a new generation of cancer 
therapeutic.  
 
This study demonstrates that despite the dynamic and variable nature of 
fluorescent and bioluminescent imaging, reproducible results can be obtained if 
appropriate precautions are taken. The models developed herein will expedite 
cancer drug development whilst reducing and refining the use of animals in 
research. 
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1 Introduction 
1.1 Cancer 
Cancer is a disease that is caused by interactions between genetic and 
environmental factors. The incidence of cancer also rises sharply with 
increasing age. In the UK almost 300,000 individuals are diagnosed with cancer 
every year (excluding non-melanoma skin cancer), and despite a fall in cancer 
death rates over the past decade, 1 in 4 people still die from the disease in the 
UK every year (CancerResearchUK, 2009). The most commonly observed 
cancers are breast (13.5%), colorectal (12.9%) and lung (21.1%). With regard to 
mortality, lung cancer is the leading cause of death (19.7% of total), followed by 
colorectal (12.2%), breast (7.7%) and stomach (7%) (Ferlay et al., 2007). There 
are a lot of lifestyle factors such as smoking, a diet high in saturated fats/low in 
fibre and obesity, which are known to increase the risk of developing certain 
types of cancer. Other factors include genetic predisposition, exposure to 
ionising radiation, chemical exposure and certain viruses (such as the human 
papilloma virus) (CRUK, 2008).   
 
1.2 The Hallmarks of Cancer 
Cancer encompasses a range of diseases characterised by the loss of 
regulated cell growth leading to the growth of a cell mass that has the potential 
to invade surrounding tissues and migrate to new sites via a process known as 
metastasis. Multiple successive genetic alterations caused by various external 
or internal processes gradually lead to loss of the cells‟ ability to maintain 
normal cellular functions and regular growth patterns; a process termed 
2 
 
carcinogenesis. Hanahan and Weinberg suggested cancers require a 
manifestation of 6 essential alterations, known as the “Hallmarks of cancer”: self 
sufficiency in growth signals, insensitivity to anti-growth signals, evasion of 
apoptosis, limitless replicative potential, sustained angiogenesis and the ability 
to invade and metastasise (Hanahan and Weinberg, 2000). A decade on and 
there are two further hallmarks; the de-regulation of cellular energetics and the 
ability of cancer cells to avoid destruction by the immune system, although at 
the moment it is unclear whether these hallmarks fall within the original set 
(Hanahan and Weinberg, 2011). There are also two new enabling 
characteristics; „genome instability and mutation‟ and „tumour-promoting 
inflammation‟. The former characteristic is essential for the tumour to acquire 
the Hallmarks as they depend on a succession of alterations in the cancer 
genome. The latter characteristic regards the manipulation of innate immune 
cells that supply bioactive molecules to the tumour microenvironment, including 
growth factors, survival factors, proangiogenic factors, extracellular matrix 
(ECM)-modifying enzymes and inductive signals that lead to the activation of 
the epithelial-mesenchymal transition (EMT) (Hanahan and Weinberg, 2011).  
 
1.3 The tumour microenvironment 
The tumour microenvironment is a highly complex mixture of tumour cells and 
host stromal cells (Hanahan and Weinberg, 2011; Visvader and Lindeman, 
2008) and understanding of tumour biology must encompass the role of all the 
cell types involved. Figure 1.1 indicates the heterogeneous nature of a tumour, 
with its different cell types, growth signals and host cells.  
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Figure 1.1 – The complex tumour microenvironment. Cancer cells are surrounded by a 
microenvironment comprising endothelial cells of the blood and lymphatics, fibroblasts, bone 
marrow-derived cells (BMDC), which include macrophages, myeloid-derived suppressor cells 
(MDSC), TIE-2 expressing monocytes (TEM) and mesenchymal stem cells (MSCs). The whole 
tumour microenvironment must be understood in order to understand tumour progression and 
metastasis. Figure adapted from (Joyce and Pollard, 2009).  
 
 
The intricate relationships between tumour and stromal cells are important in 
cancer progression, leading to the development of a variety of the Hallmarks; 
the progression of angiogenesis for example. Unfortunately this heterogeneous 
mixture is poorly understood, due in part to a lack of suitable models (Yang et 
al., 2007). The complexity of the microenvironment also affects the efficacy of 
drugs as stroma/tumour interactions and heterogeneity of the tumour cells 
themselves lead to different mutagenesis profiles and metastatic potential of the 
tumour as a whole.  
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Mouse models have shown that bone marrow-derived cells, (including 
macrophages, mesenchymal stem cells and mast cells) also play a crucial role 
in promoting tumour angiogenesis, invasion, intravasation and metastasis 
(Condeelis and Pollard, 2006; Schmid and Varner, 2010). Similarly, 
inflammation within the tumour and the infiltration of immune cells (both innate 
and adaptive), originally thought to be a defence mechanism by the host, is now 
thought to be a requirement in the progression and enhancement of 
tumourigenesis and to help neoplastic lesions to acquire hallmark 
characteristics (Hanahan and Weinberg, 2011).  
 
1.4 Tumourigenesis  
Each step of tumour development progresses due to instability and mutations 
within the cancer cells‟ genome, one of the recently described “enabling 
characteristics” (Hanahan and Weinberg, 2011), and signalling between the 
tumour cells and the host stromal cells. Within the boundaries of the original 
Hallmarks this leads to self – (autocrine) regulation of cancer cells, deregulated 
receptor signalling, growth factor independence, disruption of negative feedback 
mechanisms, evasion of growth suppressors such as the p53 and Rb proteins, 
corruption of the TGF-β pathway, resistance to cell death via autophagic and 
necrotic pathways, promotion of telomere protection mechanisms, the induction 
of angiogenesis via inducers such as vascular endothelial growth factor-A 
(VEGF-A) and the fibroblast growth factor (FGF) family (Carmeliet and Jain, 
2000; Hanahan and Weinberg, 2011).  
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1.4.1 The epithelial-mesenchymal transition and metastasis 
Neoplastic cells have inherent genetic and epigenetic instability, generating 
multiple cell populations within one tumour and leading to a loss in 
responsiveness to normal regulatory signals. Additionally cancer cells receive 
biological signals from the surrounding stromal cells, including those that are 
associated with the EMT (Polyak and Weinberg, 2009). The EMT is a complex 
pathway during which epithelial cells being to lose their differentiated 
characteristics and acquire mesenchymal features, which include motility, 
invasiveness, and resistance to apoptosis (Polyak and Weinberg, 2009). 
Currently, it appears that EMT-inducing transcription factors can coordinate the 
majority of steps (see figure 1.2) in the invasion/metastatic cascade (Hanahan 
and Weinberg, 2011). 
 
The process of metastasis is a series of rate-limiting steps that must occur in 
order for cancer to disseminate to sites other than the primary tumour. 
Metastasis is the most important cause of cancer mortality and if the cancer has 
spread the prognosis for the patient worsens dramatically compared to if the 
cancer is diagnosed in its primary stage. Unfortunately it is often the case that 
metastasis has already begun to occur by the time the primary cancer has been 
diagnosed. Figure 1.2 shows a simple overview of the metastatic cascade. 
 
Tumour pathogenesis and metastasis follows a set pattern of steps, as follows: 
(A) the primary tumour begins to form an avascular mass acquiring its nutrients 
from the host tissue; (B) the tumour invades through the local basement 
membrane; (C) the tumour, through angiogenesis, develops its own blood 
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supply; (D) cells that detach from the primary tumour can enter the circulation 
through intravasation, possibly due to the conversion of phenotype from 
epithelial to mesenchymal; (E) surviving cells have the potential to adhere to 
endothelial cells in the blood vessels; (F) if the microenvironment is suitable for 
tumour development, the tumour cells extravasate through the vessel wall; (G) 
cells migrate to nearby sites; (H) micrometastases may form, which can remain 
dormant until the tumour stimulates angiogenesis; (I) following initiation of 
angiogenic signals, blood vessels can form and rapid metastatic tumour growth 
can occur. 
 
 
Figure 1.2 - The basic steps of the metastatic pathway 
(Figure adapted from (Zetter, 1998) 
 
 
Some sites of metastasis are dependent on the tumour type; for example 
colorectal cancer commonly metastasises to the peritoneum, whilst prostate 
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cancer to the bones and lung cancer to the adrenal gland, however all three of 
the cancers named above also commonly metastasise to the liver and lung 
(NCI, 2011), making these the most common sites for metastasis in all cancers.  
 
1.5 Cancer Treatment  
Treatment for cancer is dependent on the tumour type, histology and whether it 
is diagnosed at an early or late stage. Early diagnosis leads to much better 
prognosis than cancer that has spread to either local lymph nodes or to distant 
sites. Basically treatment can be assigned to three categories; surgical 
resection, localised treatment, and systemic chemotherapy. These are briefly 
discussed below. 
1.5.1 Local Resection 
Local resection (surgical removal) of a tumour mass is often the first line of 
treatment against cancer. If the tumour has not invaded surrounding tissues 
then this form of treatment can be very effective. If however the cancer has 
spread from the primary location or the tumour is located in an inaccessible 
area, the brain for example, then alternative forms of therapy are necessary to 
attempt to eradicate the disease. In the majority of cases surgery is used in 
combination with other strategies such as radio- or chemotherapy. 
1.5.2 Radiotherapy  
Radiation therapy uses intense ionising radiation to kill cells and is a localised 
treatment targeted directly to the site of a tumour thereby avoiding damage to 
other tissues and minimising side-effects. Often radiation therapy is used in 
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conjunction with surgery by reducing the tumour volume prior to resection 
(Camporeale, 2008). 
 
The actual physiochemical events within a cell that are triggered by irradiation 
are largely unknown. Some cell types, acute lymphoblastic leukaemia for 
example, are extremely radiosensitive however other cell types can be more 
resistant and have repair mechanisms rendering the radiation sub-lethal 
(Souhami and Tobias, 2005). It is thought that the majority of cell death is 
induced by the formation of free-radicals which damage the DNA, rather than 
radiation-induced direct DNA damage.  
1.5.3 Chemotherapy  
In its generic sense chemotherapy is the use of chemicals to treat a disease. It 
is the most widely used method for the treatment of cancer because once the 
disease has spread or disseminated, localised therapies are no longer effective. 
Chemotherapy can be used in various ways depending on the stage and also 
the type of cancer. It can be used a) to treat patients with advanced disease 
where more localised treatment methods are no longer useful, b) to treat a 
patient following control or removal of a primary tumour and c) to treat primary 
localised disease (DeVita and Chu, 2001).  
 
The major therapeutic agents utilised clinically are reliant upon the fact that 
cancer cells divide more rapidly than normal body cells and are therefore more 
susceptible to DNA damage. Based on this, there are variety of drug types that 
target various mechanisms within the cell including prevention of DNA 
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replication, inhibition of cell division or perturbing pathways involved in cell 
growth or cell death (Souhami and Tobias, 2005). 
1.5.3.1 Alkylating agents 
Alkylating agents are highly reactive compounds that covalently link an alkyl 
group (R-CH2) to nucleic acids, thereby directly damaging the DNA. The 
manner of the cross-link along with the nature of the chemical reaction on the 
cross-linked strand and the sequence of bases accounts for differences in 
response of different cancers to the same treatment (Souhami and Tobias, 
2005).  
 
 
 
 
 
 
 
Figure 1.3 - The structures of common clinically utilised alkylating agents a) melphalan b) 
chlorambucil and c) cisplatin (adapted from (DeVita and Chu, 2001) and (Souhami and Tobias, 
2005) 
 
 
Alkylating agents that are commonly used in the clinic are melphalan, 
chlorambucil and cisplatin (figure 1.3). The latter drug is a very active anticancer 
drug and is mainly used to treat tumours of the ovaries, testes and head and 
neck (Siddik, 2003). It forms covalent adducts with DNA, the most prevalent 
being the 1, 2-intrastrand crosslinks (Zamble and Lippard, 1995), which are 
detected by a range of damage recognition proteins, leading to inhibition of 
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DNA synthesis, suppression of RNA transcription, effects on the cell cycle, and 
the therapeutically beneficial process of apoptosis (Siddik, 2003). Cisplatin 
activates kinases involved in the regulation and stability of p53, namely the ATR 
(ATM- and Rad3-related protein), leading to an increase in p53 levels and 
consequently transactivation of the p21 gene (Damia et al., 2001) and arrest of 
the cell cycle. 
1.5.3.2 Antimetabolites 
Antimetabolites are structural analogues of normal biochemical molecules and 
function by acting as nucleic acid mimics, thus inhibiting DNA synthesis. 
Broadly speaking there are 3 classes of antimetabolites; folic acid antagonists, 
purine antagonists and pyrimidine antagonists. Methotrexate, a folic acid 
antagonist, inhibits folic acid reductase leading to prevention of the biosynthesis 
of purines and pyrimidines, whilst hydroxyurea, a ribonucleoside reductase 
inhibitor, blocks both the conversion of cytosine into its de-oxy derivative and 
the inclusion of thymidine into the DNA strand (Ophardt, 2003). 
 
The most commonly used agent within this class is 5-fluorouracil (5-FU), a 
fluorinated pyrimidine analogue that has specific activity in the S-phase of the 
cell cycle. It requires activation to a cytotoxic metabolite involving a complex 
process that entails inhibition of thymidylate synthase by 5dUMP (the 5-FU 
metabolite) and incorporation of another metabolite (FUTP) into RNA or DNA 
resulting in inhibition of DNA synthesis (DeVita and Chu, 2001).  
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1.5.3.3 Anthracyclines  
The anthracyclines are very common anticancer agents and include doxorubicin 
(figure 1.4) and daunorubicin. Doxorubicin is a broad spectrum 
chemotherapeutic agent (Jung et al., 2002) used in the clinic to treat many solid 
tumours including breast, ovarian, bladder and non-Hodgkin‟s and Hodgkin‟s 
lymphoma (CRUK, 2011). 
 
 
 
Figure 1.4 – The chemical structure of doxorubicin, an anthracycline antibiotic. Taken from 
(ChemBlink, 2011) 
 
 
Doxorubicin works via a number of mechanisms; i) intercalation into DNA, 
leading to  inhibited synthesis of macromolecules; ii) generation of free radicals, 
leading to DNA damage or lipid peroxidation; iii) DNA binding and alkylation; iv) 
DNA cross-linking; v) interference with DNA unwinding or DNA strand 
separation and helicase activity; vi) direct membrane effects; vii) initiation of 
DNA damage via inhibition of topoisomerase II; and viii) induction of apoptosis 
in response to topoisomerase II inhibition (Gewirtz, 1999). However when the 
concentration of the drug normally used in vitro is taken into account, the most 
likely mechanism by which doxorubicin exerts its effect in the clinic is likely due 
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to the topoisomerase II inhibition at clinically relevant concentrations (Gewirtz, 
1999; Pecorino, 2005).  
1.5.3.4 Microtubule-binding agents  
Microtubules, along with actin filaments and intermediate filaments, determine 
cell shape and are involved in intracellular movement of organelles and 
contraction (Kanthou and Tozer, 2002). They are composed of heterodimers of 
α- and β- tubulin which assemble into linear, hollow cytoplasmic filaments 
(Schwartz, 2009). Exceptionally important in cell division, they form spindles to 
allow chromosome replication and are active in the M-phase of cell division. All 
tubulin-binding agents interfere in mitotic spindle formation in tumour cells, 
block proliferation, and induce apoptosis, all of which contribute to their clinical 
efficacy (Jordan and Wilson, 2004; Schwartz, 2009). These drugs will be 
introduced in more detail in Chapter 5.  
1.5.3.5 Hormonal therapy 
Steroid hormone receptor proteins are found in the cell membrane, the nucleus 
and the cytoplasm of cells and interactions between the hormones and their 
receptors modify DNA activity, thus affecting growth and replication of the cells. 
There are various ways in which this system can be targeted to attempt to 
modify tumour growth including lowering the plasma concentration of the 
hormone or preventing binding of the hormone to receptors to try and prevent 
further growth. Hormone therapy is used to treat early stage cancers in 
hormonally responsive tissues such as the breast, prostate and endometrium. 
Eventually all cancers become hormone-independent and at this point hormonal 
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therapy is no longer an advantageous treatment option (Souhami and Tobias, 
2005).  
 
1.6 Issues regarding classical chemotherapy  
Despite advances in the treatment of some cancers, response of many tumour 
types is sub-optimal and in many cases not curative. The two main hindrances 
to drug efficacy are resistance; acquired, apparent or inherent, and off-target 
toxicity, which limits the dose that can be administered.  
 
The majority of commonly used anti-cancer agents do not target cancer cells 
specifically and wide-ranging toxic side-effects are observed. Dividing cells 
within the body such as bone marrow, hair follicles and the lining of the intestine 
are most commonly affected as well as a variety of other organs such as the 
kidneys (Souhami and Tobias, 2005). More common side effects are 
depression of the immune system (myelosuppression, immunosuppression and 
neutropenia), alopecia, problems with the digestive track and problems 
associated with general toxicity of the chemicals used (nausea and vomiting, 
decreased appetite, nephrotoxicity, neurotoxicity and hepatic toxicity) (Souhami 
and Tobias, 2005). These dose-limiting toxicities affect the clinical usefulness of 
cytotoxic agents and although there are drugs that can appease some side-
effects there is a clear requirement for the development of new, more targeted 
therapies that have limited off-target effects. Druggable targets and 
mechanisms for such therapies must be identified and new molecules found to 
home in on them. 
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Another drawback to treatment of cancer with cytotoxic chemotherapies is the 
development of resistance to the drugs. A multi-drug resistant (MDR) phenotype 
results in a decreased efficacy in a range of anticancer drugs and is not limited 
to the drug that was used initially (Lage, 2008). Mechanisms of MDR 
phenotypes include the enhanced efficiency of drug pumps such as the ATP-
binding cassette (ABC), modulation of cellular death pathways and the 
alteration and repair of target molecules (Lage, 2008) which eventually leads to 
a decrease in efficacy. One of the central mechanisms of the MDR phenotype is 
the permeability-glycoprotein (P-gp) pump that leads to eventual failure of 
tumour chemotherapy by increasing drug efflux and leading to acquired drug 
resistance to many structurally and functionally unrelated agents, preventing 
optimum cellular drug concentrations being reached (Fusi et al., 2006). 
Although there have been studies to look into reversal of the MDR phenotype, 
mainly with respect to the expression of P-gp (Fusi et al., 2006; Jeon et al., 
2010) novel agents that could avoid instigating MDR phenotype development 
would be a substantial breakthrough. Bearing in mind that the stromal cells that 
infiltrate and grow alongside the tumour cells are now assumed to be 
importantly linked into carcinogenesis, targeting these cells may avoid the 
initiation of such resistance mechanisms. The development of drugs targeting 
the tumour vasculature is an example of how targeting the stroma may be 
efficacious in avoiding resistance and will be discussed in more detail in 
Chapter 5.  
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1.7 Targeted anticancer therapies 
Modern drug research is mechanism based (Rudin, 2009) and most new 
anticancer drugs in development are aimed at specific molecular pathways, 
allowing a more targeted approach to therapy. Ideally this lowers the cytotoxicity 
of anti-cancer agents whilst improving delivery and efficacy, especially when 
used in combination. As knowledge of complex pathways involved in 
oncogenesis and mutagenesis improves it is acceptable to presume that this 
will lead to an improvement in the number of drugs advancing through the drug 
development process and a higher success rate in getting drugs through to 
patients. There are a large number of targeted therapies in development 
however the main molecular targets are the EGFR, the VEGF and the p53 
pathways. 
 
The epidermal growth factor receptor (EGFR) family of receptor tyrosine 
kinases mediate cell signalling via the binding of extracellular growth factors, 
which activates intracellular pathways that promote tumour growth and survival 
(Ballas and Chachoua, 2011). There are now a number of drugs that are used 
clinically, which are classified into two groups: 1) small molecule EGFR tyrosine 
kinase inhibitors (TKIs), such as gefitinib, that inhibit the intracellular receptor 
kinase domain and 2) large molecule anti-EGFR antibodies such as 
traztuzumab, that inhibit the extracellular ligand-binding domain (Huang et al., 
2004). Treatment with such drugs has been linked to a complementary impact 
on downstream signalling, apoptosis, proliferation, and tumour growth (Huang 
et al., 2004).  
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The VEGF-R pathway is important in angiogenesis (Ballas and Chachoua, 
2011), allowing tumours to grow beyond a couple of millimetres in diameter. 
VEGF binds to tyrosine kinase receptors on the surface of cells and initiates 
activation of the signalling pathway that leads to endothelial cell survival, 
migration and proliferation (Rini and Small, 2005). Bevacizumab is an antibody 
that binds to circulating VEGF and prevents it binding to VEGFR, thus 
preventing downstream effects. Similarly to EFGR, there a also a number of 
small molecule TKIs, namely sunitinib, sorafenib and pazopanib that inhibit 
VEGF signally by targeting the intracellular domain (van der Veldt et al., 2010). 
 
The tumour suppressor p53 is absent or mutated in more than 50% of solid 
tumours and has received much attention as a possible target for new 
therapies. The potential of restoring function of p53 activity using small 
molecules has been investigated as a mechanism that leads to tumour 
regression and is therefore considered a promising strategy for treatment of 
cancer (Wang and Yan, 2011). Murine double minute -2 (MDM2) inactivates 
p53 through repressing its transcriptional activity and promoting its proteosomal 
degradation and small molecules such as nutlin, RITA and MI-219 that interrupt 
the MDM2-p53 interaction can reactivate p53 and lead to tumour regression in 
vivo (Vassilev et al., 2004).  
 
Overall, targeted approaches to anticancer drug development are likely to lead 
to the development of more compounds that can be used to treat patients in a 
more specific and personal way. Unfortunately although there are many 
targeted therapies emerging from preclinical studies with promise, the attrition 
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rate during clinical trials is high, thus costing the pharmaceutical industry billions 
of pounds. Improvements in preclinical drug testing have the potential to 
distinguish promising compounds more quickly and to highlight less hopeful 
compounds prior to entry into clinical trials, thereby reducing cost.  
 
1.8 Anticancer drug development  
The development of a new cancer drug can take up to 15 years (Cai et al., 
2006), progressing through a number of specific steps indicated in figure 1.5a.  
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1.5 – From bench to bedside: how a new drug gets to market (PMH, 2011) 
 
 
Following target identification, most commonly a protein, high-throughput 
screening is performed where thousands of potential compounds are tested to 
identify those that impact specifically on the target. The compounds are refined 
and optimised for target specificity. Possible administration methods and dosing 
levels will also be considered (PMH, 2011). Favoured compounds can then go 
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through into in vitro and in vivo testing where the emergence of lead 
compounds that have potential for development are distinguished. 
 
Preclinical testing imparts information regarding the safety of the compound and 
identifies potential toxicities. Initially in vitro testing is carried out in a range of 
cell lines. The National Cancer Institute have a 60 cell line (NCI60) screen 
(DTP/NCI, 2008) which includes nine distinct tumour types namely leukaemia, 
colon, lung, CNS, renal, melanoma, ovarian, breast and prostate and gives 
information regarding the mechanisms of growth inhibition and tumour cell kill 
(Shoemaker, 2006). The automated COMPARE analysis provides a quantitative 
method for integrating cellular responses with the large database of statistics 
that have been combined for the NCI60, and produces rank order lists of 
compounds or targets based on correlation analysis of the NCI60 profiles 
(Shoemaker, 2006). If a lead compound shows efficacy towards carcinoma cell 
lines, with limited toxicity on non-cancerous cells during in vitro screening, it can 
go forward to in vivo experimental models. Here, further toxicity information is 
collected, the impact of the compound on major organs is assessed and 
pharmacokinetic issues are studied in detail (PMH, 2011). Potential combination 
treatments with existing drugs can also be assessed and recommendations on 
dosing and schedule are made. If promising results are seen at this stage the 
compound can then enter clinical trials, where drug safety and disease specific 
activity are monitored and compared to currently available drugs.  
 
The attrition rate for new compounds is extremely high; millions of new 
chemicals are tested every year, with only a handful of these eventually 
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reaching the clinic. Even compounds that have high efficacy in in vivo models 
will not necessarily reach later stage clinical trials if they do not work 
significantly better than current drugs, if the expenditure required for mass 
production and introduction into the clinic is unwarranted, or if there is an 
equally efficacious therapy already available. Only if there are considerably 
fewer negative side-effects as a result of treatment with the new compound will 
it be taken through into clinical use. 
 
As knowledge of molecular systems and pathways expands and improves, 
development of novel agents that are directed to specific molecular targets has 
become forefront. This approach reduces the likelihood of resistance and the 
selective toxicity to cancer cells limits the morbidity in patients commonly 
associated with chemotherapy. The development and improvement of these 
„molecular targeted‟ therapies is a major goal of current anticancer drug 
development. Analytical tools that enable the assessment of new therapies 
targeted specifically to individual pathways/molecules in living mammals are 
already benefitting researchers, with the potential to provide a lot more 
information in the future.  
 
1.9  Limitations of current preclinical in vivo models in cancer 
drug development. 
In vitro studies can be used to give basic information regarding the toxicity of 
the drug towards cancer cell lines, to evaluate drug target interactions and to 
define biochemical and gene expression pathways (Massoud and Gambhir, 
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2003). It does not however answer questions regarding clinical response in the 
whole body and ultimately the value of laboratory and preclinical studies depend 
on their capacity to accurately predict clinical response as a surrogate to 
humans (de Jong and Maina, 2010). Over the past decades animal models 
have played a key part in revealing many biochemical and physiological 
processes involved in the onset of cancer and its development in living 
organisms. Though more information comes from improved animal models it is 
still hard to extrapolate to humans with regard to dose-limiting toxicity (Suggitt 
and Bibby, 2005). 
 
Two primary objectives of animal models are firstly to mimic the human disease 
as closely as possible and secondly to proficiently test new therapies (Liao et 
al., 2007). In cancer research mice are the most commonly used animal for 
study due to a number of factors; they are small and easy to handle, they breed 
readily allowing a high throughput of experiments, they are relatively easy to 
genetically modify and under most circumstances are economical (de Jong and 
Maina, 2010). In vivo models can yield pharmacokinetic and pharmacodynamic 
information as well as target-orientated drug screening which is clinically 
relevant. The use of animal models does give valuable information regarding 
the basic efficacy of a drug however there are concerns that should be 
considered. The succinct review by de Jong and Maina covers many of the 
issues that may arise whilst translating data from mice to humans (de Jong and 
Maina, 2010).  
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Traditionally the measurement of drug/target interactions during in vivo studies 
relies on transplanting human cancer cells into immunocompromised host 
animals, measuring subcutaneous tumour response to the test agent via 
calliper-based measurements, and monitoring the lifespan of animals (Suggitt 
and Bibby, 2005; Zhang et al., 2007a). Although this is a non-invasive technique 
which does allow longitudinal measurements to be made, there are certain 
issues that arise. Firstly if drug-target interactions need to be investigated then 
ex vivo experiments are required to confirm these interactions. Secondly, whilst 
the tumour cells themselves express human homologies of possible target 
molecules, the stromal components are murine. This affects the intra- and peri-
tumoural vasculature as well as the tumour histology and does not allow 
complete replication of tumour-host interactions (Cho, 2009). Thirdly, 
subcutaneous tumours do not accurately mimic the environment that the tumour 
would be in humans, meaning that extrapolation to clinical testing is often 
questionable. Despite this, such a strategy has proved successful for several 
agents now in the clinic, including traztuzumab for treatment of HER2-
overexpressing breast cancer (Baselga et al., 1998; Vogel et al., 2002), 
melphalan in the treatment of rhabdomyosarcoma (Horowitz et al., 1988) and 
SAHA for treatment of cutaneous T-cell lymphoma (Kelly et al., 2003; Marks 
and Breslow, 2007). On the other hand there are a number of novel compounds 
shown to be active in preclinical subcutaneous murine models, but were less 
effective in initial clinical trials in human subjects (Attia et al., 2008; Khan et al., 
2008).  
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Cancer drug discovery has now become more focussed on targeting specific 
molecular abnormalities of cancer cells rather than inducing a generic cytotoxic 
effect. In addition, the development of agents targeting the tumour vasculature, 
including vascular disrupting and anti-angiogenic agents is now commonplace. 
Therapeutic strategies such as these that may exert their effect very efficiently 
but are not cytotoxic, will not necessarily lead to a measureable decrease in 
tumour size; rather they will have a cytostatic effect (Cai et al., 2006). In such 
cases monitoring tumour size using callipers could underestimate the effect of 
these agents, give little information regarding the internal structure of the 
tumour and thus provide inconclusive information regarding their efficacy. 
 
Although traditional in vivo models often give informative, high-quality 
information on therapeutics prior to their entry into clinical trial, there are still 
many inconsistencies between these two stages of drug discovery. One reason 
is that there is still a lack of animal models which successfully represent human 
metastatic disease (Suggitt and Bibby, 2005). Metastasis is the leading cause of 
death among cancer patients so the development of robust model systems for 
front-line drug discovery in this area is an urgent requirement. Spontaneously 
arising metastatic tumours in small animals are normally very small and unlikely 
to be located subcutaneously, making them impossible to measure using 
callipers. To retrieve information regarding tumour burden in these animals 
several would have to be sacrificed in order to evaluate and determine 
metastatic spread (Grosios et al., 1999). Furthermore, in the clinic the primary 
tumour is often removed and it is the metastatic lesions that eventually cause 
mortality, however in mouse models the animal will normally die as a 
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consequence of the primary tumour before any spontaneous metastasis has 
occurred (de Jong and Maina, 2010). Current preclinical models available to 
evaluate development of metastatic lesions are time consuming and labour 
intensive. Injection of cancer cells into the tail vein or spleen leads to metastatic 
deposits in the lungs and liver respectively, however this is somewhat artificial 
and is not representative of the human disease. Orthotopic tumours may be 
established that metastasise spontaneously which are superior with regard to 
translation but are more difficult (Nogawa et al., 2005). Consequently, there is a 
need for improved preclinical models or strategies which translate and 
represent the clinical situation. 
 
1.10 The 3Rs 
It is established good practise to look after the welfare of animals used in 
medical research and the 3Rs, reduction, refinement and replacement, are a 
widely accepted ethical framework for conducting scientific experiments using 
animals humanely (NC3Rs, 2011). The 3Rs principles were introduced in a 
1959 book by Russell and Birch; “The principles of humane experimental 
technique” (Russell and Birch, 1959). 
 
The principles of the 3Rs are that if animals are to be used in experiments, 
every effort should be made to Replace them with non-sentient alternatives, to 
Reduce the number of animals to a minimum and to Refine experiments which 
use animals so minimum pain and distress is caused (Flecknell, 2002). 
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1.10.1 Replacement 
Replacement refers to methods that avoid or replace the use of animals defined 
as “protected” under the Animals (Scientific Procedures) Act 1986. “Protected 
animals include all living vertebrates (except humans) including some immature 
forms and one invertebrate, Octopus vulgaris (NC3Rs, 2011). Replacement 
methods include computer modelling and in vitro methodologies.  
1.10.2 Refinement  
Refinement refers to improvements of procedures and husbandry that minimise 
pain, suffering, distress or lasting harm and/or improve animal welfare in cases 
where the use of animals is unavoidable. Examples include ensuring that 
accommodation meets the animals‟ needs, environmental enrichment, 
appropriate use of anaesthetics and analgesics and the use of noninvasive 
imaging techniques (NC3Rs, 2011).  
1.10.3 Reduction 
Reduction refers to new methods that result in fewer animals being used, whilst 
maintaining comparable levels of information and statistical power. This 
includes improved design and statistical analysis techniques, sharing of data 
and resources between research groups and as previously, the use of 
noninvasive imaging techniques, which allows the same animal to be monitored 
over time (NC3Rs, 2011).  
 
Current Home Office legislature regarding the use of animals in research is that 
experimentation is only permitted when there is no alternative research 
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technique and the expected benefits outweigh any possible adverse effects. It is 
also reported that the number of animals used in research has been halved in 
the last 30 years (HomeOffice, 2008).  
 
1.11  Non-invasive molecular imaging as a tool for preclinical 
cancer pharmacology studies  
Modern drug development, as discussed in section 1.7, is mechanism based: 
Cancer is regarded as a result of irregular metabolic and cellular processes that 
affect intracellular signalling. Consequently, the development of new therapies 
requires identification and effective targeting of the key players in these 
processes (Rudin, 2009). Non-invasive imaging techniques have the potential to 
give information regarding quantitative assessment of target expression and 
function and show promise in allowing the assessment of interactions between 
drugs and their target molecules/pathways (Rudin, 2009). With regards to the 
3Rs, molecular imaging both reduces and refines the use of animals in 
experiments as the same animal can be followed over a period of time, thereby 
reducing the numbers of animals being used whilst simultaneously improving 
the data set as each animal serves as its own control (Contag and Ross, 2002; 
Fomchenko and Holland, 2006).  
 
Molecular imaging is a rapidly emerging field with a multitude of characteristics 
that make it useful for the drug discovery process. Technically it has many 
advantages over traditional techniques as it is rapid, can be high-throughput, is 
non-invasive and is less labour intensive than pathology- and chemistry-based 
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assays (Massoud and Gambhir, 2007). It allows imaging to be performed at the 
cellular and molecular level in living animals, in real-time and with a quantitative 
outcome (Laxman et al., 2002; Wessels et al., 2007). 
 
Following tumour pathogenesis in one animal means that information regarding 
the possible behaviour of a tumour in humans, especially regarding metastasis 
and therapy response, is more achievable. Earlier detection and 
characterisation of disease are additional benefits of bioimaging, as is the 
information that can be obtained which is specific to particular molecular events 
for example in the evaluation of therapeutic interactions (Contag and Ross, 
2002; Laxman et al., 2002). In vivo, bioimaging can be used for target validation 
and validation of experimental therapeutic agents in a dynamic environment 
(Gwyther and Schwartz, 2008; Laxman et al., 2002). It also allows quicker 
assessment of drug/target interactions and identification of therapeutic efficacy 
prior to any macroscopic or phenotypic changes (Massoud and Gambhir, 2007; 
Morse et al., 2007). Clinically this is important as efficacy of a treatment can be 
determined earlier and if necessary the treatment regime can be altered (Morse 
et al., 2007). As non-invasive imaging techniques advance it has become 
possible to image specific intracellular pathways, a feature which was 
previously illusive (Laxman et al., 2002) without the use of ex vivo analysis 
techniques.  
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1.11.1 Imaging modalities in preclinical cancer drug discovery 
There are seven main types of bioimaging; magnetic resonance imaging, 
positron emission tomography, single positron emission computed tomography, 
computed tomography, ultrasound and optical imaging (including 
bioluminescent imaging and fluorescent imaging). All of these techniques 
demonstrate merit during drug development, with each of them having 
advantages and disadvantages. 
1.11.1.1 Magnetic resonance imaging  
Magnetic resonance imaging (MRI) is based on the absorption and emission of 
energy in the radio frequency range of the electromagnetic spectrum. The body 
is made up of primarily fat and water and therefore has numerous hydrogen 
atoms. When induced by a strong magnetic field the hydrogen nuclei emit a 
nuclear magnetic resonance signal that is determined by the direction of the 
spin induced. MRI gives high spatial resolution of about 50µm3 (Czernin et al., 
2006). MRI is a versatile technique that can be used both in small animal 
imaging and in humans, and is therefore beneficial with regards to translation 
between the species.  
 
Historically in preclinical drug development, MRI has been used to determine in 
vivo efficacy of putative anticancer therapies (Lee and Shogen, 2008; Samano 
et al., 2010) and to track metastasis of cancer cells (Winnard et al., 2007). It has 
also been used more specifically to monitor changes in the tumour 
microenvironment due to apoptosis following therapy (Steegmaier et al., 2007) 
and to demonstrate successful infiltration of gene therapy into a xenografted 
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prostate tumour (Kassouf et al., 2007). Image-supervised drug delivery and 
subsequent monitoring of therapeutic efficacy may also be possible (Strijkers et 
al., 2010).  
 
MRI has low sensitivity and a relatively long acquisition time (up to one hour), 
thereby limiting its utility for preclinical drug development studies (Lyons, 2005). 
However, the development of techniques such as high-field MRI has improved 
imaging of small animals, where spatial resolution is more important (Fei et al., 
2007) and has the potential to be able to monitor the effects of targeted 
therapies on tumours and metastatic lesions in vivo (Baboi et al., 2010). 
Dynamic contrast enhanced (DCE)-MRI which can be used to investigate the 
structure and function of tumour microvasculature and microcirculation will be 
discussed in Chapter 5.  
1.11.1.2 Positron emission tomography  
Positron emission tomography (PET) is a medical imaging technique which 
produces a three-dimensional image or map of functional processes in the body 
to enable measurement of biological function. This provides an insight into the 
nature of diseases, the function of specific genes and the performance of 
established and novel pharmaceuticals (Zaidi and Prasad, 2009). Uptake of an 
injected probe that comprises of a metabolically active molecule (such as 
glucose or water) incorporating a γ-ray emitting radioisotope, most commonly 
18-fluoro-deoxy-glucose (FDG) reflects glucose metabolism and highlights 
enhanced glycolysis associated with malignant cells. This enables 
differentiation between malignant and benign tissue (Otsuka et al., 2007). 
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Negative aspects of PET in small animal imaging are a) that it has relatively low 
resolution than other noninvasive imaging techniques and b) the isotopes used 
for PET imaging have short half lives and their production and use requires an 
expensive on-site cyclotron and radiochemistry facilities (Brindle, 2008).  
 
Information regarding changes in glucose metabolism, cell proliferation, tumour 
perfusion of drugs, and drug biodistribution or pharmacokinetics, all of which 
can reflect drug efficacy, can be measured by PET (Avril and Propper, 2007). 
Drugs that have been assessed using this technique include antibody therapies 
(Chen et al., 2007), histone deacetylase (HDAC)-inhibitors (Leyton et al., 2006), 
EGFR-TKIs (Diaz et al., 2010) and antivascular agents (Kim et al., 2007).  
1.11.1.3 Single positron emission computed tomography 
Single positron emission computed tomography (SPECT) is an imaging 
technique that detects low energy γ-rays arising from radioisotope decay and 
has resolution of 1-2mm. An advantage of this technique over PET is the 
capacity to detect multiple probes simultaneously but conversely SPECT has 
lower sensitivity and requires higher amounts of radioactive probe (Lyons, 
2005). Radio-labelled monoclonal antibodies have successfully been tracked 
using SPECT and show localisation of the antibodies to sites of tumour 
development, for example anti-HER2 molecules homing to HER2+ tumours 
(Ahlgren et al., 2009). Analysis of vascular endothelial growth factor (VEGF)-
induced signalling pathways as a result of treatment with antiangiogenic drugs 
has also been performed using SPECT (Ali et al., 2010). Activatable molecules 
such as technetium-99m that can be cleaved by matrix metalloproteinase 
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(MMP)-14 in vivo may potentially serve as a guide to develop targeted 
molecular therapies (Watkins et al., 2009).  
1.11.1.4 Computed tomography 
Computed tomography (CT) is a medical imaging method where digital 
geometry processing is used to generate an internal 3-D image using a series 
of 2-dimensional X-ray images. Intravenously administered contrast agents are 
injected prior to imaging. CT is the most commonly used tool for clinical 
assessment of the structural features of cancer and along with MRI is the 
modality of choice to monitor tumour response to therapy (Torigian et al., 2007). 
In preclinical studies resolution is vitally important since the most common use 
of CT is to monitor micrometastatic deposits (Ohta et al., 2006; Proschek et al., 
2008), which may be impossible to detect unless scans of exceptional quality 
are achieved. Consequently, higher resolution often involves exposure to a 
higher dose of radiation which in itself results in issues regarding exposure 
levels, although advances in technology have decreased this somewhat.  
1.11.1.5 Ultrasound  
Ultrasound (US) technology is based on pulse-echo systems by which the 
return waves (echo) of acoustic pulses generated from a transducer propagated 
into body tissue are detected and converted into images for visual inspection. 
The resolution of the image and depth of tissue penetration is largely dependent 
on the frequency of the ultrasound transducer (Mallidi et al., 2011; Wang and 
Hashemi, 2010). Imaging with US has involved the use of microbubbles, which 
produce an acoustic signal because of their resonant properties in the 
ultrasound field. Tumour targeting can be achieved by chemical modification of 
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the microbubble shell or by attaching a targeted ligand against a tumour specific 
receptor (Brindle, 2008). Microbubble diameter is 1-4µm which prevents them 
from leaving the intravascular space limiting molecular imaging to this 
compartment (Brindle, 2008). 
 
In the preclinical development of anticancer agents US has been successfully 
used in a variety of ways, including in the development of new xenograft models 
by using US-guided injection of cells (Huynh et al., 2011), to monitor tumour 
angiogenesis using integrin targeted microbubble contrast agent (Anderson et 
al., 2011; Deshpande et al., 2011) to monitor gene delivery to tumour models 
(Chen et al., 2010) and to detect apoptosis following administration of 
chemotherapy (Czarnota et al., 1999). US has also shown great promise in 
monitoring tumour microvasculature (Loveless et al., 2008) and the effects of 
antiangiogenic therapy (Pysz et al., 2011). 
1.11.1.6 Optical Imaging: Overview 
The term optical imaging encompasses preclinical approaches using either 
luminescence or fluorescence detection as a means for evaluating drug activity, 
molecular events or biological activity of potential drug targets. These 
techniques require less equipment and expertise, are more cost-effective, do 
not require the use of radio-labelled molecules and enable faster imaging 
acquisition than the methodologies described above. This makes them more 
suitable techniques for smaller laboratories.  
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Optical imaging relies upon detection of either a fluorescent or luminescent 
event and provides no results regarding the physical characteristics or 
pathology of the tissue or animal, requiring the overlay of the detected events 
on a photographic image of the animal or tissue. 
 
The use of optical imaging for monitoring biological changes is now a well 
established methodology within drug discovery and pharmacology (Fomchenko 
and Holland, 2006). Early in the drug discovery process BLI can be used in vitro 
to determine the therapeutic or pharmacological effect on cancer cell lines 
treated with different compounds, the transcriptional upregulation following 
treatment (Weiss et al., 2010) or to study specific protein expression following 
drug treatment (Sakoguchi-Okada et al., 2007). Furthermore, mechanistic 
information can be obtained through the use of tagged proteins or promoter-
driven reporter expression within these experimental models. In preclinical 
cancer pharmacology, there are now a wide range of cancer cells available 
which express optical imaging proteins or probes, representing all the major 
human solid tumour types. 
 
A downside to the use of optical imaging is that the target or investigated cells 
require genetic modification to express either luciferase or a fluorescent protein 
prior to their use, making it unlikely that such an approach will ever translate to 
the clinic. Nevertheless, the high selectivity, specificity and applicability of this 
approach remain a valuable tool for preclinical evaluation of cancer therapeutics 
and their acceleration and progression into the clinic. 
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1.11.1.7 Optical imaging: Fluorescence 
The principle of fluorescence imaging (FLI) relies upon detection of photons that 
are emitted upon excitation of the fluorophore using a light or laser source. Cell 
lines to be used in vivo must be genetically modified to express a fluorescent 
protein and they can then be used to establish tumours in animals. There are 
now a vast number of fluorescent proteins, both natural and engineered, with a 
wide variety of emitted colours across the visible spectrum from blue to far red. 
The utility of these fluorescent proteins for in vivo preclinical cancer 
pharmacology studies has been shown in many studies representing all areas 
of the preclinical cancer drug discovery and pharmacology process, including 
drug efficacy, monitoring of tumour growth and detection and analysis of 
angiogenesis and metastatic tumour spread (Liu et al., 2007).  
 
Relative to BLI (introduced in section 1.11.1.8), fluorescent imaging has lower 
sensitivity and a higher background signal due to the requirement of an external 
illumination source to facilitate fluorescent emission. This high background is 
due to biomolecules having intrinsic fluorescence and the fact that cells and 
tissues can both quench and scatter emitted light. Consequently, this can limit 
the depth of penetration of light as the emitted light is absorbed and scattered 
by various tissues, including haemoglobin (Tung, 2004). As such, important 
criteria for selection of fluorescent proteins for in vivo molecular imaging studies 
are the required signal intensity, photostability and potential for tumour 
autofluorescent interference. The use of fluorescent signals with excitation and 
emission wavelengths within the near infrared (NIR; 650-900 nm) region of the 
spectrum has now proven highly applicable in this context. Lower background 
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signals and noise are observed with NIR, due principally to the fact that it is 
poorly absorbed by haemoglobin and lipids (Weissleder and Pittet, 2008). 
Despite these apparent limitations, fluorescent imaging has proved invaluable in 
extending understanding of cancer biology, drug efficacy and preclinical cancer 
pharmacology.  
 
Due to the large range of fluorescent proteins available that have differential 
emission spectra, several processes or molecular events within the same cell or 
preclinical tumour model can be simultaneously monitored (Hoffman, 2009). 
Dual imaging using fluorescent reporter proteins has also been used for the 
evaluation of novel anti-angiogenic compounds (Amoh et al., 2006; Dunphy et 
al., 2009) however these methods are not truly noninvasive as intravital 
microscopy and ex vivo analysis were required respectively.  
1.11.1.8 Optical imaging: bioluminescence  
Similarly to FLI, the principle of bioluminescent imaging (BLI) relies upon 
detection of photon emission; however exposure to an exogenous substrate is 
required. The emission of light in this case is as a result of the oxygen-mediated 
conversion of luciferin to oxyluciferin by cells genetically-modified to express 
luciferase, a process which does not necessitate an external light source (Gould 
and Subramani, 1988). Several luciferase genes have now been identified and 
cloned from various natural sources, the most common ones for imaging 
purposes being the ATP-dependent luciferase isolated from the North American 
firefly (Photonis Pyralis) and ATP-independent luciferase from the anthozoan 
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sea pansy (Renilla Reniformis) (Gould and Subramani, 1988; Snoeks et al., 
2010).  
 
The Firefly luciferase enzyme is a 61kDa single-subunit protein that catalyses 
D-luciferin, whilst Renilla luciferase is a 36kDa monomeric enzyme that 
catalyses coelenterazine (Bhaumik and Gambhir, 2002). The two enzymes are 
structurally unrelated, as are their substrates, however in all luciferase/substrate 
reactions visible light is emitted during relaxation of the excited metabolite to its 
ground state (Nakatsu et al., 2006). Co-factors required in the Firefly luciferase 
reaction are ATP, O2 and Mg
2+, whilst for the Renilla reaction O2 is the only co-
factor (figure 1.6). The light emitted from the Firefly reaction is at a wavelength 
of 560nm (Nakatsu et al., 2006) whilst that emitted from the Renilla reaction is 
482nm (Bhaumik et al., 2004). The lack of background signal emitted from 
animal tissue means that there is very little noise associated with BLI and the 
signal is not hampered by background light emission as is the case with 
fluorescent imaging.  
 
 
 
 
Figure 1.6 – The chemical structures and reactions of D-luciferin and coelenterazine that 
culminate in the emission of measureable light. Adapted from (Promega, 2011) 
 
+AMP+PPi+CO2+Light 
+CO2+Light 
36 
 
The most common use of BLI in the preclinical development of drugs is to 
monitor change in tumour volume following treatment of xenograft 
(subcutaneous or orthotopic) tumours in rodents, usually mice. As with 
fluorescent imaging, cell lines must be modified in order to express the 
luciferase gene before they can be used to establish tumours in animals. 
Following injection of the appropriate substrate the luciferase enzyme catalyses 
the reaction to produce a metabolite, and photon emission is a by-product of the 
reaction (see figure 1.6). The utility of this system comes from the fact that 
luciferase-driven photon emission can be detected externally, even when the 
cells are located several millimetres below the skin (Lyons, 2005; Moriyama et 
al., 2008). Importantly in terms of the utility of BLI to cancer pharmacology, it is 
now established that neither luciferase itself or bioluminescent imaging affect 
tumour growth in vitro or in vivo (Tiffen et al., 2010). 
 
In drug efficacy studies, a decrease in luminescence is attributed to the 
cytotoxic effects of the drugs as a result of either induction of cell death or a 
reduction in cell metabolic ability. In terms of this application of BLI, there have 
been an extensive number of preclinical cancer pharmacology studies across a 
wide range of tumour cell types including non-small cell lung carcinoma, glioma, 
brain tumours (Grozio et al., 2007; Holzmuller et al., 2010; Ozawa and James, 
2010). Real-time determination of drug uptake into cells and tumours in vivo is 
also possible (Jones et al., 2006; Wender et al., 2007). Furthermore, activity of 
the metabolic enzyme cytochrome P450 3A4 has been monitored in vivo using 
BLI (Weisheng et al., 2005) an important factor when considering 
pharmacokinetics, metabolism and clearance of a novel anticancer agent. 
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Preclinical models of metastasis for assessment of new therapeutic strategies 
are extremely hard to develop and there are limited systems that adequately 
represent the human disease. Unlike conventional preclinical tumour models, 
BLI has the capability to detect micrometastatic disease thereby permitting 
tumour dissemination and appearance of micrometastatic disease to be traced 
longitudinally and non-invasively (Cordero et al., 2010; Drake et al., 2010; 
McNally et al., 2010 ). Similarly, spontaneous tumour growth can be monitored 
using genetically modified murine models which can provide vital information 
regarding tumour pathogenesis and treatment strategies (Hawes and Reilly, 
2010). 
 
In light of the evolution of molecular-targeted cancer therapeutics and the need 
to extract as much information from in vivo studies as possible, the most 
significant advantage and potential for BLI is the assessment of molecular-
target interactions and drug pharmacodynamics. When cloned into 
promoter/enhancer sequences or engineered into fusion proteins, imaging 
reporters enable fundamental processes such as transcriptional regulation, 
signal transduction cascades, protein–protein interactions, protein degradation, 
oncogenic transformation, cell trafficking, and targeted drug action to be 
temporally and spatially registered in vivo (Dothager et al., 2009). This 
approach has now been demonstrated in several studies with general success: 
BLI using Firefly luciferase (Fluc) has been used to monitor apoptosis using a 
variety of methods linked to caspase 3/7 activation (Coppola et al., 2008; Lee et 
al., 2007; Scabini et al., 2010), to monitor receptor tyrosine kinase activity  
(Contessa et al., 2010) and p53 as a result of chemically induced DNA damage 
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(Briat and Vassaux, 2008). Protein-protein interactions have also be monitored 
in vivo using Fluc BLI (Rudin, 2008; Villalobos et al., 2007) as have HIF-1 
activity and autophagy (Ju et al., 2009; Lehmann et al., 2009; Viola et al., 2008).  
 
Renilla luciferase (Rluc) has also been used for preclinical cancer research, 
although is less commonly used than Fluc due to decreased stability of the 
substrate and higher tissue attenuation due to the lower wavelength of the 
emitted light (Bhaumik and Gambhir, 2002). However, it has successfully been 
engineered into tumour-targeted viruses to track the localisation of the virus to 
Fluc expressing tumour cells (Heikkila et al., 2010; Kelly et al., 2008). It has also 
been used as a constitutive tumour marker in orthotopic gliomas (Shah et al., 
2008) and prostate cell lines (Dobrenkov et al., 2008) whilst other luciferase 
enzymes were used to monitor localisation of human neural stem cells and viral 
delivery respectively. These are examples of dual-luciferase systems which are 
successful due to the lack of cross-reactivity between the different luciferase 
enzymes and their substrates.  
 
Potential confounding factors when using BLI include the size of the tumour and 
its anatomical location within the animal, the amount of necrosis, and levels of 
hypoxia in the centre of the tumour that may lead to a decrease in the 
magnitude of the emitted signal as the tumour reaches a larger size (Dickson et 
al., 2007; Jurczok et al., 2008). The presence of dominant signals from one 
organ can mask weaker signals potentially being produced elsewhere (Jurczok 
et al., 2008; Nogawa et al., 2005). 
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1.11.1.9 Benefits of optical imaging for preclinical cancer research  
The cost of bioluminescence imaging systems is significantly less than other 
imaging technologies such as SPECT, PET, or MRI. Acquisition time is also 
much quicker (between 1 second – 10 minutes depending on the application) 
and 3 or 5 mice can be imaged concurrently. Conversely MRI and PET only 
enable imaging of one animal at a time and may require 30 to 60 minutes for 
data acquisition and in practical terms the total number of mice that could be 
imaged in a single day would be between eight and ten for most experiments 
(Zinn et al., 2008). Another disadvantage of PET and SPECT is that the 
preparation and injection of radiolabelled molecules is necessary as the image 
contrast. Additionally, the imaging systems detect the radioactive label in all 
locations, including that which is metabolized or excreted by normal routes. This 
“background” signal often requires imaging to be conducted at later time points 
when it is reduced, and reduces sensitivity to detect the desired process (Zinn 
et al., 2008). The 3D images and the ease in translation to human imaging are 
areas where MRI, PET and SPECT are advantageous. Recently there have 
been developments in the technology of BLI that may lead to acquisition of 3D 
images in the future, however it is very unlikely that the technique will ever be 
used in the clinic due to the requirement of genetically modified cells and the 
issue of penetration through tissue. However, for preclinical studies in small 
laboratories, the main issue with the majority of noninvasive imaging modalities 
(with the exception of US) such as MRI and PET is cost.  
 
40 
 
1.12 Aims and objectives  
The overall aim of this project was to develop in vivo tumour models with the 
ability to demonstrate drug pharmacodynamics and report drug target 
interactions non-invasively. The use of such models will permit observation of 
drug-target interactions over time (rather than the „snap-shot‟ view currently 
available), interrogation of in vivo pharmacological mechanism of action, non-
invasive investigation of both sub-tumoural distribution and temporal drug-target 
interaction and ultimately proof-of-principle.  
 
The concept involves modulation of human cancer cell lines to express reporter 
proteins, both constitutively and pharmacologically activated. Once created and 
demonstrated in vitro these reporter cell lines were used to assess drug effects 
in both subcutaneous (s.c) and orthotopically transplanted in vivo tumour 
models. The pharmacokinetics of the luciferase/luciferin reaction were also 
investigated to try and better understand the distribution of the substrates and 
the light emission kinetics associated with bioluminescent imaging.  
 
Also, the newly created reporter cell lines were used to validate whether BLI is a 
suitable method for the assessment of vascular disruption in xenograft tumours 
as a result of treatment with vascular disrupting agents and to assess the 
viability of using gene-driven luciferase reporter cell lines to assess proof-of-
principle mechanisms of action of novel therapeutic agents. This could 
ultimately lead to improved preclinical testing of such agents whilst adhering to 
the 3Rs principles.  
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2 Development of reporter cell lines for evaluation of 
anticancer drug pharmacology 
2.1  Introduction 
As previously discussed in section 1.8, there is a significant drop-off from the 
number of drugs demonstrating anticancer activity in in vitro studies to those 
demonstrating efficacy in the in vivo setting. Despite showing good results in 
vitro and in conventional in vivo tumour models, many cancer therapeutics fail 
to progress into the clinic as a consequence of poor bioavailability, drug 
resistance and target selectivity (Jones et al., 2006; Wender et al., 2007). 
Identifying and predicting the potential for these limitations preclinically has 
often proved difficult, involving ex vivo drug and tissue analysis or extensive 
pharmacokinetic studies. Although many factors are known to play a role in 
these failures, two of the commonest pharmacological factors are poor drug 
delivery to the tumour site and rapid drug metabolism, culminating in lack of 
efficient drug activity. In addition, the majority of anti-tumour studies performed 
in vivo utilise subcutaneous tumour models where the ability to palpate and 
measure these tumours through the skin means that drug efficacy can be 
monitored without animal sacrifice. The major disadvantage of these models, 
which is likely to contribute to the apparent failure of many novel cancer 
therapeutics, is the lack of clinical relevance and inappropriate tumour location. 
Furthermore, it is also essential that drugs and molecular targets that will not 
make it to the clinic are identified earlier in the drug discovery process, thereby 
saving enormous late-stage development costs and allowing resources to be 
focused on the drugs most likely to succeed. In this context, the development of 
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strategies to firstly monitor drug-target interaction, secondly to temporally 
determine therapeutic activity and pharmacodynamics, and thirdly to monitor 
therapeutic response in „clinically relevant‟ tumour settings is of the upmost 
importance for preclinical cancer pharmacology. 
2.1.1 The use of bioluminescent reporters for cancer pharmacology  
Genetic modification of cells in the preclinical setting via introduction of a 
fluorescent or luminescent protein for “cellular tagging” has been utilised over 
many years in various different disease models, both in vitro and in vivo. This 
system relies upon detection of either a fluorescent or luminescent event 
produced from the „modified‟ cell. In the in vivo setting, although this technology 
does not provide results regarding the physical characteristics or pathology of 
the tissue or animal (Gheysens and Mottaghy, 2009), it does allow the presence 
of the tumour cell to be identified and its growth or movement monitored with 
ease.  
 
There are now a vast number of fluorescent proteins, both natural and 
engineered, with a wide variety of emitted colours across the visible spectrum 
from blue to far red for use in this application. The downside to the use of these 
proteins in the in vivo environment is that there is a high fluorescent background 
in vivo due to biomolecules having intrinsic fluorescence and the fact that cells 
and tissues can both quench and scatter emitted light. Consequently, this can 
limit the depth of penetration of light as the emitted light is absorbed and 
scattered by various tissues, including haemoglobin (Tung, 2004). As such, 
important criteria for selection of fluorescent proteins for in vivo molecular 
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imaging studies are the required signal intensity, photostability and potential for 
tumour autofluorescent interference.  
 
One strategy closely related to fluorescent imaging is luminescent imaging, 
utilising the Firefly or Renilla luciferase genes to „label‟ cells. In general the 
background signal emitted by luminescence is lower than that given off by 
fluorescence so for orthotopic tumour tracking, luminescent tumour cells are 
preferable. Although in the natural world there are a variety of luciferases, a 
small number of these have been exploited in the laboratory, including Gaussia 
(from the marine copepod Gaussia princeps), Renilla reniformis (sea pansy), 
Pyrophorus plagiophthalamus (red click beetle) and Photinus pyralis (firefly) 
(Dothager et al., 2009). The Firefly and Renilla luciferase genes are most 
commonly used for monitoring and tracking in vivo tumour development and 
treatment response and are readily available for such purposes.  
 
The principle of BLI relies upon detection of photons emitted from the oxygen-
mediated conversion of luciferin to oxyluciferin by cells genetically-modified to 
express luciferase, a process which does not necessitate an external light 
source (Gould and Subramani, 1988). A lack of cross-reactivity between Firefly 
and Renilla luciferase substrates also means that the BLI system can be utilised 
for dual-label and target imaging. The most common use of BLI in the preclinical 
development of drugs is to monitor any change in tumour volume following 
treatment of xenograft (subcutaneous or orthotopic) tumours in rodents, usually 
mice. The utility of this system comes from the fact that luciferase-driven photon 
emission can be detected externally, even when the cells are located several 
44 
 
millimetres below the skin (Lyons, 2005; Moriyama et al., 2008). In drug efficacy 
studies, a decrease in luminescence is attributed to the cytotoxic effects of the 
drugs as a result of either induction of cell death or a reduction in cell metabolic 
ability. In terms of this application of BLI, there have been an extensive number 
of preclinical cancer pharmacology studies across a wide range of tumour cell 
types, including brain, breast and lung carcinoma (Grozio et al., 2007; 
Holzmuller et al., 2010; Kemper et al., 2006; Lim et al., 2009; Ozawa and 
James, 2010; Zeng et al., 2010), as well as sarcomas (Rousseau et al., 2010; 
Wang et al., 2010) and multiple myeloma (Jia et al., 2010). Importantly in terms 
of the utility of BLI to cancer pharmacology, it is now established that neither 
luciferase itself or bioluminescent imaging affect tumour growth in vitro or in vivo 
(Tiffen et al., 2010). 
 
In light of the need to extract as much information from in vivo studies as 
possible, the most significant advantage and potential for BLI over invasive 
methods is the assessment of molecular-target interactions and drug 
pharmacodynamics in live animals. An example which demonstrates the 
potential of such a strategy involved measurement of induction of tumour 
apoptosis simultaneously with retardation of tumour growth observed in a non-
invasive preclinical in vivo study (Scabini et al., 2010). In this study, induction of 
apoptosis was demonstrated using a conjugate of luciferin and the caspase 3/7 
substrate Z-DEVD, and tumour cells engineered to express luciferase. Upon 
apoptosis induction, the conjugated substrate is cleaved by the caspases and 
releases luciferin which is converted by the luciferase-expressing tumour cells 
to produce the bioluminescent signal . Although this strategy clearly supports 
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the rationale for luciferase activity as a marker for in vivo drug activity, it falls 
short of an approach where pharmacodynamics of a wide variety of putative 
therapeutics can be monitored with ease. In order to evaluate such agents, a 
system is required where the tumour cell itself is „responsible‟ for indicating 
drug-target interaction or therapeutic effect, and where such events can be 
monitored in vivo non-invasively. The development of such a system is one of 
the major objectives of this study. 
2.1.2 Development of promoter-driven reporter constructs for preclinical 
cancer pharmacology 
Over the last decade many advances have been made to move away from 
„conventional‟ DNA-targeted agents (discussed in section 1.5) to therapeutics 
developed to exploit the altered molecular signature of tumours, termed 
„molecular targeted therapeutics‟ (discussed in section 1.7). Although such 
therapeutics are showing clinical efficacy, it is important to remember that the 
culminating effect of the majority of these therapeutics is to either inhibit cell 
replication or induce selective cancer cell death. Consequently, the majority of 
agents developed will cause cell cycle arrest, activate the cell death pathway, or 
potentially induce both effects. Ultimately it would be of great interest to have an 
in vivo system that could be used in orthotopic, metastatic and subcutaneous 
models that was able to give information on induction of cancer cell cycle arrest 
or/and cell death by novel drugs. By using different luciferase genes it is 
possible to have a dual reporter in one animal allowing assessment of multiple 
drugs or multiple pathways activated by one drug in the same animal. This 
could be used to show different drugs working in different ways or that one drug 
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works via one pathway either with, or independently from another pathway. To 
enable this to happen, the two genetic response elements need to be in control 
of different reporter genes.  
 
Reporter constructs can be seen to be composed of three components; i) 
luciferase reporter protein, such as Firefly or Renilla luciferase, ii) a gene 
promoter that would be activated via the activity of the putative therapeutic and 
enable proof-of-principle to show that these drugs were working via the 
expected cellular mechanisms and iii) stable integration of the genetic construct 
into cellular genome to allow comparison and reproducibility of studies. In this 
project, a p53 and a p21 promoter were used to be linked to a luciferase 
reporter for reasons discussed below. 
2.1.3 p53- and p21-promoter driven reporters 
The p53 protein was first discovered in 1981 by Crawford et al who identified 
that a 53kDa protein was present in cell lines that had come from 
spontaneously formed tumours and in those that were transformed in vitro 
(Crawford et al., 1981). Wild type p53 is a potent inducer of apoptosis and cell 
cycle arrest in response to various cellular stresses such as DNA damage and 
works via the transactivation of a variety of target genes in the pathway of 
apoptosis and cell cycle arrest (Pietsch et al., 2008; Wang and El-Deiry, 2003).  
The cellular expression of p53 is very tightly regulated as loss or gain of 
function leads to faulty cell growth. The p53 protein has a very short half life and 
is usually maintained at very low levels within the cell. When a cell is exposed to 
stress, for example from DNA damaging agents, p53 is stabilised and activated 
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(Crawford et al., 1981), maintained by posttranslational modifications, principally 
phosphorylation and acetylation (Zhao et al., 2006), leading to an increase of 
p53 in the cells and ultimately to inhibition of cell cycle synthesis. The p53 
protein can be thought of as the central point between stressful stimuli and the 
ultimate fate of the cell (Sohn et al., 2002).  
 
The mechanisms by which cell cycle arrest is mediated were not elucidated until 
a decade following, where the p21Waf1/Cip1 protein was discovered. The nuclear 
p21Waf1/Cip1 gene, from here termed „p21‟, was discovered in 1993 by Wafik El-
Deiry and his colleagues when looking to identify biologically important genes 
that are transcriptionally regulated by p53 (el-Deiry et al., 1993; Hunter, 1993). 
In the same issue of “Cell” Harper et al published the same gene sequence 
under the name “Cip1” whilst they were investigating potential cyclin-dependant 
kinase (Cdk)-2 regulators (Harper et al., 1993). This led El-Deiry et al to suggest 
that following stimulation, p53 would bind to p21 and transcriptionally activate its 
expression. p21 would then bind to and inhibit Cdk2 which would block cell 
cycle progression by blocking exit from G1 (el-Deiry et al., 1994). In cells where 
p53 was mutated i.e. in many cancers, cell cycle regulation via this mechanism 
would be faulty, thus leading to unregulated cell growth (el-Deiry et al., 1994; el-
Deiry et al., 1993).  
 
Depending on the cell type, environment, and oncogenic alterations, p53 can 
induce senescence, differentiation and apoptosis as well as cell cycle arrest 
(Pietsch et al., 2008). Transcription dependant apoptosis is achieved through 
the activation of genes such as Apaf1, Fas and Bax. Downstream effectors 
48 
 
such as Bax exert an effect on mitochondrial cytochrome c that forms the 
apoptosome with Apaf-1 and dATP which in turn leads to the proteolytic 
activation of pro-caspases 9 and 3 that mediate in demise of the cell through 
apopotic cell death (Poulaki et al., 2001). It has also been suggested that p53 
can directly activate components of the apoptotic machinery: It has been shown 
that in response to genotoxic stresses p53 translocates to the mitochondria, 
which precedes the loss of mitochondrial membrane potential and caspase 
activation that ultimately leads to apoptosis (Marchenko et al., 2000; Pietsch et 
al., 2008).  
 
The p53 protein is biallelically mutated or deleted in approximately 50% of all 
human cancers (Pietsch et al., 2008) and in almost all of the remaining tumours 
the p53 pathway is deficient due to either mouse double minute 2 (MDM2) 
overexpression or alternative reading frame (ARF) deficiency (Wang et al., 
2003). In most cases where the p53 gene is mutated a stable mutated protein 
accumulates. Mutant p53 protein loses its tumour suppressor activities whilst 
gaining additional oncogenic functions that endow cells with growth and survival 
advantages (Rivlin et al., 2011).  
 
Deficiency of p53 activity in tumour also promotes resistance to chemo- and 
radiotherapy and a more malignant phenotype (Wang et al., 2006). This was 
shown in early studies, for example when a range of DNA damaging agents, 
including etoposide, nitrogen mustard and cisplatin, were used to treat Burkitt‟s 
lymphoma and lymphoblastoid cell lines: All agents failed to cause cell cycle 
arrest in G1 in those cells containing mutated p53, whereas some arrest was 
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seen in those cells with wild type p53 suggesting that p53 mutations were 
associated with decreased sensitivity to DNA damaging agents (Fan et al., 
1994).  
 
Similarly, and more recently, etoposide was shown to be ineffective at 
increasing the levels of mutant p53 mRNA in cancer cells, however, other 
anthracyclines including doxorubicin did increase the amounts of mutant p53 in 
the cell (Bug and Dobbelstein, 2011). Using siRNA to reduce the levels of 
mutant p53 has been shown to increase the  chemosensitivity of cell lines (Bug 
and Dobbelstein, 2011). Conversely it has been shown that doxorubicin induces 
more cell death in p53 negative tumours (Manna et al., 2011) and was less 
cytotoxic on human neuroblastoma cells expressing wild type p53, whilst in cells 
that either did not express, or expressed mutated p53, it induced transduction of 
p21 (Vikhanskaya et al., 1995).  
 
The impact of cancer chemotherapy on mutant p53 levels is not well 
understood, however it has been shown that doxorubicin, as well as other 
anthracyclines, can increase the amount of mutant p53 protein in cancer cells 
(Bug and Dobbelstein, 2011). Doxorubicin can also lead to stabilisation and 
accumulation of wild type p53 (Shah and El-Deiry, 2004). As well as inducing 
the p53 response element, doxorubicin can also activate the p21 gene and thus 
the response element. In vivo, 20mg/kg of doxorubicin was shown to increase 
the expression levels of p21 in a transgenic mouse line (expressing firefly 
luciferase under control of the p21 gene) 24 hours following treatment (Ohtani 
et al., 2007).  
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As well as being a downstream effecter of the p53 gene, it was determined that 
p21 also possessed the ability to suppress tumour cell growth in culture 
irrelevant of p53 and that novel drugs could act through activation of the p21 
gene whilst bypassing the p53 gene (el-Deiry et al., 1993). Both p53-dependent 
and –independent mechanisms for p21 up-regulation were put forward in the 
mid 1990s (Johnson et al., 1994; Li et al., 1994; Michieli et al., 1994; 
Vikhanskaya et al., 1995) with some emphasis on the regulation on p21 by 
TGF-β (Datto et al., 1995; Elbendary et al., 1994). 
 
One class of molecular targeted therapeutics which is now demonstrating 
clinical efficacy are the HDACs. Unlike conventional chemotherapeutics, such 
as doxorubicin, it is now clear that the HDACs can induce p21 in a p53-
independent manner (Richon et al., 2000). Mechanistically, HDACs catalyse the 
removal of acetyl groups from lysine residues of core nucleosomal histones, are 
involved in chromatin remodelling and thus are important for the regulation of 
gene expression through transcriptional repression (Huang, 2006; Richon et al., 
2000). The increase in expression of the p21 protein caused by HDAC-
inhibitors, linked to an increase in transcription of the gene (Richon et al., 2000), 
leads to growth inhibition, cell cycle arrest, cell differentiation and apoptosis 
(Huang, 2006).  
 
Being able to distinguish between the mechanisms of action of novel drugs that 
target the p21 and/or the p53 pathway in a noninvasive in vivo model would be 
valuable for preclinical testing and could indicate that a putative therapeutic was 
working via the expected cellular mechanisms. 
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2.1.4 Preclinical tumour models of colorectal cancer 
Colorectal cancer is the 3rd most common cancer in the UK and the 2nd largest 
cause of mortality (CRUK, 2008). Over recent years treatment for colorectal 
cancer has improved but there is still an urgent need for improved therapeutics, 
as outlined in section 1.6. One of the major hurdles to identification of new 
therapeutics for colorectal cancer is the deficiencies in representative preclinical 
models. Although there are now a few orthotopic models of colorectal cancer, 
the majority of preclinical screening is still undertaken in subcutaneous models 
of colorectal cancer. The main reasons for this are the current inability to either 
monitor tumour volume from an orthotopic site, the prohibitively large number of 
mice required for such studies, and a lack of predictive or indicative 
pharmacodynamic markers of tumour response.  
 
Accordingly there remains a need for improved orthotopic and metastatic 
models of this disease that could be used to more accurately represent human 
malignancy. Furthermore, different patients exhibit discrete geno- and 
phenotypes of colorectal cancer, which manifest themselves as differences in 
aggressiveness, metastatic potential and cell surface markers, among other 
things. Therefore, preclinical colorectal tumour models are required to also give 
a more diverse and picture of the effect of different type of therapeutic agents 
on the disease and whether they react differently to specific cytotoxic therapies, 
including resistance. 
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In light of these requirements, a panel of human colorectal cancer cell lines with 
various pathophysiological characteristics were chosen for development within 
this project (table 2.1). 
 
Table 2.1 – Cell line information  
Cell line Genotype Background p53 expression 
DLD-1 Pseudodiploid 
(46 occur in 86% 
chromosomes)* 
45 yr Caucasian. ♂ 
Adenocarcinoma 
Sigmoid colon 
Duke‟s C
‡
 
Poor differentiation
†
 
+ve 
Mut. C→T 
241 Ser→Phe* 
LS174T 45, X* 
No other aberrations* 
58yr Caucasian ♀ 
Adenocarcinoma 
Epithelium derived 
Duke‟s B
‡‡ 
Well differentiated
†
 
+ mRNA* 
- Antigen* 
Colo205 Stemline hypertriploid 
Other chromosomes 
present in monosomic, 
disomic and trisomic 
condition although most 
monosomic* 
70yr Caucasian ♂ 
Ascites derived 
1° = epithelial colon 
5-FU treated 
Duke‟s D*
+
 
+ve  
Mut. G→A 
266 Gly→Glu** 
HT-29 Stemline hypertriploid 
modal number = 71; range 
= 68 to 72* 
44yr Caucasian ♀* 
Epithelial colorectal 
adenocarcinoma* 
Antigen 
overproduced* 
Mut. G→A 
273 Arg→His* 
* (LGC/ATCC, 2011), † (Tsuiji et al., 1998), ‡(Dexter et al., 1981), ‡‡ (Tom et al., 1976), 
+(Semple et al., 1978), ** (O'Connor et al., 1997) 
 
 
 
2.1.4.1 Cell line tumourgenicity in nude mice  
DLD-1 cells are tumourigenic in nude mice (Dexter et al., 1979) and have been 
shown to exhibit good vascularisation in subcutaneous xenograft models 
(Shnyder et al., 2007). They have been used extensively in subcutaneous 
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models and are commonly used to set up metastatic models including injection 
into the spleen to create liver metastases (Jiang et al., 2011; Kato et al., 2004). 
They have also been used to set up orthotopic models, which occasionally 
exhibit spontaneous metastasis, depending on the method used to set up the 
model (Cespedes et al., 2007; Tsutsumi et al., 2009). 
 
LS174T, although less commonly used than DLD-1, cells have been used to 
successfully establish subcutaneous, orthotopic and metastatic models (Bading 
et al., 2008; Bhullar et al., 2011; Fidarova et al., 2008; Kalber et al., 2008; Lisy 
et al., 2008; Sakuma et al., 2010). 
 
Colo205 cells have been used in a variety of nude mouse models including 
subcutaneous (Golas et al., 2005; Motani et al., 2010; Vangestel et al., 2010; 
Yamaguchi et al., 2011), where they lead to well differentiated 
adenocarcinomas with no invasion into the surrounding tissue (Ghoul et al., 
2009). However, few studies have used Colo205 in metastatic or orthotopic 
models, with the exception of a recent study where Colo205 luciferase 
expressing cells were injected via the tail vein, however overall survival 
following treatment, rather than dissemination patterns and tumour growth were 
reported as end points in this case (Sawada et al., 2011).  
 
During the project HT29-CMV-luc (Caliper LS) were also used for some in vivo 
work. This was to compare the suitability of transfected cell lines that could be 
bought from imaging companies to the cell lines that were created in house. 
The Firefly luciferase stably transfected into the HT-29 cell line is under control 
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of the CMV promoter and Caliper LS report that the in vitro and in vivo growth of 
the cell line appears to be slower than that of the parental cell line (CaliperLS, 
2011). This cell line was chosen as it was the same cancer type as the three 
cell lines primarily being used in the project. 
2.1.5 Aims and Objectives 
The overall aim of this project was to develop in vivo tumour models with the 
ability to demonstrate drug pharmacodynamics and report drug target 
interactions non-invasively. Use of such models will permit observation of drug-
target interactions over time (rather than the „snap-shot‟ view currently 
available), interrogation of in vivo pharmacological mechanism of action, non-
invasive investigation of both sub-tumoural distribution and temporal drug-target 
interaction and ultimately proof-of-principle.  
 
The specific objectives were to modulate human colorectal cancer cell lines to 
express reporter proteins, both constitutively and pharmacologically activated. 
Initially cell lines incorporating fluorescent reporter cell lines were developed to 
optimise the methods being used, followed by luciferase expressing cell lines 
that constitutively expressed luciferase, under control of the simian virus-40 
(SV) promoter; SVFluc and SVRluc. Finally the promoter driven p53Fluc and 
p21Rluc cell lines were created to allow investigation into drug mechanisms of 
action. Proof of concept for these cell lines was demonstrated in vitro, with 
successful models being used to assess drug effects in both s.c and 
orthotopically transplanted in vivo tumour models.   
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2.2 Materials and Methods 
2.2.1 Molecular Biology – Bacteria and Plasmids 
2.2.1.1 Transformation and plasmid isolation 
All plasmids were obtained from Promega unless otherwise stated and all 
restriction enzymes were purchased from New England Biolabs (NEB). 
Transformation of E.Coli (either JM109 or JM110, Stratagene, UK) cells using 
the manufacturers‟ protocol was performed as follows: Briefly, competent cells 
were incubated for 10 minutes on ice with beta-mercapto-ethanol before 
addition of approximately 50ng of plasmid DNA and further incubation for 30 
minutes on ice. The cells were then heat-shocked for 45 seconds at 42°C and 
rapidly cooled on ice for 2 minutes before adding 1ml of SOC media and 
incubating with shaking at 37°C for 1-2 hours. The cells were then plated out on 
1.5% LB-Agar containing the relevant antibiotic (ampicillin at 50µg/ml or 
kanamycin at 10µg/ml) and incubated overnight at 37°C. A negative (no 
plasmid) and a positive control (Puc10) were produced in parallel. Colonies 
were picked using a sterile pipette tip and grown overnight in 10ml LB broth, 
again containing the relevant antibiotic.  
 
Plasmid DNA extraction was performed using a QIAfilter Plasmid Midi Kit 
(QIAGEN, UK) as per manufacturers‟ instructions. Briefly, bacteria cells were 
harvested by centrifugation at 5500g for 15 minutes at 4°C. The resulting pellet 
was resuspended in 4ml of resuspension buffer (50mM Tris-HCl, pH8.0; 10mM 
EDTA; 100µg/ml RNAse A) and mixed by pipetting and vortexing to create 
alkaline lysates. 4ml of lysis buffer (200mM NaOH, 1% SDS (w/v)) was added, 
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mixed by inversion and incubated at room temperature for 5 minutes. 4ml of 
pre-chilled neutralisation buffer (3M potassium acetate, pH 5.5) was added, 
gently mixed by inversion, incubated at room temperature for 10 minutes and 
then filtered using a QIAfilter (midi) (QIAGEN, UK). The resulting filtrate was 
poured into a Qiagen-tip (midi) containing Anion-Exchange Resin (QIAGEN, 
UK) (previously equilibrated using equilibration buffer, 750mM NaCl; 50mM 
MOPS, pH 7; 15% isopropanol (v/v); 0.15 Triton X-100 (v/v)). After the lysate 
flowed through, the Qiagen-tip was washed twice with 10ml wash buffer (1M 
NaCl; 50mM MOPS, pH 7; 15% isopropanol (v/v)) and the resulting wash 
fractions were discarded. The plasmid DNA was finally eluted from the resin by 
the addition of 5ml of elution buffer (1.25M NaCl; 50mM Tris-HCl, pH8.5; 15% 
isopropanol (v/v)). 
 
Plasmid DNA was precipitated by the addition of 3.5ml isopropanol and 
centrifugation at 15000g for 30 minutes at 4°C. The resulting pellets were 
washed with 70% ethanol, centrifuged at 15000g for 10 minutes at 4°C, air-
dried for 10 minutes and then dissolved in dH2O. Concentration of plasmid DNA 
samples was ascertained by measuring the absorbance at 260nm, whereby an 
absorbance of 1.0 is equivalent to 50μg/ml (Warburg and Christian, 1942). 
Plasmid DNA samples were stored at -20°C. 
 
DNA integrity was assessed by electrophoresis. 10µl of DNA sample was mixed 
with 2μl loading dye (30% glycerol, 0.25% bromophenol blue) and loaded 
alongside a 1kb Plus DNA Ladder (Invitrogen Ltd, UK) onto a 0.5% TBE gel 
containing 0.01% ethidium bromide. Electrophoresis was run at 120-150V for 2 
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hours. DNA was visualised by ultra violet illumination on a BioRad Molecular 
Imager® FX (BioRad, UK). Gel images were analysed using Quantity One 1-D 
Analysis Software (BioRad, UK). 
2.2.1.2 Restriction digests 
Restriction digests of the host plasmid and construct containing the insert was 
undertaken using the appropriate restriction enzyme(s) and the reaction was set 
up with 5µg plasmid, 1 unit of the appropriate restriction enzyme, 10% enzyme 
buffer, 10% BSA (if required) and made up to 40µl final volume with dH2O. 
Incubation was at 37°C for 1.5 – 2 hours depending on the restriction enzymes 
being used.  
2.2.1.3 Gel separation and extraction of plasmid DNA 
Following digestion, DNA was separated through a 1% agarose gel at 100V for 
1-2 hours, the required bands cut out of the gel and the DNA was extracted 
from agarose gel using a QIAquick® Spin Kit (QIAGEN, UK) as per 
manufacturers‟ instructions. Briefly, the gel slice was resuspended in 100µl of 
Buffer QG (solubilisation and binding buffer, QIAGEN, UK). The mixture was 
vortexed and then incubated at 50°C for 10 minutes in a water bath with 
continued vortexing every 2 minutes during the incubation. After the gel had 
completely dissolved, an equal volume of isopropanol was added and the 
solution was applied to a QIAquick column and centrifuged at 18000g for 1 
minute at room temperature. 0.5ml Buffer QG was added to the QIAquick 
column, which was then centrifuged again at 18000g for 1 minute at room 
temperature. The column was washed by the addition of 750µl of Buffer PE 
(QIAGEN, UK), which was then allowed to stand for 5 minutes before 
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centrifugation at 18000g for 1 minute at room temperature. After discarding the 
flow through, the QIAquick column was spun again at 18000g for 1 minute at 
room temperature to remove any residual Buffer PE. The DNA was eluted by 
the addition of 30µl dH2O to the column, incubation for 1 minute and 
centrifugation at 18000g for 1 minute at room temperature. The eluted DNA was 
stored at -20°C. 
2.2.1.4 Ligation 
The gene insert containing the appropriate compatible DNA overhangs or blunt 
ends was ligated into the vector using the T4 DNA Ligase kit (NEB). Briefly, 
50ng of vector was combined with a 3-fold molar excess of insert and adjusted 
to a final volume of 10μl with dH2O. 10μl of 2X Quick Ligation Buffer and 1µl of 
Quick T4 DNA Ligase were added, mixing after each. The reaction was then 
centrifuged briefly and incubated at room temperature for 5 minutes.  
2.2.1.5 5‟ Phosphate terminal removal  
To prevent re-ligation during construction of the p21Rluc plasmid, calf intestinal 
alkaline phosphatase (CIP) (NEB) was used to remove the 5‟ phosphate 
terminal of the WWP-luc sticky ends that were left following initial enzyme 
digestion of the two plasmids, preventing self-ligation. Heat inactivation (65°C 
for 20 minutes) immediately following the enzyme digests was followed by 
addition of CIP at a 0.5/1 ratio (CIP units/µg of vector). The mixture was then 
heated at 37°C for 1 hour before the sample was run on a 1% agarose gel as 
previously described.  
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2.2.1.6 Determining DNA purity and concentration 
DNA content and purity was ascertained using a spectrophotometer (Cary 50 
Bio UV- Visible spectrophotometer, Varian Ltd, UK) and quartz cuvettes. The 
absorbance was read at 260nm and 280nm with the 260nm reading used to 
calculate the DNA content of the sample and the ratio of the two readings to 
calculate the presence of protein contamination. A ratio ≥1.8 was indicative of 
good quality DNA extraction.  
2.2.2 Specific Construct Information 
2.2.2.1 SVFluc 
The SVFluc plasmid was created by insertion of the 0.7kb promoter fragment 
from the pGL4.13[luc2/SV40] vector into the SpeI/HindIII site of the 
pGL4.17[luc2/Neo] vector. Checks to confirm positive insertion were performed 
using the HindIII and BamHI restriction enzymes, which cut the plasmid at the 
points shown in figure 2.1.   
 
 
 
 
Figure 2.1 – Restriction map of SVFluc indicating the insertion sites (SpeI and HindIII) as well 
as the confirmation digests sites (HindIII and BamHI). The expected band widths from the 
confirmation digests are presented in figure 2.5. 
 
 
 
2.2.2.2 SVRluc 
The SVRluc plasmid was created by insertion of the 0.7kb promoter fragment 
from the pGL4.13[luc2/SV40] vector into the SpeI/HindIII site of the 
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pGL4.82[hRluc/Puro] vector. Checks to confirm that the fragment was inserted 
correctly were done using the HpaI and NheI restriction enzymes, at the points 
marked on figure 2.2. 
 
 
 
 
 
Figure 2.2 – Restriction map of SVRluc indicating the insertion sites (SpeI and HindIII) as well 
as the confirmation digests sites (HpaI and NheI). The expected band widths from the 
confirmation digests are presented in figure 2.5. 
 
2.2.2.3 p53Fluc 
The p53Fluc plasmid was created by inserting the pp53 section (flanked by 
NheI and BamHI) of the pp53-EGFP vector (BD Biosciences, UK) into the 
NheI/BglII site of the GL4.17 vector (figure 2.3). The BglII and BamHI restriction 
enzymes leave compatible sticky ends following digestion. The insertion was 
confirmed using the HindIII restriction enzyme that cuts at either end of the 
inserted motif.  
 
 
 
 
 
 
Figure 2.3 – Restriction map of p53Fluc indicating the insertion sites (NheI, BglII and BamHI) as 
well as the confirmation digests sites (HindIII). The expected band widths from the confirmation 
digests are presented in figure 2.5. 
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2.2.2.4 p21Rluc 
The p21Rluc plasmid (figure 2.4) was created by inserting the p21/WAF1 
section of the WWP-luc vector (Addgene plasmid 16451, Addgene, UK) into the 
HindIII restriction site of the GL4.82 vector and confirmed using the combination 
of PstI and SacI enzymes, the resulting bands of which would confirm entry of 
the fragment in the correct orientation.  
 
 
 
 
 
 
Figure 2.4 – Restriction map of p53Fluc indicating the insertion sites (NheI, BglII and BamHI) as 
well as the confirmation digests sites (HindIII). The expected band widths from the confirmation 
digests are presented in figure 2.5. 
 
2.2.3 In Vitro reporter cell line construction and characterisation 
2.2.3.1 Materials and Cells  
The human colorectal adenocarcinoma cell lines DLD-1, LS174T and Colo205 
were purchased from ECACC (Salisbury, UK). The human epithelial colorectal 
cell line HT29-Luc, stably transfected with Firefly luciferase under control of the 
CMV promoter was purchased from Caliper Life Sciences (Runcorn, Cheshire, 
UK). Cells not genetically modified are termed „wild type‟ (w.t). All plasticware 
was purchased from Corning (Amsterdam, The Netherlands). Cell culture 
medium and supplements including foetal calf serum, L-Glutamine, sodium 
pyruvate, Hanks Balanced Salt Solution, trypsin/EDTA and Non-essential amino 
HindIII HindIII 
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acids were bought from Sigma Aldrich (Gillingham, UK). G418 was from 
Invitrogen (Paisley, UK) and Puromycin from Sigma-Aldrich. A stock solution of 
Coelenterazine (CET) was made at 1mg/ml in methanol and stored at -20°C. 
For in vitro work the working concentration was 15μg/ml. D-luciferin potassium 
salt was dissolved in dH2O to a stock concentration of 30 mg/ml, which was 
further dissolved 1:2 (15mg/ml) in complete medium prior to use. The working 
concentration required was 1:200 i.e. 150μg/ml, so further dilutions were 
performed as necessary in media appropriate for the cell type being assayed. 
2.2.3.2 Plasmids 
The pCMV-dsRed-Express (pCMVdsRed) plasmid was bought from BD 
Biosciences (Oxford, UK). The remaining 4 plasmids used (SVFluc, SVRluc, 
p53Fluc and p21Rluc) were constructed as described previously in this chapter.  
2.2.3.3 Cell culture 
Cells were grown on plastic tissue cultureware and maintained in RPMI-1640 
(DLD-1, Colo205 and HT29-luc) or Modified Essential Medium Eagles 
(LS174T). RPMI was supplemented with 10% foetal calf serum (FCS), 2mM L-
glutamine and 2.5mM pyruvate whilst MEME was supplemented with 10% FCS, 
2mM L-glutamine and 5mls of 100x MEM non-essential amino acids. Cells were 
cultured in T75 flasks at 37°C in a 5% CO2 atmosphere. The cells were 
maintained by passage when they reached 70-90% confluence.  
 
For passage, adherent cells were washed with Hanks Balanced Salt Solution 
(HBSS) before harvesting using 0.25% Trypsin/EDTA and incubation for 2-5 
minutes (depending on cell line) at 37°C until the cells had become detached 
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from the flask. The appropriate media was added to block further action of the 
trypsin/EDTA before the cells were centrifuged for 5 minutes at 1500g. 
Supernatant was discarded and the cells resuspended in the required amount 
of medium and re-passaged. 
2.2.3.4 Determining the optimum antibiotic concentrations for stable 
transfection 
To determine the appropriate antibiotic concentration to select mammalian cells 
expressing the required plasmid DNA, kill curves were set up for each cell line. 
Briefly, wild type cells were diluted to 5 x 105 cells/ml and 1ml seeded in each 
well of a 24 well plate. A range of concentrations of the antibiotic being tested 
were added to the plate in triplicate, leaving control wells where no antibiotic 
was added. Cells were observed and their condition noted over 4-5 days. For 
Puromycin the selection concentration that results in total cell death between 1 
and 4 days after addition of the antibiotic is the optimal concentration for 
generating stable transfectants (OpenBiosystems, 2011), whilst 3-4 days is the 
ideal time for G418 (SSOM, 2000). This protocol was performed for both G418 
and Puromycin for all cell lines (DLD-1, LS174T and Colo205).  
2.2.3.5 Transfection methods 
ExGen 500 – In vitro transfection of adherent cells in a 6-well plate 
ExGen 500 was purchased from Fermentas (York, UK). Cells were passaged 
using the regular protocol and 1.5 x 105 cells were seeded in each well of a 6 
well plate (2mls total). 3µg of DNA was diluted in 200µl of 150mM NaCl, 
vortexed gently and spun down. Optimisation of the protocol was performed by 
adding a range of ExGen 500 quantities (representing 5, 6 and 7 equivalents of 
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nitrogen to DNA ratios) before vortex-mixing the solution and incubation at room 
temperature for 10 minutes. The required amount of ExGen 500 depends on the 
amount of DNA and the number of equivalents needed, where 1 equivalent is 
the amount required to neutralise the negative charges of the DNA phosphate 
groups (Fermentas, 2009). 200µl of ExGen 500/DNA solution was added to 
each well of the 6-well plate. This is equivalent to 10% of the total volume 
already in the well (recommended). The plate was gently rocked back and forth 
to achieve an even distribution of the ExGen 500/DNA complexes, before being 
incubated at 37°C for 48 hours. Fresh cell culture medium was applied and cells 
were allowed to recover prior to selection of stably expressing clones as 
described in section 2.2.4. 
 
Electroporation 
Briefly, cells were allowed to grow until 70% confluent then 1x107cells /ml were 
harvested in serum-free media. 400μl of this solution was pipetted into a 2mm 
micro-cuvette (Bio-Rad, Hemel Hempstead, UK) on ice. Cells were transfected 
with approximately 15µg of the appropriate reporter plasmid using 
electroporation. The appropriate parameters were set on the BioRad Gene 
Pulser XCell (Hemel Hempstead, UK); preliminary investigations were used to 
determine the optimum parameters for each cell line.  
 
Following optimisation DLD-1 cells were transfected using an exponential 
electric pulse method with a high (1000) capacitance value at 250V whilst 
LS174T cells had a better transfection rate with a pulsed field method, using a 
single 10ms square wave of at 200V. 
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2.2.4 Cloning 
Cells were maintained for up to three weeks in the appropriate antibiotic before 
undergoing selection for highly expressing cells. Single cell clones were 
selected using one of two methods; ring cloning using a Petri dish or dilution 
cloning using a 96 well plate. In both cases cells were diluted to give 1cell/100μl 
before being seeded. 
2.2.4.1 Ring Cloning  
Colonies were allowed to form and for both methods described colonies were 
removed from plastic-ware using 0.25% trypsin/EDTA. Cells were counted and 
diluted to 1cell/100µl. 15mls were poured into a 10cm Petri-dish, which was 
enough to cover the base. Cells were allowed to establish until colonies were 
seen forming (usually around 2 weeks). Media was removed for the dish and 
the cells washed with HBSS. Wells (cut off pipette tips) were placed over 
individual colonies using high vacuum grease (Dow Corning GmbH, 
Wiesbaden, Germany) and trypsin/EDTA solution was added to the well. The 
Petri-dishes were incubated for 5-10 minutes at 37°C before the trypsin was 
gently agitated using a pipette. The cells were removed from the well, and half 
were re-seeded between two 24 well plates so that analysis for luciferase 
expression could be performed without the risk of infection. Cells were allowed 
to grow to 70-90% confluence before they were analysed for expression of 
luciferase. 
2.2.4.2 Dilution cloning 
As for ring cloning cells were diluted to 1 cell/100µl. 100µl of the cell suspension 
was placed into each well of a 96 well plate and cells were allowed to adhere 
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overnight. Wells that contained 1 cell were noted the following day so colonies 
that grew in those wells would be known to be from a single clone, which was 
important to generate a stably expressing cell population. When a reasonable 
number of cells were present in the well the cells were split between two 24 well 
plates and allowed to proliferate till they were 70-90% confluent before analysis 
for luciferase expression.  
2.2.5 Selection of stably expressing clones 
One plate of the two 24 well plates was used for choosing positive clones. For 
the SVFluc/Rluc cell lines D-luciferin or CET were added respectively. For the 
SVRluc cells media was removed and replaced with 100µl of fresh media 
containing 5µg of CET (50µg/ml). This was later dropped to 1.5µg (15µg/ml) 
which was adequate for comparing the expression of different clones. For the 
SVFluc cells 300µg D-luciferin was added to 100µl of media (3mg/ml). Cells 
were immediately imaged in the IVIS 50 for a 1 minute exposure. The wells that 
showed the highest relative luminescent units (RLU) (see section 2.2.8) were 
deemed to be the most highly expressing cells and were chosen as the clone to 
take through into further in vitro and in vivo work.  
2.2.6 In Vitro characterisation of mammalian cancer cell lines 
2.2.6.1 Growth curves 
Cells were seeded at concentrations ranging from 0.2x104/ml - 1x104/ml in T25 
flasks in triplicate. At varying time points depending on cell type and speed of 
proliferation, flasks were trypsinised and cells counted.  
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2.2.6.2 Cell chemosensitivity assays 
Chemosensitivity was assessed using a standard MTT assay (Carmichael et al., 
1987; Jabbar et al., 1989). Briefly, DLD-1, Colo205 and LS174T cells and all 
their transfected daughter cell lines were incubated for 96 hours with various 
concentrations of doxorubicin (Dox), cisplatin (Cis), azademethylcolchicine 
(ICT-2552) or trichostatin A in standard complete medium. 3-(4,5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) in RPMI was 
added to the cells at a concentration of 0.5mg/ml. The cells plus MTT were then 
incubated for 4 hours at 37°C before the supernatant was removed and 
replaced with 150μl DMSO, which dissolved the formazan crystals that had 
formed. Absorbance was measured on a microplate reader at 540nm. 
Cytotoxicity was expressed as an IC50 value which is the concentration of drug 
required to reduce cell survival by 50%. 
2.2.6.3 Serial Dilutions 
Serial dilutions were performed on the pCMVdsRed, SVFluc and SVRluc cells. 
Cells were trypsinised as usual and diluted to concentrations ranging from 1 x 
107/ml to 1 x 103/ml. The cells were seeded on a 96 well plate in triplicate. For 
BLI the relevant substrate (either CET or D-luciferin) was applied and cells 
imaged on the IVIS 50 for 1 minute.  
2.2.6.4 Cross-reactivity of the substrates 
Cross reactivity of the two substrates being used was checked simply by plating 
Fluc- and Rluc- expressing cells in a 24 well plate and adding the “non-reacting” 
substrate at the appropriate concentration to each of the cultures before 
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imaging. I.e. coelenterazine was added to Fluc cells and D-luciferin was added 
to Rluc cells to ensure that there was no cross-reactivity. 
2.2.6.5 In vitro drug exposure studies 
DLD-1/SVFluc, /p53Fluc or p21Rluc cells were seeded on a 96 well plate at 5 x 
106/ml and allowed to adhere. Doxorubicin or trichostatin A were added at 
various concentrations and for varying lengths of time. The cells were imaged 
following addition of the appropriate substrate and the signal emitted from 
treated cells was analysed with respect to the drug concentration and the time 
that the cells were exposed for. Control wells received no drug and were 
imaged at the same time. 
2.2.7 Image acquisition (in vitro and in vivo) 
Acquisition and analysis of images on the IVIS 50 were made using Living 
Image Software, version 3.0 (Caliper LS). For acquisition of bioluminescent 
images the following parameters were used: medium binning, f/Stop = 1, 
excitation filter blocked and emission filter open. The field of view was 
constantly set at „D‟ (12cm) which was suitable for obtaining in vitro and in vivo 
images. Subject height was set at 1.5cm. For acquisition of fluorescent images 
the following parameters were used: Medium binning, f/stop = 2, excitation and 
emission filters set to dsRed (558/583nm respectively), high lamp level with 
filter block. Field of view and subject height were „D‟ and 1.5cm respectively. A 
150-watt quartz tungsten halogen (QTH) lamp with a dichroic reflector provides 
light for fluorescence excitation. For both luminescent and fluorescent subjects 
images were acquired over 1 minute. 
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2.2.8 Data analysis  
For analysis of images obtained for IVIS imaging all data was normalised to 1 
minute (the majority of images had been acquired over this time period so 
normalisation was rarely required). For both in vitro and in vivo image 
acquisition, regions of interest (ROIs) were highlighted manually using Living 
Image 3.0 software. The parameter used for quantification of bioluminescent 
light detected was „relative luminescent units‟ (RLU) or „total counts‟, which is 
equal to the sum of all counts for all pixels inside the ROI and is proportional to 
the number of photons detected in one pixel. For fluorescent light detection 
„total counts‟ (which is relative to the number of photons detected in a pixel) 
were used. Data analysis was performed in Excel (Microsoft Office 2007) and 
graphs were created in SigmaPlot (version 8.0, Systat Software Inc., Chicago, 
IL).  
 
Comparisons in proliferation and chemosensitivity between cell lines were made 
using t-tests. Regression analysis was performed to analyse the relationship 
between light emission and cell number. In all cases significance was 
determined by a p-value of <0.05.   
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2.3 Results 
2.3.1 Restriction digests to confirm the identity of the new vectors 
Restriction enzyme digests resulted in the creation of 2 plasmid fragments for 
each the SVFluc, SVRluc and p53Fluc constructs: SVFluc 4.1kb and 1.9kb, 
SVRluc 3.5kb and 1.6kb, p53Fluc 5.3kb and 1.2kb (figure 2.5A-C). Due to the 
use of HindIII alone for linearization the p21 promoter, in theory this meant the 
fragment could insert in either direction. The use of a third restriction enzyme 
confirmed the correct orientation of all factors, with bands of 3.4kb, 2.05kb, 
1.1kb and 130bp (figure 2.5D).  
 
 
                                             
 
 
 
 
 
 
Figure 2.5 – Confirmation of the expected band widths of (A) SVFluc digested with 
HindIII and BamHI, (B) SVRluc digested with HpaI and NheI, (C) p53Fluc digested 
with HindIII and (D) p21Rluc digested with PstI and SacI. M1 = 1kb DNA ladder (NEB, 
UK), M2 = 100bp DNA ladder (NEB, UK). All digests ran in lane 1 (L1) of the gel. 
Refer to figures 2.1-4 for restriction maps 
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2.3.2 Optimising transfection methodology for colorectal cell lines 
Electroporation and lipid-based, ExGen 500, transfection were both utilised to 
incorporate the SVRluc plasmid into DLD1 cells. Low level luciferase activity 
was observed in cells with ExGen 500, with the manufacturers‟ “optimum” 
concentration resulting in a higher signal (figure 2.6). Using a square 
electroporation voltage resulted in low level transfection (1x105 RLU). In 
contrast, using an exponential electroporation voltage gave high levels of 
luciferase activity (4x105 RLU) (figure 2.6). As a result, all further DLD-1 
transfections were performed using the square wave protocol.  
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Figure 2.6 –Efficiencies of electroporation and ExGen 500 to transfect DLD-1 cells with the 
SVRluc plasmid. The graphs show values normalised to background values. ExGen 1-3 
represent ExGen 500 used at 5-7 equivalents respectively. Electroporation 1 was an 
exponential wave, 250V, ∞ resistance and 1000 capacitance. Electroporation 2 was a square 
wave, 250V, 1 pulse, 10ms. “Elec1” gave the highest transfection efficiency 
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LS174T cells were transfected with pCMVdsRed using a variety of 
electroporation parameters: 1) 160V, 500 capacitance, exponential wave, 2) 
155V, 1000 capacitance, exponential wave, 3) 100V, 25ms pulse, square wave. 
The highest fluorescence percentage following initial selection using G418 was 
number 3 (data not shown), so this was chosen as the generic protocol for 
transfection of these cells.  
 
Colo205 cells were initially transfected using 1) an exponential wave, 250V, 
1000 capacitance protocol, and 2) a square wave, 200V, 25ms, single pulse 
protocol. The exponential protocol was chosen as the total counts value was 
around 10-fold higher in cells transfected using this method compared to those 
cells transfected using the square wave protocol (p<0.05), shown in figure 2.7.  
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Figure 2.7 –The transfection efficiency of Colo205 cells using the SVFluc plasmid. The 
Exponential protocol was superior to the square wave protocol I.e. 250V, 1000 capacitance,∞ 
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2.3.3 Determining the optimum concentration for stable transfection of 
cell lines with Geneticin (G418) and Puromycin  
LS174T, DLD-1 and Colo205 cells were seeded at 8 x 104, 5 x 104 and 5 x 
104cells/ml respectively and allowed to adhere overnight. Puromycin was added 
at concentrations ranging between 2µg/ml and 10µg/ml whilst G418 was added 
at concentrations ranging from 500µg/ml to 1300µg/ml. Figures 2.8-2.9 show 
percent cell death at various time points ranging from 1-5 days.  
 
Figures 2.8 and 2.9 indicate that optimum concentrations of antibiotic for 
selection in each cell line were slightly different. LS174T appeared to be highly 
resistant to G418, as 100% cell kill was only achieved at day 5 with 1300μg/ml 
of the antibiotic. The most suitable selection concentration of G418 for DLD-1 
and Colo205 cells was 1000μg/ml and 700μg/ml respectively, whilst for LS174T 
1300µg/ml was used. For puromycin the optimal selection concentrations were 
6μg/ml (LS174T and DLD-1) and 4μg/ml (Colo205).  
 
2.3.4 Comparing in vitro proliferation of parental and transfected cell 
lines 
Growth kinetics of cell lines were analysed in order to assess the effect of stable 
expression of reporter constructs. Cell counts revealed no marked difference in 
cell line proliferation in transfected compared to parental cell lines (p<0.05; 
figure 2.10). All cell lines entered the exponential growth phase and plateau 
phase at the same time (figure 2.10).  
74 
 
      Day
1 3 4 5
%
 C
e
ll 
K
ill
0
20
40
60
80
100
 
      Day
1 3 4 5
%
 C
e
ll 
K
ill
0
20
40
60
80
100
 
      
Day1 2 3 4
%
 C
e
lll
 K
ill
0
20
40
60
80
100
120
 
Figure 2.8 – G418 Kill curves (A) LS174T (B) DLD-1 (C) Colo205 w.t. Arrows indicate the ideal 
day where 100% cell death should occur and the lowest concentration that achieved this was 
selected  
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Figure 2.9 – Puromycin kill curves (A) LS174T (B) DLD-1 (C) Colo205. Arrows indicate the ideal 
day where 100% cell death should occur and the lowest concentration that achieved this was 
selected  
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Figure 2.10 – Cell growth curves. Graphs confirm the similarity of cell proliferation between w.t 
and transfected cells in all three cell types (A) LS174T (B) DLD-1 and (C) Colo205 
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2.3.5 In vitro chemosensitivity testing 
Figures 2.11 - 2.14 indicate the viability of DLD-1, LS174T and Colo205 
transfectants respectively treated with a range of concentrations of doxorubicin, 
cisplatin and ICT-2552. Figure 2.15 indicates the viability of DLD-1 and LS174T 
treated with trichostatin A. DLD-1 w.t and transfectants showed no significant 
differences when exposed to doxorubicin; however there were differences 
between the strains when they were treated with cisplatin (although again these 
differences were not significant compared to wild type), where the SVRluc strain 
had an IC50 value (table 2.2) of 0.96μM compared to a value of 4.67μM for the 
p53Fluc strain. The SV40 strains (Fluc and Rluc) were more sensitive to ICT-
2552 and had lower IC50 values than the p53Fluc strain. DLD-1 w.t had the 
highest IC50 value when treated with ICT-2552. LS174T w.t and SVRluc cells 
treated with doxorubicin had similar IC50 values of around 0.1μM whereas 
SVFluc cells had an IC50 of 0.68, which was slightly higher. Colo205 w.t and 
SVFluc cells had very similar IC50 values with all 3 drugs, and appeared much 
more resistant to Cisplatin, where the IC50 values were over 30µM.  
 
Table 2.2 – IC50 values of all drugs tested on cell lines 
 
  IC50 value (µM) 
Parent cell line Transfection status  Doxorubicin Cisplatin Trichostatin A ICT-2552 
DLD-1 w.t 0.084 2.07 0.17 0.1 
 SVFluc 0.054 3.0  0.056 
 SVRluc 0.034 0.96  0.05 
 p53Fluc  0.04 4.67  0.087 
LS174T w.t 0.132 0.107 0.388 0.02 
 SVFluc 0.681 0.3  0.02 
 SVRluc 0.092 0.14  0.026 
Colo205 w.t 0.0087 31.86  0.00022 
 SVFluc 0.0097 33.63  0.00024 
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Figure 2.11 – MTT viability assays indicate minimal difference between various DLD-1 
transfectants when treated with doxorubicin (A), cisplatin (B) or ICT-2552 (C) p >0.05 
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Figure 2.12 – MTT viability assays indicate minimal difference between various LS174T 
transfectants when treated with doxorubicin (A), cisplatin (B) or ICT-2552 (C). p>0.05 
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Figure 2.13 – MTT viability assays indicate minimal difference between Colo205 w.t and 
Colo205/SVFluc when treated with doxorubicin (A), cisplatin (B) or ICT-2552 (C). p>0.05 
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Figure 2.14 – MTT assay to determine IC50 values and workable concentrations of trichostatin 
A for the DLD-1 and LS174T cell lines. p>0.05 between cell lines 
 
2.3.6 Assessing cross-reactivity between the luciferase substrates D-
luciferin and coelenterazine 
To show that there was no cross-reactivity between D-luciferin or Renilla and 
CET or Firefly luciferase, DLD-1/p21Rluc and /p53Fluc cells were exposed to D-
luciferin and CET respectively. Neither of these combinations lead to photon 
emission (figure 2.15). 
 
 
Figure 2.15 – Substrates do not show cross-reactivity. p21Rluc + D-luciferin, p53Fluc + CET, 
p21Rluc + CET and p53Fluc + D-luciferin from L→R respectively 
 
p21Rluc + D-luc p53Fluc + CET p21Rluc + CET p53Fluc + D-luc 
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2.3.7 Correlation between cell number and fluorescent output  
In order to determine whether cell number relates to cellular fluorescence, cells 
were plated at varying densities and cell number compared to relative 
fluorescent output. Each well contained 100µl cell suspension. A good 
correlation was observed between cell number and total count values for both 
DLD-1/ and LS174T/pCMVdsRed cells (figure 2.16). This correlation was 
confirmed with R2 values of 0.99 and 0.98 (p<0.05) for DLD-1 and LS174T 
respectively. 
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Figure 2.16 – The relationship between cell number and RLU in pCMVdsRed cell lines A) DLD-
1 and B) LS174T. Cells were seeded from 3 x 10
6
/well to 5 x 10
2
/ml. Both cell lines showed 
good correlation between cell number and fluorescent signal. The images are representative of 
1x10
4
-5x10
6
 cells/ml. Error bars = SEM 
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2.3.8 Correlation between cell number and luminescent output  
As with the fluorescent cell lines, in order to determine whether cell number 
relates to cellular bioluminescence, cells were plated at varying densities (100µl 
cell suspension per well) and cell number compared to light emission following 
substrate administration. 
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Figure 2.17 – The relationship between cell number and RLU in bioluminescent cell lines. A) 
DLD-1/SVFluc imaged on separate occasions over 3 years (2008-2010). Cells were seeded 
from 1 x 10
7
/ml to 1 x 10
4
/ml. R
2 
values were 0.98, 0.998 and 0.99 for 2008, 9 and 10 
respectively (p<0.05) B) DLD-1/Rluc cells. This data was from cells imaged a year after initial 
transfection. R
2 
= 0.94 (p<0.05).Images represent 2008 (A) and all points (B). Error bars = SEM. 
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A good correlation was observed between cell number and light emission for 
both DLD-1/SVFluc and /SVRluc cells (figure 2.17). This correlation was 
confirmed with R2 values of 0.99 and 0.94 (p<0.05) for DLD-1/SVFluc and DLD-
1/SVRluc respectively. Stable transfection of the SVFluc cell line was confirmed 
by imaging the cells over three years and showed that the signal remained very 
high throughout (figure 2.17A). Stable transfection of the SVRluc cell line was 
confirmed as the data used to plot this correlation was collected a year after 
initial transfection of the DLD-1 cell line (figure 2.17B). 
 
Figure 2.18 shows the serial dilution graphs for LS174T/SVFluc and /SVRluc 
cells. The SVFluc cell line maintained high expression over the three years 
following transfection (figure 2.18A) whilst the SVRluc strain had similar RLU 
values in vitro (a maximum of ≈1 x 106) but the correlation was lower. Both cell 
types showed a plateau in the count values when cell number reached 5 x 
105/ml (5 x 104 cells).  
 
Colo205/SVFluc cells showed good correlation (p<0.05) between 
bioluminescent output and cell number (figure 2.19). Maximum RLUs for this 
cell line were in the same order of magnitude as that seen in the DLD-1/SVFluc 
and LS174T/SVFluc lines where cells plated at 1 x106/ml gave an approximate 
count value of 1 x106.  
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Figure 2.18 – The relationship between cell umber and RLU in bioluminescent cell lines A) 
LS174T/SVFluc imaged in 3 consecutive years. R
2
 values are 0.99, 0.99 and 0.97 for 2008, 9 
and 10 respectively. Images are representative of 2010 data. B) LS174T/SVRluc R
2
=0.76. Error 
bars = SEM 
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Figure 2.19 – The relationship between cell number and RLU in Colo205/SVFluc cells. Cells 
were seeded in numbers ranging from 1 x 10
6
 – 5 x 10
3
/ml. R
2
= 0.99. Error bars = SEM. 
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2.3.9 In vitro validation of the effect of doxorubicin and trichostatin A on 
p53- and p21-luciferase expressing cell lines  
2.3.9.1 Evaluation of the induction of luminescence in DLD-1/p53Fluc cells 
exposed to doxorubicin  
DLD-1/SVFluc and DLD-1/p53Fluc cells were exposed to varying doxorubicin 
concentrations for either 7 or 24 hours. The SVFluc cell line showed no change 
in photon output after treatment with doxorubicin (p>0.05) and there was a high 
degree of variability as indicated by the large standard error bars (figure 2.20B). 
Conversely the p53Fluc cell line showed a gradual increase in light emission as 
drug concentration increased, after both 7 and 24 hours exposure (figure 
2.20A): After 24 hours exposure to 3µM doxorubicin there was a significant 
increase in light emission (p<0.05), whist the 3µM treatment for 7 hours led to a 
value that was significantly higher than the non-treated cells (p<0.05). Cells 
imaged at 24 hours gave an overall higher signal than those imaged at 7 hours 
(p<0.05; figure 2.20A). 
2.3.9.2 Evaluation of the induction of luminescence in DLD-1/p21Rluc cells 
exposed to doxorubicin and trichostatin A 
DLD-1/p21Rluc cells were exposed to varying doxorubicin or trichostatin A 
concentrations for a range of time points and concentrations. After 6 hours 
doxorubicin exposure there was an overall increase in photon output in those 
cells treated with 10µM compared to untreated cells (*=p<0.05; figure 2.21A) 
whilst the difference between the two intermediate concentrations (0.1/1μM) 
was not significant. Light emission from cells treated for 24 hours with 0.1µM 
doxorubicin was no different to untreated cells, and was significantly lower than 
those cells exposed to this concentration for 6 hours (p<0.05). 
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Figure 2.20 – The effect of doxorubicin on light emission from DLD-1/p53Fluc (A) and /SVFluc 
(B) cells. The cells were treated for varying lengths of time with a range of doxorubicin 
concentrations. All data is normalised to untreated cells, signified by y=0. Experiments were 
performed in triplicate and data combined. * signifies p<0.05, error bars = SEM. 
 
 
At 24 hours there was an increase in photon output as doxorubicin increased 
and light emission measured from cells treated with both 0.1µM and 1µM was 
significantly lower than those treated with 10µM († = p<0.01). Overall light 
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emission was lower in cells exposed for 24 hours than those exposed for 6 
hours. Trichostatin A exposure for 7 hours led to an increased photon output as 
drug concentration increased (*p<0.05; figure 2.21B).  
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Figure 2.21 – The effect of cytotoxic drugs on the light emission from DLD-
1/p21Rluc cells treated with a range of concentrations of (A) Doxorubicin for 6 or 
24 hours and (B) TSA for 7 hours. Experiments were performed in triplicate and 
results combined * = p<0.05, † = p<0.01. Error bars = SEM.  
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2.4 Discussion 
In the development of anticancer therapeutics it is important to develop cell 
lines that can be used for in vivo studies that more accurately represent the 
human disease than those currently available. Bioluminescent cell lines have 
the potential to help improve preclinical drug testing by 1) allowing animals to be 
monitored over time, thereby improving data sets whilst conforming to the 3Rs 
principles and 2) allowing investigation of drug-target interactions in the live 
animal environment rather than in ex vivo tests. For bioluminescent cell lines to 
be usable in vivo they must display certain characteristics such as high 
luminescent output, a good correlation between cell number and photon 
emission and exhibit similar growth characteristics as non-transfected cells i.e. 
the inclusion of foreign DNA into the mammalian cell genome should not cause 
excessive growth inhibition.  
 
This study has demonstrated the development of a panel of reporter cell lines 
that could potentially be used to test novel anticancer agents against colorectal 
cancer non-invasively in vivo.  Four reporter plasmids were successfully created 
for transfection; Stable clones of DLD1 cells expressing all four constructs 
(SVFluc, SVRluc, p53Fluc, p21Fluc) were developed, both constitutive reporters 
(SVFluc and SVRluc) were used to create stable cell lines in the LS174T cell 
line whilst SVFluc was successfully introduced into the Colo205 cell line. 
 
Several studies have confirmed that transfection using Firefly and Renilla 
luciferase does not negatively affect cell line growth in vitro (Tiffen et al., 2010). 
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The lack of effect of luciferase expression upon cell growth seen here is in 
agreement with previous studies, in which a luciferase-transfected cell line 
(HEYC2), grown in vitro in the presence of D-luciferin displayed no growth 
inhibition. Interestingly, when this same cell line was grown as a subcutaneous 
model, high levels of growth inhibition were seen following bi-weekly injections 
of D-luciferin (Brutkiewicz et al., 2007), relative to solvent controls. This issue is 
obviously of concern for this project, but may also be cell type and model 
dependent, and will be discussed in further detail in Chapter 4. Importantly, it 
must also be appreciated that if luciferase expressing cell lines grow at a similar 
rate to each other in vivo it does not necessarily matter that they do not grow at 
the same rate as their wild type parental cell lines. However, the results 
presented in figure 2.10 show that there was no significant differences between 
parental and transfected cell lines in the current study so this was not seen as a 
matter of concern.  
 
Serial dilutions of all the constitutively expressing cell lines gave significant 
results with regards to the correlation between cell number and photon output 
following exposure to the relevant substrate. One interesting observation was 
that in cells plated at high density and left overnight before imaging, a highly 
significant reduction in photon output was observed, with both DLD-1 and 
LS174T cell lines (data not shown). This may be due to a masking effect of 
overlying cells over the cells at the bottom of the well leading to a plateau effect; 
it may also be a reflection of exhaustion of nutrients in the culture media leading 
to a hypoxic environment in which the oxygen-dependent luciferase reaction 
cannot proceed efficiently. This clear in vitro effect, which was seen regularly in 
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cells left overnight prior to imaging, may have some concordance with data 
seen in vivo where a plateau in photon emission has been reported when 
tumours reach a larger size (Dickson et al., 2007; Jurczok et al., 2008), an 
observation attributed to necrosis and hypoxia.  
 
One important criterion for development of these models is that the constitutive 
promoter being used should not affect treatment response of the cell lines. 
Previous studies have reported that the CMV promoter, commonly used in 
studies such as this, can be affected by a variety of cytotoxic agents whereas 
the SV40 promoter is less affected by extracellular processes (Svensson et al., 
2007). In particular doxorubicin was previously shown to increase induction of 
the CMV promoter and thus of the luciferase gene under its control when 
normalised to tumour volume. Conversely when SV40 was used this increase 
was not seen (Svensson et al., 2007). Other reports have suggested that the 
CMV promoter is dependent on the host-cell transcriptional environment 
(Kamensek et al., 2011).  
 
The theory that SV40 is not upregulated by doxorubicin was supported in the 
current study, as no increase in luciferase expression was observed in cells 
transfected with the SV40 DNA following treatment with this drug (figure 2.20b). 
Theoretically this allows dual imaging where an SV40 driven promoter could be 
used to monitor tumour burden whilst a gene-driven reporter could be used to 
elucidate pharmacodynamic response.  
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Although the CMV and SV40 promoters are expressed well in many cell types 
they may also be regulated by biological influences and although the SV40 
promoter was not influenced by doxorubicin treatment here it cannot be 
concluded that this would be the case with other treatments in other contexts, 
as concluded elsewhere (Svensson et al., 2007). It may be possible the SV40 
promoter is responsive to other stimuli involved in viral replication that may be 
activated by particular chemotherapeutic drugs that were not tested here. To 
prevent this when new compounds are tested, it would be important to check for 
in vitro increases in photon emission from SV40 expressing cells as a result of 
exposure to the new drug.  
 
To compare the chemosensitivity of newly transfected cell lines with their wild 
type parental counterparts MTT assays were performed. IC50 values for 
treatment of all of the transfected cell lines with doxorubicin suggest that, at 
least in vitro, although the values of the transfected cells are often lower than 
the wild type cells, this difference is not significant. Conversely when treated 
with cisplatin it appeared (although again it did not reach significance) that the 
SVFluc cell lines, in all 3 instances, were more resistant to treatment (table 2.2). 
The DLD-1/p53Fluc line also showed a lower sensitivity to cisplatin than its wild-
type counterpart. If this data were to be translated into the in vivo setting it could 
indicate that the dose required to slow the growth of tumours established from 
wild type cell lines may not be sufficient to affect the growth of those tumours 
established from cells transfected with SVFluc. However, maximum tolerated 
doses must be adhered to which may prevent higher drug concentrations being 
used.  
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Finally, the effect of treatment with doxorubicin and trichostatin A on the 
luminescent output from cells carrying the p21Rluc and p53Fluc DNA was 
evaluated. Importantly, results indicated that there was an increase in 
luminescence from cells containing both the p21- and p53- promoter, when cells 
were treated with trichostatin A/doxorubicin and doxorubicin respectively. This is 
in accordance with other reports where trichostatin A has been shown to induce 
p21 expression in a variety of tumour cell lines (Emonds et al., 2010; Richon et 
al., 2000; Sowa et al., 1999) from as soon as 1 hour following treatment with 
expression remaining elevated for 6-8 hours (Archer et al., 1998; Wu et al., 
2001) depending on the cell type. Trichostatin A has previously been shown to 
maintain upregulated luciferase via the same p21 promoter in vitro at similar 
concentrations (≈2µM) at 24 hours exposure, which was linked to an increase in 
p21 protein as measured by Western blotting (Sowa et al., 1999).  
 
Doxorubicin was shown to increase expression of p21Rluc at 6 hours but which 
appeared to return to background levels following 24 hours exposure. This 
result is unexpected as elsewhere p21 levels have been shown to remain 
elevated up to 24 hours following treatment with the same drug (Wang et al., 
2002). Further investigation would be required to confirm whether this decrease 
in bioluminescence was mirrored in a decrease of transcriptional activity of the 
p21 promoter.  
 
Similarly exposure to doxorubicin lead to an increase in bioluminescence from 
cells expressing p53Fluc which was more pronounced after 24 hours exposure  
Comparable results have been seen in other studies where doxorubicin 
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treatment at similar concentrations led to an increase in p53 activation, 
measurable from between 4 and 24 hours depending on the cell lines being 
used (Elmore et al., 2002; Kong et al., 2009). Interestingly, low dose 
doxorubicin (50ng/ml), has been shown not to induce expression of p53 in a 
hepatocellular carcinoma line Huh-7 as indicated by Western blot (Eom et al., 
2005) and in another study that used DLD-1 cells 100nM (approximately 
6ng/ml) doxorubicin did not lead to increased p53 expression (Wang et al., 
2002). In accordance with this data, the concentration of doxorubicin required to 
induce a response that could be measured indirectly by a photon emission 
increase was equivalent to ≈1.74µg/ml (3µM) in the current study. Although the 
uptake of doxorubicin varies between cell lines, most achieve intracellular 
steady-state levels between 2-8 hours (Jackson, 2003) and the data presented 
in figure 2.20 indicates that at 7 hours the p53 transactivator present in the 
DLD-1/p53Fluc cell line had begun to increase in activity, but that 
transactivation was higher at 24 hours indicated by elevated light emission.  
 
2.5 Conclusions  
In this chapter the development of a panel of constitutive and gene-driven 
reporter cell lines (DLD-1/, LS174T/ and Colo205/SVFluc, DLD-1/ and 
LS174T/SVRluc and DLD-1/p21Rluc and /p53Fluc) has been reported that were 
suitable to be taken forward for use in in vivo models. The vectors used for 
transfection of these cell lines were developed from combinations of 
commercially available plasmids but engineered so that both Firefly and Renilla 
luciferases were present in different models. This was important as the intention 
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was to enable dual-imaging at a later stage of the project. The absence of any 
cross-reactivity between Fluc/CET and Rluc/D-luciferin confirmed that this was 
possible.  
 
The gene-driven luciferase reporters (p53Fluc and p21Rluc) showed no growth 
inhibition when compared to their parental cell line and showed an in vitro dose-
response relationship between treatment with doxorubicin and trichostatin A. 
This confirmed their suitability for use in vivo. The constitutive luciferase 
expressing cell lines (those carrying the SVFluc and SVRluc DNA) expressed 
luciferase at very high levels, indicated by high relative light units in the 
presence of the substrate. The relationship between luminescent output and cell 
number was also highly significant and there was no significant difference in 
proliferation or chemosensitivity to the wild type cells. These features make 
them ideal for monitoring tumour growth in vivo where the intensity of light 
emitted must be strong enough to penetrate tissue even when it is located in 
deeper anatomical locations.  
 
The development of such a panel of transfectants derived from the same 
parental cell line has not previously been reported. 
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3 The distribution and kinetics of luciferase substrates in vivo 
3.1 Introduction 
Bioluminescent imaging is an important tool for localising tumours, quantifying 
their growth and monitoring the effects of therapy, as previously discussed in 
Chapters 1 and 2. However, there are several drawbacks and challenges that 
have been identified. In vivo luciferase reporter systems require successful 
delivery of the substrate to the luciferase-expressing tumour cells, which allows 
imaging of animals to be performed in a uniform way, at the same time point 
during each imaging session and ensures that a true reading is obtained for 
each animal. It also allows enhanced comparability between treatment groups 
and between different animals within the same group. However, high levels of 
variability have been seen for the time course of light emission (Sim et al., 
2011). This variability was suggested to be dependent on the route of injection, 
which in turn affected the sensitivity and reproducibility of results (Cho and 
Yoon, 2007; Sim et al., 2011). Other contributory factors affecting the time 
course kinetics of luciferase substrates were suggested to be tumour size and 
tumour site (Sim et al., 2011). These observations and theories suggest that 
biokinetics and distribution of the substrate may have a significant impact upon 
levels of light emitted (Berger et al., 2008). This has implications for 
administration, since the injection route affects the appropriate time for imaging 
most acutely. Whereas intravenous administration of D-luciferin or CET means 
they enter the circulation immediately, intraperitoneal and subcutaneous 
delivery takes longer to reach the blood stream, as they must first diffuse across 
cell layers into the vasculature. Although different research groups use different 
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methodologies for luciferase administration, this in itself is not a problem as long 
as the same protocol is used each time. However, even when the same method 
is consistently used there is still likely to be variability. 
 
In in vitro studies D-luciferin and CET are present in excess and the consequent 
light emission is directly proportional to cell number (Berger et al., 2008); this is 
not normally the case with in vivo studies. Due to the complexity of the in vivo 
system several confounding factors exist, such as poor perfusion and reduced 
tumour penetration and exposure, leading to low substrate concentrations of 
luciferase-enzyme concentrations in the tumour tissue (Keyaerts et al., 2011). 
This means that in contrast to the in vitro system, the enzyme is not fully 
saturated with substrate in the in vivo setting (Lee et al., 2003) and the reaction 
rate will be suboptimal (Keyaerts et al., 2011). Therefore, greater understanding 
of the distribution, kinetics and consequences of substrate administration is 
required.  
3.1.1 Use of D-luciferin and coelenterazine in vivo 
D-luciferin is commonly administered intraperitoneally, with occasional studies 
using intravenous or subcutaneous routes. Administered concentrations of D-
luciferin range from 100 to 400 mg/kg (Contero et al., 2009; Cui et al., 2008) 
with imaging time points ranging from 5-20 minutes (Burgos et al., 2003; 
Contero et al., 2009; Shah et al., 2003). In general, a concentration of 150mg/kg 
(Burgos et al., 2003; Shah et al., 2003; Tiffen et al., 2010; Zhang et al., 2007b) 
and time points between 10 and 20 minutes are most commonly reported as 
being optimal (Burgos et al., 2003; Contero et al., 2009). The concentration of 
98 
 
injected D-luciferin has been shown to directly correlate with the photon 
emission from a tumour (Wang and El-Deiry, 2003) so it is important to use the 
same concentration in all experiments to allow data to be compared.  
 
Rluc is used less frequently than Fluc but again it is important to be able to 
assess methodological reproducibility of the method and formulate suitable 
methodologies for its use in vivo. The substrate for Renilla luciferase, CET, is 
usually administered via the tail vein and imaging performed sooner after 
injection than for D-luciferin (Bhaumik and Gambhir, 2002; Wang et al., 2009a), 
at around 5 minutes (Shah et al., 2008). The concentration of injected CET has 
been shown to directly correlate with the light emission from a tumour and 
0.7mg/kg is suggested as a concentration at which cost effectiveness and 
imaging sensitivity are balanced (Bhaumik and Gambhir, 2002), although it is 
regularly used at 0.5mg/kg (Dobrenkov et al., 2008; Shah et al., 2008). 
Interestingly in one study CET was administered intraperitoneally as low as 
2µg/ml, with imaging as usual at 5 minutes post-injection (Klopp et al., 2007).  
3.1.2 Relationship between D-luciferin/CET PK and photon emission 
Despite luciferase-based systems now being widely used across many 
applications, the choice of imaging time course is largely dependent upon the 
specific application, luciferase system used and previously reported studies. In 
light of the variability in optimal time course, such comparisons are important in 
terms of assessing whether variances in light output are a reflection of 
differences in tumour levels of D-luciferin. Distribution of D-luciferin in vivo in 
mice was previously determined using radiolabelled D-Luciferin (Berger et al., 
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2008; Klopp et al., 2007; Lee et al., 2003), and biochemical monitoring of the 
luciferase reaction and formation of metabolites and intermediates has been 
monitored in vitro using high pressure liquid chromatography (HPLC) (Fontes et 
al., 1998; Gomi and Kajiyama, 2001; Oba et al., 2008). However, no substantial 
study has yet appraised the relationship between tissue distribution, 
pharmacokinetics and peak photon output in these systems. Furthermore, there 
have been no reported studies of the distribution or pharmacokinetics of the 
Renilla luciferase substrate coelenterazine in vivo, with previous studies purely 
being based upon administered dose versus peak photon output detected. 
3.1.3 Aims and Objectives  
The aims and objectives for this chapter were to address the lack of information 
regarding in vivo pharmacokinetics of D-luciferin and CET, and its relationship 
to magnitude of photon emission. The overall objectives were to determine the 
optimal time point for luciferase-based imaging in a mouse model system. 
Initially the route of injection, the time to peak emission and the time taken for 
detectable bioluminescence to disappear from tumours established from DLD-
1/SVFluc or /SVRluc cells will be assessed. This was determined by analysing 
the light emission kinetics following administration of the relevant substrate and 
subsequently HPLC will be used to analyse substrate distribution in tumour 
bearing mice. This requires initial method development for HPLC analysis of 
CET and D-luciferin. Comparisons were drawn between light emission kinetics 
and the pharmacokinetic analyses of the substrates to try and elucidate the 
relationship to the magnitude of photon emission.  
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3.2 Materials and Methods 
3.2.1 Cell lines 
DLD-1/SVFluc and DLD-1/SVRluc cells were used. Cell culture conditions were 
as described in Chapter 2.  
3.2.2 Animal models and tumour systems 
Male BALB/cOlaHsd-Foxn1nu mice (Harlan, Blackthorn, UK), aged 6-8 weeks 
were used. Mice received Teklad 2018 diet (Harlan) and water ad libitum. Mice 
were kept in cages in an air-conditioned room with regular alternating light and 
dark cycles. All animal procedures were carried out under a project licence 
issued by the UK Home Office and UKCCCR guidelines (Workman et al., 2010) 
were followed throughout.  
 
Cells were harvested from cell culture flasks by trypsinisation and 1 x106 cells 
were injected s.c into both flanks of nude mice. Tumours were allowed to 
establish and reach volumes of approximately 200mm3 before being grouped 
using restricted randomisation to minimise mean tumour size variation.  
3.2.3 Substrate administration and sample collection 
D-luciferin from a stock concentration of 30mg/ml in dH2O was diluted 1:2 in 
RPMI medium to 15mg/ml, for i.p injection at 150mg/kg. Coelenterazine from a 
stock concentration of 1mg/ml in methanol was further diluted in sterile 
phosphate buffered saline to 35µg/ml before injection i.v into the tail vein of 
mice at 350µg/kg.  
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At specified time points, mice were imaged (as described below) prior to being 
sacrificed and having tumour and blood removed. Blood samples from mice 
were taken by cardiac puncture under terminal isoflurane anaesthesia (2.5% 
isoflurane/O2) and placed into heparinised tubes on ice. Plasma was separated 
by centrifugation at 3000g for 10 minutes at 4°C. Plasma was stored at -80°C 
prior to analysis. Tumours were removed, wrapped in foil, snap-frozen in liquid 
nitrogen and stored at -80°C until required. 
3.2.4 Bioluminescent Imaging  
Mice were administered with either D-luciferin or CET, and were imaged 1 
minute prior to the required time point for plasma and tumour extraction. 
Imaging was performed using a cooled charge coupled device camera system 
(IVIS imaging system 50, Xenogen/Calliper Life Sciences, Almeda, CA). Mice 
were initially anaesthetised using 2.5% isoflurane/O2, which was maintained at 
the same level throughout the imaging procedure in the light-tight chamber of 
the IVIS system. Imaging was performed 1 minute prior to the pre-determined 
time points. Image acquisition, analysis and presentation of bioluminescent data 
(in RLU) were performed as described in sections 2.2.7 and 2.2.8.  
3.2.5 Analysis of D-luciferin and CET in tumour and plasma samples 
Plasma samples (100ul) were precipitated in 100% methanol at a 1 in 4 dilution, 
centrifuged at 7000g for 10 minutes to pellet proteins and the supernatant 
analysed by HPLC. For extraction of D-luciferin from tumour samples, tumours 
were weighed and homogenised 1:4 in PBS. Homogenate was diluted 1:4 in 
ice-cold methanol in order to prevent further substrate metabolism, centrifuged 
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at 7000g for 10 minutes to pellet proteins and the resultant supernatant 
analysed by HPLC. For extraction of CET from tumour samples tumours were 
weighed and homogenised 1:4 in ice-cold methanol in order to prevent further 
substrate metabolism, centrifuged at 7000g for 10 minutes to pellet proteins and 
the resultant supernatant analysed by HPLC. 
 
Reverse phase chromatographic separation of D-luciferin and CET was 
performed using a Waters Alliance system (Waters Ltd., Watford, UK), 
comprising a Waters 2690 separation module for solvent delivery and 
autosampling and a C18 Hichrom RPB column (25 x 4.6-mm) (Hichrom Ltd., 
Reading, UK). Detection was performed using a photodiode array detector 
(Waters 996) with Millenium Software.   
 
Mobile phases were as follows: Mobile phase A consisted of 10% HPLC grade 
water, 90% methanol and 0.05% triflouric acetic acid. Mobile phase B consisted 
of 90% methanol, 10% HPLC grade water and 0.05% TFA. Mobile phase was 
degassed before introduction into the chromatography system by vacuum 
filtration through a 0.45µm pore cellulose nitrate filter. Chromatographic flow 
rate was maintained at 1.0 ml per minute.  
 
For D-luciferin, linear calibration over a range of 0.094 - 3µg/ml was achieved 
by diluting 30mg/ml stock solution in mobile phase B. For CET, linear calibration 
over a range of 0.001–0.035 mg/ml was achieved by diluting 1mg/ml stock 
solution further in methanol. For both substrates, serial dilutions were run using 
the same gradient as the samples for analysis. 
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3.2.6 Data analysis  
Data from a number of light-emission time course experiments were grouped 
and analysed to increase the size of the dataset. This data was used to 
determine the optimal time for imaging based on average time to peak 
bioluminescent emission. Bioluminescent data was analysed as described in 
section 2.2.8. 
 
For HPLC data peak areas were obtained for each sample at each time point 
and normalised to tumour weight or volume. T-tests or regression analysis were 
performed for data comparison and a p-value of <0.05 was deemed to be 
significant.  
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3.3 Results 
3.3.1 Analysis of the effect of injection route on D-luciferin induced 
signal 
Mice were injected either intraperitoneally or intravenously with 150mg/kg of D-
luciferin before being placed under anaesthetic. The mice were imaged from 8 
minutes at 2 minute intervals until 40 minutes post injection. The differences in 
light emission over time were analysed.  
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Figure 3.1 – Tracking light emission following intraperitoneal versus intravenous injection of D-
luciferin. Representative graph indicates that injection route of D-luciferin does not significantly 
affect the total count values (p >0.05, n= 6) 
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No significant difference in photon signal was observed between i.v and i.p 
administration (figure 3.1; p=0.77). Although an initial higher signal was 
detected following i.p injection, after 14 minutes values for both i.p and i.v were 
comparable and decayed at the same rate. Based on this data intraperitoneal 
injection was chosen for the subsequent experiments as this method requires 
one animal handler and is less distressing for the mice. Repeat injections are 
also less problematic using this route of injection.  
3.3.2 Detection of D-luciferin by HPLC  
Analysis of D-luciferin using HPLC showed that the substrate was easily 
detectable and that the concentration correlated with area under the peak 
(AUP) (figure 3.2). This methodology was also shown to be applicable to 
analysis of D-luciferin when extracted from cells (figure 3.2B). An initial increase 
in the amount of D-luciferin entering the cells was observed which peaks at 
around 5 minutes before decreasing as it is metabolised. No signal was 
detectable after 30 minutes post-administration. This is mirrored in the light 
emission data from imaging the eppendorf tube throughout the study (figure 
3.2C).  
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Figure 3.2 – Detection of D-luciferin using HPLC A) a 1:2 serial dilution of D-luciferin correlates 
highly with AUP data, B) D-luciferin detection by HPLC in cells incubated with the substrate over 
a time course of 30 minutes. The first aliquot of cells taken was taken for analysis 5-10 seconds 
after injection of the substrate into the cells. C) Cell aliquots were imaged in the IVIS 50 
immediately following injection of the substrate and then subsequently at 5, 10 and 20 minutes. 
Error bars = standard deviation.  
A 
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A 
         
C 
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3.3.3 Investigating the light emission kinetics of the Fluc/D-luciferin 
reaction in vivo   
3.3.3.1 Light time course kinetics  
In order to determine the most appropriate time for imaging following D-luciferin 
administration, a number of time course studies were undertaken and the 
results grouped to provide a more detailed analysis. The mean time to reach 
maximal light output following i.p administration of D-luciferin was determined 
as 15.3 ± 9.7 minutes, however large variability was observed between studies 
(table 3.1).  
 
In order to assess the influence of time and to relate tumour size with signal, a 
group (table 3.1, study 1) of tumour bearing mice were reimaged following a 
further 7 days of tumour growth (table 3.1, study 2). When the same animals 
were imaged one week apart the average time to peal light emission following 
substrate injection reduced from 18.7 +/- 3.65 minutes to 7 
+/- 1.4 minutes whilst 
the average tumour volume increased from 206.2 +/- 153.9 mm
3 to 305.2 +/- 64.7 
mm3. This indicates that there may be a relationship between increased tumour 
volume and a quicker time to peak signal as measured by BLI. However group 
4 had an average tumour size that was lower than both group 1 and 2 yet the 
time to peak signal was 14.7+/-11.8. Regression analysis using all the available 
data similarly contradicted any relationship between tumour size and time to 
peak emission (figure 3.3) as there was no correlation between size of tumour 
and time to peak emission.  
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It may also be stipulated that the time of day had an effect on the time to peak 
signal, insomuch as those animals imaged later in the day (group 1) had a 
higher average time to peak signal than groups imaged earlier (groups 2 and 3). 
Data taken from a further group of animals (table 3.1, group 4) that had a lower 
average tumour size (101.3mm3) displayed a time to peak light emission of 
14.7+/-11.8 minutes.  
 
Table 3.1 – Light time course kinetics of the D-luciferin/luciferase reaction 
Study 
Number 
N Time of day at 
which imaging 
was performed 
Average tumour 
volume in group 
(mm3) +/- SEM  
Average time to 
peak total counts 
(mins) +/- SEM  
1 12 14:00 206.2 +/- 153.9 18.7 +/-  3.65 
2 12 09:20 305.2 +/- 64.7 7      +/-  1.4 
3 4 09:05 - 13    +/-  3.8 
4 6 11:15 101.3 +/- 70.8 14.7 +/- 11.8 
Grouped 34 N/A N/A 15.3 +/-  9.7 
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Figure 3.3 – Regression analysis to investigate the correlation between tumour volume and time 
to peak light emission following injection of D-luciferin (n= 28) 
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3.3.4 Analysis of the relationship between D-luciferin pharmacokinetics 
and light emission time course kinetics 
3.3.4.1 Light time course kinetics  
When using BLI for pharmacodynamic investigations the time at which the 
reaction ceases and no more light emitted is important: This prevents falsely 
high results, which could enhance or negate any effects that are being seen.  
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Figure 3.4 – A) Light time course kinetics of the D-luciferin/Fluc reaction. Light output ceased 
after 3 hours following injection of the D-luciferin substrate (n=3 tumours). B) Representative 
images of one animal at 20 minutes, 40 minutes and 3 hours following D-luciferin injection  
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DLD-1/SVFluc tumour bearing mice were injected i.p with 150mg/kg of D-
luciferin and initial imaging performed over 40 minutes. Imaging was then 
repeated, without re-injection of the substrate, at 3, 6, 9 and 24 hours. The 
signal decreases a small amount over the first 40 minutes, and by the 3 hour 
time point light emission from the tumours had returned to baseline levels 
(figure 3.4). To investigate whether this fall in signal was related to the 
metabolism of D-luciferin within the mouse, HPLC was used to analyse the 
concentration of the substrate in the tumour and the plasma of mice over time. 
3.3.4.1 Pharmacokinetics  
DLD-1/SVFluc tumour bearing mice were injected i.p with 150µg/kg of D-
luciferin. HPLC was performed on tumour and plasma samples taken at 2 and 
20 minutes and at 4 and 24 hours. The mice were also imaged at each time 
point.  
 
In all cases, the amount of the substrate extracted from the plasma and the 
tumour was similar. In the tumour, D-luciferin was already at its maximum 
concentration 2 minutes following injection and remained at the same level at 
20 minutes; however there was more variance at this point (figure 3.5A). In the 
plasma the concentration peaked at 20 minutes and there was less variation 
between the animals (figure 3.5B). Regression analysis between area under the 
peak and light emission from each of the tumours was very low, with a non-
significant R2 value of 0.02 (figure 3.5C).  
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Figure 3.5 – HPLC analysis of D-luciferin concentration in the tumour (A) and plasma (B) n=3 
mice (6 tumours) per time point. C) Regression analysis of AUP versus bioluminescent emission 
(R
2 
= 0.02)  
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The half life of the substrate could not be calculated as there were not enough 
values between the peak (20 minutes) and the baseline levels seen at 4 hours 
and further analysis of the interim period would be needed to enable calculation 
of this parameter. This data appears to support light emission time-course 
kinetics in the sense that the amount of D-luciferin injected i.p increases 
between 2 and 20 minutes, and then by 4 hours has returned to baseline. 
Taken together, this data was used later to justify suitable time-points for 
pharmacodynamic studies. 
3.3.4.2 The relationship between D-luciferin concentration and light emission  
The concentrations of D-luciferin were assessed by HPLC over a 30 minute 
period post-administration of the substrate. Images were taken prior to sacrifice.  
Despite variation seen in light emission (figure 3.7A), no significant difference 
was observed with increasing time (p>0.05). This is in agreement with the PK 
analysis in which tumour D-luciferin remained at a similar level for 30 minutes 
(figure 3.7B). At each time point the concentration of D-luciferin was also shown 
to be highly variable (figure 3.7B). In contrast plasma levels of the substrate 
were less variable and although not significant, did demonstrate a gradual 
decrease over 30 minutes (figure 3.7B). The presence of another peak, 
undetectable in the plasma control was also seen, which may be attributable to 
oxyluciferin, the metabolite of D-luciferin in the luciferase reaction. Mass 
spectrometry analysis of the molecule would be required to confirm this 
however and this peak was not detected in any other HPLC analyses. The 
correlation between tumour light emission and the concentration of D-luciferin 
found within that tumour was poor (R2=0.24, figure 3.6C). 
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Figure 3.6 – HPLC analysis of D-luciferin concentration in tumour and plasmas samples over 30 
minutes following injection. A) RLU detected from the tumours B) the amount of D-luciferin 
detected in tumour and plasma samples at 10, 20 and 30 minutes following i.p injection. The 
regression analysis (C) indicates that there is a poor correlation between light output and the 
amount of D-luciferin measured in the tumour using HPLC. Most data points fall outside the 
95% confidence intervals and a low R2 value (0.24) is obtained.  
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3.3.5 Analysis of the effect of injection route of coelenterazine induced 
bioluminescence in DLD-1/SVRluc tumours  
Mice were placed under anaesthetic before being injected either 
intraperitoneally or intravenously with 0.35mg/kg of CET. The mice were 
imaged from 1 minute at 2 minute intervals until 20 minutes post injection. The 
differences between RLUs were analysed.  
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Figure 3.7 – Light emission kinetics of CET. A) Representative plots comparing the light 
emission kinetics of coelenterazine injected i.v and i.p. in 2 mice B) I.v injection in one animal 
over time. C) Three mice injected i.p with CET and imaged after 5 minutes  
 
 
Intravenous injections led to peak light emission at an average of 6 +/- 1.1 
minutes. I.p injections were much less reliable; only 1 mouse could be used for 
A 
B C    2 min   5 min    15 min       M1                M2            M3 B C 
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data analysis as light emission was not detected from two of the mice in the 
group (figure 3.7C). After 20 minutes tumour light emission from the mouse 
injected successfully i.p was still increasing and had not reached levels of the 
mice injected i.v. Based on this data intravenous injection was chosen for the 
subsequent experiments. 
3.3.6 Determination of the optimum concentration of coelenterazine for 
intravenous injection 
Coelenterazine was injected i.v at 0.35, 0.7 or 1.0mg/kg. The time course of 
light emission, the time to peak RLU, and the relationship between tumour 
volume and light emission were investigated. 
 
Table 3.2 – Time course kinetics of the D-luciferin/luciferase reaction 
CET (mg/kg) Average to peak 
RLU (mins) 
St.Dev (mins) R2 value (from 
figure 3.9) 
0.35 6.5 2.9 0.72* (p<0.05) 
0.7 5.2 1.03 0.39 
1.0 5.0 0.83 0.00006 
 
 
The average detected light emission between the three groups was not 
significantly different (p >0.05) however the regression analysis was highest 
when the lowest concentration of CET (0.35mg/kg) was used (figure 3.8/ table 
3.2). Based on this data, subsequent imaging using CET was performed using 
0.35mg/kg.  
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Figure 3.8 – Assessment of the correlation between tumour volume and light emission following 
administration of CET at three concentrations; 0.35, 0.7 and 1.0 mg/ml n=3 mice (6 tumours) 
per group  
 
 
3.3.7 Light time course kinetics 
Similarly to results presented for D-luciferin, it is important to investigate the 
time at which the reaction between the luciferase enzyme and the substrate 
ceases to emit measureable light. CET was injected i.v into mice bearing DLD-
1/SVRluc s.c tumours. Imaging was performed at 10, 20, 30 and 40 minutes 
and again at 4 hours. By 4 hours the signal had returned to background levels 
(figure 3.9). 
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Figure 3.9 – Light emission from SVRluc tumours following CET injection (n=4 tumours). No 
signal above baseline was detectable 4 hours following CET injection. Images and the graph 
represent one mouse over the time course of the experiment.  
 
 
3.3.8 Detection of CET by HPLC 
Although the detection of CET was possible using HPLC there was a high 
degree of instability at room temperature (figure 3.10A-C). Initial analysis of 
CET at a concentration of 0.035mg/ml gave a different peak pattern to that seen 
for the consequent analyses of the same concentration and the serial dilutions.  
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The same sample was analysed at time points 0, 5 and 20 hours. Across the 
time course of the experiment the dominant peak 2a (wavelength = 262nm) 
gradually reduced in area whilst a peak at 20 minutes (peak 1, wavelength = 
282nm) increased. A number of smaller peaks (labelled 3-6, figure 3.10B-C) 
also developed that showed similar wavelengths to the dominant peaks 2a and 
1. Peak 2a is likely to represent the actual CET molecule with all other peaks 
representing breakdown products of the parent molecule.  
 
 
 
 
                                         
 
 
 
 
 
 
 
 
 
                                      
     
      
 
 
 
               
 
 
 
 
 
 
 
 
 
 
 
 
 
 
        
 
Figure 3.10 – HPLC analysis of CET in vitro indicates the breakdown of CET over time at room 
temperature (A) 0.035mg/ml, 0 hours (B) 0.035mg/ml, 5 hours (C) 0.035mg/ml, 20 hours.  
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3.3.8.1 HPLC analysis of CET serial dilutions 
Figure 3.11 indicates that HPLC analysis of CET lead to detection of two main 
peaks with wavelengths of 283nm (peak at approximately 19.7 minutes; peak 1) 
and 261nm (peak at approximately 22 minutes; peak 2).  
 
 
 
  
 
Figure 3.11 – Chromatogram (A) and associated wavelengths (B and C) of the CET substrate 
used to analyse the correlation between area under the peak and CET concentration 
 
 
Analysis of the areas of the peaks 1 and 2 led to a good correlation (R2=0.98 
and 0.96 respectively) between the concentration of CET and both of the main 
peaks eluted (figure 3.12).  
A 
B 
C 
Peak 1 
Peak 2 
Peak 2 
Peak 1 
120 
 
Concentration CET (mg/ml)
0.00 0.01 0.02 0.03 0.04
A
re
a
 o
f 
th
e
 p
e
a
k
 
0.0
5.0e+4
1.0e+5
1.5e+5
2.0e+5
2.5e+5
Peak 1
R2 = 0.98
Peak 2
R2 = 0.96
  
 
Figure 3.12 – HPLC analysis of CET. A 1:2 serial dilution of CET lead to the detection of two 
main peaks which both decreased with good correlation as the CET concentration decreased. 
The R2 values are significant (p<0.05) 
 
 
3.3.8.2 Detection of CET from tumour and plasma samples using HPLC   
Mice bearing DLD-1/SVRluc subcutaneous tumours were injected with 
0.35mg/kg CET. Mice were imaged at 1, 5 and 20 minutes and at 4 hours 
following injection before plasma and tumour samples were collected and 
processed for HPLC. Although light emission was detected at the usual 
magnitude, HPLC analysis was unable to detect the CET molecule or its 
breakdown products (data not shown).   
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3.4 Discussion 
Bioluminescent imaging has been used for more than a decade to analyse 
tumour growth and drug efficacy in mouse models and is now being used to 
analyse more specific drug target interactions, gene response, transgene 
expression and cellular tracking studies. Despite the clear benefits, including its 
non-invasive nature and immediate results, there are concerns with the 
reproducibility of the technique, with many groups reporting somewhat 
inconsistent behaviour with regards to optimisation of sampling time and time to 
maximal light emission. Size of tumour, location and route of injection have all 
been named as causes of this flaw (Cho and Yoon, 2007; Sim et al., 2011).  
 
One of the main discrepancies is the difference in reported “optimum measuring 
times”, especially for imaging using Firefly models, which range from as low as 
5 minutes, up to 20 minutes (Burgos et al., 2003; Contero et al., 2009; Shah et 
al., 2003). Ideal time points for imaging Renilla models are more commonly 
reported between 2 and 5 minutes post CET injection (Heikkila et al., 2010; 
Shah et al., 2003).  
 
The results in this chapter indicate that the highly variable nature of the D-
luciferin/luciferase reaction was reinforced during this project. Initial light-
kinetics indicated that the optimum time to image would be at approximately 19 
minutes; however the same animals injected one week later gave an average 
peak time of 7 minutes (table 3.1). Clearly this is a cause for concern because 
imaging a large number of animals over long periods of time is not viable. 
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Previously tumour volume and location have been suggested as potential 
reasons for the variable nature of the peak signal and the fluctuating signals 
that are seen (Sim et al., 2011); however based on analysis of D-luciferin 
concentrations and the light emission kinetics demonstrated in this chapter two 
reasons may be as follows; route of injection and intra-animal differences. 
Another parameter, tumour volume, did not appear to have an effect on time to 
peak light emission in this study (figure 3.3).  
 
The route of injection has previously been suggested by a number of groups as 
a reason for the variability of peak signals following D-luciferin injection (Cho 
and Yoon, 2007; Sim et al., 2011). Intraperitoneal is generally preferred over 
intravenous administration by many groups as it allows repeat measurements in 
one day which is a requirement for most pharmacodynamic studies. Over use of 
the tail vein for injections can lead to vascular collapse making injection very 
difficult. Previously it had been suggested that i.v administration would be more 
likely to give repeatable data, due to the direct entry of luciferin into the 
bloodstream (Keyaerts et al., 2011) and this route is suitable for drug efficacy 
studies where once a day imaging is required. Data presented in this chapter 
indicate that for D-luciferin, i.p and i.v injection give similar light emission 
kinetics and either could be used effectively. Although the i.p route of injection is 
more susceptible to non-reproducibility, it was chosen for all future work due to 
the pharmacodynamic nature of experiments later in the project.  
  
Another potential complication is intra-mouse differences, especially for i.p 
administration where diffusion of the substrate into the blood and the tumour will 
123 
 
be dependent on a large number of factors. Such an explanation would account 
for the differences observed in this study (table 3.1), where the same group of 
mice exhibited a massive difference in the time to reach peak signal over the 
course of a week. Although most of the tumours had grown, tumour size did not 
appear to have an effect on the peak emission time, a result which has also 
been reported elsewhere (Paroo et al., 2004).  
 
Another possibility is the chronobiology of substrate administration: The 
differences may be accountable to the time of day of administration and 
imaging, with mice in week one being imaged at around 09:00 hours and those 
a week later at 14:00 hours. Although this in itself is unlikely to have a direct 
impact on the peak signal it may contribute to these differences: mice are kept 
in very controlled conditions regarding light and dark and although they have 
unlimited access to food and water they eat more than 60% of their daily food 
intake during the dark cycle (Fonken et al., 2010). For instance, the amount of 
food in the gut is higher in the morning and according to circadian rhythms this 
could indicate that blood flow around the gut is also higher, meaning increased 
transportation of the injected substrate from the peritoneum to the blood and 
tumour. Mice are also more active during the night and accordingly show higher 
heart rate and arterial blood pressure at this time (Sheward et al., 2010). When 
mice are imaged first thing in the morning it may be that their heart rate and 
blood pressure is still raised, speeding up delivery of the substrate to the 
tumour. By the afternoon mice would have reached lowest daily heart rates, 
which may lead to slower delivery of substrate to the tumours.  Further analysis 
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of the effect of time of day on the PK of D-luciferin would be required to prove 
these theories as currently they are observations of the data.  
 
Previously distribution of luciferin in vivo has been monitored using [125I]iodo-D-
luciferin following i.p injection (Lee et al., 2003). More recently, Berger et al  
used 14C-D-luciferin to further evaluate the biodistribution of the substrate in the 
mouse model, however tumour and plasma distribution was not monitored in 
this study (Berger et al., 2008). Mathematical modelling of D-luciferin PK has 
been used to try and explain some of the issues surrounding BLI as a method 
(Sim et al., 2011), but no study has yet reported pharmacokinetic analysis of D-
luciferin in tumours and plasma, following injection into Firefly luciferase tumour 
bearing mice.  
 
In this study, a method was developed to efficiently detect the substrate at 
330nm, as previously reported (Gomi and Kajiyama, 2001; Shinde et al., 2006). 
A good correlation was seen between peak area and the concentration of D-
luciferin by serial dilution (figure 3.2A), in agreement with previous studies (Oba 
et al., 2008). Whilst D-luciferin eluted at around 10 minutes, a smaller peak, 
potentially a metabolite, was also eluted at around 5 minutes. It has previously 
been shown that when oxyluciferin and D-luciferin were analysed the metabolite 
eluted after the substrate (Gomi and Kajiyama, 2001) so mass spectrometry 
analysis would be required to confirm whether the peak seen at 5 minutes was 
indeed oxyluciferin.  
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Although HPLC is a rarely used method of analysing the concentration of D-
luciferin in the tumour and plasma of mice, the use of the technique did improve 
understanding of the variable nature of BLI imaging. The variability in the 
amount of D-luciferin detected by HPLC in the tumours of animals at 10, 20 and 
30 minutes post-injection (figure 3.6B) supports the variation seen when 
establishing peak light output as detected by BLI. The amount of D-luciferin 
detected in the plasma showed less variability than for the tumour (figure 3.6B) 
which could be due to a number of reasons: The substrate may be metabolised 
at different rates in the tumour depending on factors such as the percentage of 
non-luciferase expressing stromal cells, the amount of oxygen available in the 
tumour and the interstitial pressure within the tumour. Conversely D-luciferin in 
the plasma is representative of circulating levels of free substrate and the 
injection concentration is more likely to determine the amount present in the 
plasma.  
 
Pharmacokinetic analysis did support the D-luciferin/luciferase reaction light 
kinetics, where no BLI signal was detected after 3 hours. By 4 hours there was 
no substrate left in the mouse and it would therefore be a suitable time point to 
perform repeat imaging sessions in the same day without interference from the 
previous imaging session. The final time point for HPLC analysis was four hour 
(as opposed to 3 hour seen with BLI) because of the importance of a 4 hour 
time point during the vascular shutdown studies presented in Chapter 5. 
Similarly the light emission kinetics CET (figure 3.10) indicated that the reaction 
of CET/Rluc had ceased by at least 4 hours. It was also confirmed that no 
cross-reactivity exists between the D-luciferin/Rluc or CET/Fluc cells in vivo 
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(Chapter 4, figure 4.31). These results are in accordance with other studies that 
have used Fluc and Rluc expressing tumours in the same animal (Bhaumik and 
Gambhir, 2002) and confirmed that dual reporting was possible in the same 
tumour and/or the same animal. If the tumours comprised mixed cell 
populations then the imaging sessions would have to be at intervals long 
enough to allow clearance of one substrate over the other. Conversely if Renilla 
and firefly luciferase expressing tumours were separate then the mice could be 
injected and imaged during the same session.  
 
The time taken for residual light emission to cease is important in the 
development of in vivo methods for pharmacodynamic analysis of novel drugs. 
Here, imaging over a range of time points may give more information regarding 
the mechanism of action than imaging at a single time point, which is more 
common (Laxman et al., 2002; Luker and Luker, 2008; Wang et al., 2006). Re-
injection of D-luciferin before the substrate has been cleared from the body as a 
result of previous injections may lead to falsely positive results and light 
emission clearance curves should be determined prior to experiments being 
performed.  
 
Renilla is another commonly used luciferase enzyme in preclinical cancer 
research but there is little data available regarding the PK of its substrate, CET, 
in mice. Presented data indicate that intravenous injection of this substrate was 
shown to give more reproducible results and less variability than intraperitoneal 
injection (figure 3.7) and this route was subsequently preferred. Based on the 
collected data, an optimum strategy for imaging with Rluc is that following i.v 
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injection of CET at 0.35mg/kg mice should be imaged a number of times 
between 2 and 8 minutes post injection and an average calculated. In 
comparison to D-luciferin, there was less variability in the time taken for light 
emission to reach its peak following substrate injection and it is possible that 
this is as a result of the injection route (Keyaerts et al., 2011).  
 
Issues regarding delivery of CET to the tumour and the metabolism of the 
substrate by the luciferase enzyme would be similar to those seen for D-
luciferin, although the Renilla reaction does not need cofactors or ATP 
(Bhaumik and Gambhir, 2002) and is therefore less affected by the tumour 
microenvironment than the D-luciferin/Fluc reaction. Intravenous injection of the 
substrate is not ideal for multi-imaging sessions on the same day as collapse of 
the vein was seen fairly commonly when using this substrate, despite half-
volumes being injected. It may be that using a higher concentration of CET 
would improve light emission following i.p injection. However, the speed at 
which the substrate reaches the tumour is likely to be more important because 
of the instability of the compound (figure 3.10).  
 
During this study “native” coelenterazine was used, which is CET in its basic 
form (figure 1.6). It has been reported that native CET is unstable in serum and 
plasma (Otto-Duessel et al., 2006) and results presented in this chapter have 
shown that it is also unstable in the tumour environment. In addition, data in this 
chapter demonstrates the instability of the molecule even in its purified form at 
room temperature. CET analogues are available such as ViviRen™ and 
EnduRen™ (Promega, Madison, WI) that have a reduced rate of degradation 
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due to a blocking group which protects the oxygenation site of CET (Otto-
Duessel et al., 2006). HPLC analysis of these more stable substrate molecules 
may be possible which would allow the PK of CET to be analysed more 
comprehensively than has so far been achieved. A further confounding factor in 
the Rluc/CET reaction may include expression of P-gp in both the gut and in 
colorectal cell lines being used (Pichler et al., 2004). This will be discussed 
further in Chapter 4.  
 
3.5 Conclusions 
In this chapter the variable nature of the pharmacokinetics of the luciferase 
substrates CET and D-luciferin has been confirmed using both light emission 
kinetics and HPLC analysis, which has not previously been utilised in such a 
way.  
 
Due to the nature of this project, where pharmacodynamics of drugs on 
luciferase expressing tumour cells are being investigated, intraperitoneal 
administration is the preferred route for D-luciferin injections as i.v injections are 
not feasible for repeat administration.  
 
To minimise the variability seen in both Firefly and Renilla luciferase systems 
taking a number of images over a short time frame is likely to be the best way of 
ensuring reproducibility of results. Regarding Fluc-expressing tumours this was 
done at 2 minute intervals 14-20 minutes post D-luciferin injection. For Rluc-
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expressing tumours imaging was performed between 2 and 8 minutes following 
CET administration.  
 
Despite the dynamic and variable nature of BLI indicated here and in many 
other studies, high-quality results can still be obtained if appropriate precautions 
are taken. Accurate information can be revealed regarding tumour burden, 
molecular interactions and treatment (Sim et al., 2011).  
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4 Characterisation of in vivo models of reporter cell lines 
4.1 Introduction 
In the development of novel therapeutic anticancer agents there is a 
requirement for pre-clinical models that accurately represent the human 
disease. As previously discussed, subcutaneous mouse models are mainstays 
of preclinical drug testing as they are technically straightforward and generate a 
lot of data (Bibby, 2004). However, they do not represent clinical presentation 
where secondary tumours and metastases are common. Often cell lines that 
show metastatic potential as orthotopic models do not metastasise when 
located subcutaneously (Fidler et al., 1990). Despite this subcutaneous tumours 
are still the most commonly used model in initial preclinical screens for drug 
efficacy due to ease of establishment and measurement, and their generally 
uniform growth pattern.  
 
In this project colorectal cancer has been selected as the cancer type to 
investigate. As outlined in section 2.1.4 colorectal cancer is the 2nd most 
common cause of death from cancer in the UK (CRUK, 2008). At the point of 
diagnosis, if the disease is localised there is a 90% 5-year survival rate which 
decreases to 11% if metastatic disease is present (Howlader et al., 2011). The 
most common sites of metastasis of colorectal cancer in the clinic are the liver, 
lungs and lymphatics (NCI, 2011), so there is clearly a requirement for models 
that mimic human metastatic disease in terms of identifying better treatments.  
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4.1.1 The development of mouse models of colorectal cancer: 
subcutaneous, orthotopic and metastatic models 
Xenografts in athymic nude mice using human colon cancer cells were first 
reported in 1969 using the CX-1 cell line (Rygaard and Povlsen, 1969) and 
there are now a large number of colon cancer cell lines that are tumourigenic in 
nude mice. In attempts to improve mouse models of colorectal cancer, 
orthotopic models that lead to spontaneous metastatic dissemination and 
pseudo-metastatic models (e.g. intrasplenic injection to create liver metastases) 
have been established using a variety of human colorectal cell lines introduced 
below.  
4.1.1.1 Orthotopic models of colorectal cancer  
Orthotopic mouse models of cancer have been used to study the disease for 
many decades (Bibby, 2004; Tan et al., 1977) and orthotopic colon models 
were one of the first murine models to be established using syngeneic murine 
adenocarcinoma cells (Tan et al., 1977). However orthotopic models are more 
labour intensive to set up and require more invasive surgical procedures with 
associated risk for the animal. Due to the deeper anatomical location they 
cannot be monitored using callipers. For initial screening this makes orthotopic 
models unsuitable, but following initial determination of efficacy in subcutaneous 
models they could be used to show that the drug retains efficacy in site specific 
tumours. The importance of orthotopic models is demonstrated by the fact that 
efficacious treatment of subcutaneous tumours with doxorubicin was not 
mirrored when lung and liver tumour deposits from the same cell line were 
treated (Fidler et al., 1994).This in itself illustrates the importance of these 
models for clinical translation of potential therapeutics.  
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There are a variety of techniques that are used to establish orthotopic tumours, 
the most common being i) injection of cell suspension into the wall of the mouse 
colon or caecum and ii) surgical orthotopic implantation (Cespedes et al., 2007).  
 
Orthotopic microinjection of populations of human colon cancer cell lines into 
the colonic mucosa and serosa has been carried out successfully using HCT-
116 (both sites), DLD-1 and SW-620 cells (colonic mucosa), which show 
metastasis to some of/all the peritoneal cavity, liver, lungs, draining lymphatics 
and spleen (Bessard et al., 2009; Cespedes et al., 2007). The growth and 
dissemination capacities of the cell lines being used is an important criterion 
when considering the type of model required for investigation and the 
hypothesis being addressed. The different take rate and route of dissemination 
of these tumour models also has major implications when tailoring the 
methodology for their development in vivo, a point that must not be taken lightly.  
 
In contrast to direct introduction of the cells into the colon, surgical orthotopic 
implantation relies on small pieces of donor tumour being implanted onto the 
wall of the colon or caecum. Although a variety of cell lines have been used to 
establish orthotopic colorectal models using this approach, the metastatic 
potential of the tumour is non-uniform and is heavily dependent on the cell line 
being used. HCT116 cells have been shown to metastasise to the liver and lung 
in 50% to 80% of mice (Guo et al., 2007; Holgren et al., 2010; Rajput et al., 
2008; Wang et al., 2009b), whereas DLD-1 and Colo205 cells transplanted 
orthotopically using this method (Guo et al., 2007; Harrington et al., 2009; 
Seiden-Long et al., 2008; Tsutsumi et al., 2009) rarely metastasise. There is no 
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evidence in the literature of LS174T cells being introduced surgically as 
orthotopic tumours.  
4.1.1.2 Development of pseudo-metastatic models of colorectal cancer  
In contrast to spontaneous development of colorectal metastasis, pseudo-
metastatic models can be created by injecting cells directly into the mouse via 
certain routes that lead to organ specific dissemination. For example, injection 
of cancer cells into the tail vein of mice leads to lung metastasis, whereas 
intrasplenic injection results in liver deposits. LS174T cells have been 
successfully used to set up liver metastases from intrasplenic injection 
(Bandapalli et al., 2009; Dearling et al., 2009; Fidarova et al., 2008; Harrington 
et al., 2009; Kalber et al., 2008) where lesions have been detected as early as 
10 days post injection (Kalber et al., 2008). They have also been used to seed 
lung metastasis via injection into the tail vein (Blumenthal et al., 2005). DLD-1 
cells have previously been used to set up metastatic liver models by injection 
into the spleen (Kato et al., 2004), where instances of liver metastasis was 
100% when the experiment was terminated after 30 days. There is no evidence 
for Colo205 cells being injected in this manner for the establishment of liver or 
lung metastatic models, most probably due to the lack of reported evidence for 
metastatic potential of this cell line.  
4.1.2 Validating optical imaging in mouse models of cancer  
The development of optical imaging techniques and specifically of luciferase 
expressing cell lines has enabled the detection and monitoring of orthotopic and 
metastatic tumours to become widespread (section 1.11.1.8). The technique is 
non-invasive and allows animals to be monitored over time following treatment, 
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allowing better understanding of disease progression. Metastases can also be 
monitored noninvasively which, before the development of such techniques, 
was impossible. Even following sacrifice, micro-metastases are often not 
obvious to the naked eye so histology is required to demonstrate their presence 
meaning very small groups of metastatic cells are easily overlooked.  
 
Validation of optical imaging techniques is required prior to use. This is 
relatively easy for subcutaneous tumours as they are palpable and measurable 
using callipers. This allows easy comparisons to be made between light 
emission and tumour volume. Conversely, orthotopic tumours are not 
measureable manually without sacrifice of the animal, making validation more 
difficult. If luciferase expressing cells are used in such models the light emission 
must be shown to accurately represent tumour volume prior to orthotopic 
implantation. For therapeutic efficacy studies it is important that a decrease in 
tumour volume is mirrored in a fall in light emission and this should be validated 
in subcutaneous models prior to orthotopic investigations. 
   
Many studies now use constitutive luciferase expression to monitor the 
development of  a variety of tumour models (Dickson et al., 2007; Hadaschik et 
al., 2008; Jurczok et al., 2008; Shi et al., 2011; Zhang et al., 2009) where it has 
been shown to be a robust strategy to monitor the effectiveness of anti-tumour 
drugs in vivo (Dothager et al., 2009). Dissemination of colorectal cancer to the 
liver (Zabala et al., 2009) and bone and pulmonary metastasis (Miretti et al., 
2008) has also been monitored.   
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Renilla luciferase expressing cell lines are used commonly to monitor changes 
in gene expression, for example changes in expression of the MDR-1 gene 
(Jeon et al., 2010), but they have also been used to monitor cancer growth in 
vivo, including orthotopic pancreatic models (Kidd et al., 2010), gliomas (Arwert 
et al., 2007; Otto-Duessel et al., 2006; Shah et al., 2008) and in subcutaneous 
murine breast cancer models (Klopp et al., 2007). In contrast to Firefly, Renilla 
luciferase has not been commonly used for tracking tumour growth and 
monitoring treatment efficacy, due to the instability of the substrate in the mouse 
(Otto-Duessel et al., 2006) and the higher amount of tissue attenuation due to 
the lower wavelength produced during the reaction (Bhaumik and Gambhir, 
2002).  
4.1.3 Validation of the newly transfected cell lines for in vivo BLI  
In Chapter 2 the development and characterisation of a range of luciferase 
reporter cell lines was described, which culminated in a range of cell lines being 
shown to be suitable for use in vivo. As outlined in section 4.1.2, it is important 
that new reporter cell lines are validated in vivo in subcutaneous, orthotopic and 
metastatic models. Similarly the effect of cytotoxic drugs (such as cisplatin and 
doxorubicin, section 1.5.3) on the light emission from tumours must be 
investigated to show that any effect of the drug on tumour size leads to a 
concurrent decrease in the luminescent signal detected. This allows results 
from orthotopic and metastatic tumours to be analysed with confidence when 
manual measurements are not possible. Such validation must be completed 
prior to the reporter cell lines being used in the development of novel agents. 
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4.1.4 Aims and objectives 
The aims of this chapter were to establish which of the constitutive luciferase 
reporter cells lines described in Chapter 2 are suitable for use in subcutaneous, 
orthotopic and metastatic in vivo models. The correlation between tumour 
volume and photon emission was investigated in all cell lines. Orthotopic 
models were established to investigate their potential for spontaneous 
metastases. Concurrently the effect of common cytotoxic therapy of both 
subcutaneous and orthotopic tumours was investigated to determine the 
suitability of the new cells lines expressing for monitoring treatment. Ultimately 
the aim was to develop reporter tumour models that could be used in the 
development of novel therapeutic agents. 
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4.2 Materials and Methods  
4.2.1 Compounds and reagents 
Doxorubicin and cisplatin (Sigma, Poole, UK) were dissolved in sterile 
physiological saline for use in vivo. Cisplatin was injected i.p at 8mg/kg. 
Doxorubicin was made up at 2mg/ml and injected intravenously in half volumes, 
thus at a final injection concentration of 10mg/kg.  D-luciferin and 
coelenterazine were prepared for injection as described previously in chapter 3 
and injected at 150mg/kg i.p. and 0.35mg/kg i.v. respectively.  
4.2.2 Animals 
Refer to Chapter 3, section 3.2.2 
4.2.3 Cell lines   
DLD-1 (pCMVdsRed, SVFluc, SVRluc, p53Fluc and p21Rluc), Colo205 (SVFluc 
and p21Rluc), LS174T (pCMVdsRed, SVFluc and SVRluc) and HT29-luc 
(Caliper, UK) cells were used in this chapter. Refer to Chapter 2, section 2.2.3.3 
for maintenance.  
4.2.4 In vivo tumour models  
4.2.4.1 Subcutaneous models 
Cells were harvested from cell culture flasks by trypsinisation and 1 x106 cells 
were injected s.c into both ventral flanks of nude mice. The tumours were 
allowed to grow until they reached the size required for the experiment. Mice 
were terminated once tumours grew to the largest permitted size (length 
measure of no more than 17mm). Calliper measurements were used to 
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calculate tumour volume using the equation a2xb/2 where „a‟ is the larger and „b‟ 
is the smaller diameter. This is the standard method to calculate subcutaneous 
tumour volume in mice.  
4.2.4.2 Intracaecal orthotopic models 
Orthotopic transplantation was performed as described previously (Cowen et 
al., 1995). Briefly, a donor s.c. tumour was aseptically removed from the s.c. 
site and placed into a Petri dish containing sterile saline, penicillin and 
streptomycin (Sigma, Poole, UK) where viable tumour was cut into ~1mm3 
pieces. Mice were anaesthetised using 5% isoflurane/O2 and placed supine 
onto a nose cone with 2.5% isoflurane/O2. The abdomen was cleaned using 
70% ethanol before a small incision was made to the lower left of the midline 
through the skin and the abdominal wall through which the caecum was gently 
externalised. A piece of the donor tumour was placed onto the caecum and 
covered using a small disc of cellulose acetate membrane (type RA- pore size 
1–2 mm, Millipore UK Ltd, Watford, UK). The implant was fixed into position 
using Histoacryl blue tissue adhesive (Davis & Gek, Cyanamid, UK). The 
caecum was then returned through the incision into the peritoneal cavity. The 
abdominal wall was closed using the tissue adhesive and the skin was closed 
with adhesive and autoclips, which were removed once sufficient healing had 
occurred, usually after 1 week (Cowen et al., 1995). Tumour growth was 
analysed using the IVIS 50 imaging system and mice were sacrificed if tumour 
size was too large or animals had lost more than 15% initial body weight or 
other deleterious effects were seen. 
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4.2.4.3 Metastatic models 
Liver metastases were initiated by injection of the cell lines into the spleen. Mice 
were anaesthetised as previously and maintained under anaesthetic on a nose 
cone. A small incision was made to the upper left of the midline through which 
the spleen was excised. 1 x 106 cells were carefully injected into the spleen in a 
volume of 50μl. Care was taken not to allow refluxed tumour cells to seed into 
the peritoneal cavity.  
4.2.5 Assessment of the effect of therapy on luciferase reporter tumour 
models 
Subcutaneous tumours were allowed to establish before animals were allocated 
into groups by restricted randomisation to keep mean tumour volume to a 
minimum. For orthotopic tumours, animals were grouped by restricted 
randomisation according to the level of light emission as measured by BLI. If 
tumours were required for later analysis animals were sacrificed by cervical 
dislocation.  
 
All mice were imaged the day prior to treatment. Mice were then imaged at 
various time points up to 7 days following treatment. Repeat treatments and 
imaging were performed at a later stage in some animals which was dependent 
on the wellbeing of the animals.  
4.2.6 Imaging  
Imaging was performed using a cooled charge coupled device camera system 
(IVIS imaging system 50, Xenogen/Calliper Life Sciences, Almeda, CA). Mice 
were initially anaesthetised using 2.5% isoflurane/O2, which was maintained at 
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the same level throughout the imaging procedure in the light-tight chamber of 
the IVIS system. For imaging of fluorescent tumours excitation and emission 
wavelengths of 558 and 583nm were used. For imaging of Rluc expressing 
tumours, animals were anaesthetised as described in section 3.2.4, before i.v 
administration of CET at 0.35mg/kg. Imaging was performed from 2-8 minutes 
at 2 minute intervals. For imaging of Fluc expressing tumours, D-luciferin was 
injected i.p at 150mg/kg. Mice were subsequently anaesthetised and imaged 
every two minutes between 12 and 20 minutes. Living image 3.0 software was 
used to determine the RLU (luminescent data) or total counts (fluorescent data) 
that were subsequently used for data analysis (refer to section 2.2.8). 
4.2.7 Statistical analysis 
When possible, inter- and intra-group/mouse analysis was performed using t-
tests, with p<0.05 deemed to be significant. Analysis of the association between 
light emission and tumour volumes was performed using regression analysis to 
produce an R2 value and calculating the significance using the equation t = r √ 
(n-2/1-r2) and using tables to calculate whether “t” is significant at the 95% level.  
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4.3 Results  
Subcutaneous tumours were established using all the available cell lines. Some 
of these tumours were then used to establish orthotopic tumours on the mouse 
caecum. Pseudo-metastatic models of liver dissemination were performed using 
LS174T/SVFluc. The results of each cell line are documented consecutively.  
 
4.3.1 DLD-1/pCMVdsRed fluorescent tumour models 
4.3.1.1 Subcutaneous DLD-1/pCMVdsRed xenografts  
Calliper measurement and light emission were monitored during the growth of 
tumours established from DLD-1/pCMVdsRed cells. Figure 4.1 indicates that in 
general the light emission tracked tumour size, although there are individual 
anomalous results indicated by the green arrows (figure 4.1A) where emission 
was lower than expected. Regression analysis of light emission versus tumour 
volume resulted in an R2 value of 0.75 (p<0.05).  
 
To determine whether the correlation was affected by tumour volume, 
regression was performed according to tumour size. There is a tighter 
correlation between tumour volume and light emission when tumours are below 
200mm3 (R2 = 0.76, figure 4.2A) then when they are larger (R2 = 0.46, figure 
4.2B), however both correlations are significant (p<0.05), i.e. as the size of the 
tumour increases so does the amount of measureable light.  
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Figure 4.1 – DLD-1/pCMVdsRed s.c growth curves. A) Representative growth curves of DLD-
1/pCMVdsRed tumours in one animal measured by callipers (solid lines) and by fluorescent 
imaging (FLI) (dotted lines), B) representative images of the same mouse and C) regression 
analysis to investigate the correlation between fluorescent output and tumour size n=30 
tumours). Green arrows in (A) signify unexpectedly low light emission values. 
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Figure 4.2 – Regression analysis of fluorescent light emission versus tumour volume A) in 
tumours less than 200mm
3
 in volume (n=22 data points) and B) tumours of between 200-
600mm
3 
(n = 9 data points). The R
2
 values are 0.76 and 0.49 respectively for (A) and (B).  
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4.3.1.2 Orthotopic DLD-1/pCMVdsRed tumours  
Following introduction of the orthotopic tumours using DLD-1/pCMVdsRed s.c 
donor tumours there was no fluorescence using noninvasive imaging detected 
in the first 3 weeks. Throughout the study DLD-1/pCMVdsRed tumours could 
not be observed by noninvasive imaging techniques (figure 4.3). Subsequently, 
weekly post-mortem imaging was performed on individual mice both with the 
peritoneal cavity exposed and on individual organs ex vivo. DLD-1/pCMVdsRed 
tumour could not be seen using noninvasive imaging techniques (figure 4.4). At 
each time point ex vivo analysis was required to confirm the presence of the 
primary tumour. No fluorescent signal was detected from any peripheral organs 
indicating that this model was not metastatic.  
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Figure ‎4.3: Development of DLD-1/pCMVdsRed orthotopic tumours from week 3 – 9 A) week 3, 
giving fluorescent signal only after exposure of the peritoneum, B) ex vivo imaging of organs 
from 1 mouse, week 5, C) post-mortem image and ex vivo week 6 and D) week 9. The primary 
tumour is circled green in each instance that it can be seen. n=6 (4 animals represented here) 
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4.3.2 Bioluminescent tumour models: Investigating the effect of 
luciferase expression on in vivo tumour growth 
Data from a variety of experiments was collated and tumour doubling times 
calculated. No significant difference in growth rate was observed between 
wildtype DLD-1 cells and those engineered to express luciferase proteins (table 
4.1).  
 
Table 4.1 – Doubling times of DLD-1, DLD-1/SVFluc and DLD-1/SVRluc s.c tumours 
 
In vivo tumour Doubling time 
(days) 
DLD-1/w.t 4 
DLD-1/SVFluc 5 
DLD-1/SVRluc 4 
 
 
4.3.3 DLD-1/SVFluc tumour models 
Similarly to the DLD-1/pCMVdsRed tumours, subcutaneous xenografts were 
established using the DLD-1/SVFluc cell line. Subcutaneous tumours were used 
as donors to perform transplants for establishment of intracaecal orthotopic 
models.  
4.3.3.1 Growth characterisation of DLD-1/SVFluc subcutaneous xenografts 
An initial pilot study on 3 mice was carried out which showed that as the size of 
the tumours increased, the light output did concordantly (representative plots; 
figure 4.4A-C). Tumours grew well across the time course of the experiment 
and light emission tracked tumour growth in most tumours. However there are 
clear anomalies, highlighted by green arrows, where the light emission was 
lower than would be expected. Overall there was a positive correlation (p<0.05) 
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between tumour volume and total count values (figure 4.4C). DLD-1/SVFluc 
tumours showed a high level of vascularity within the tumour (figure 4.4D). 
Following confirmation that this cell line was suitable for BLI, subsequent 
studies involved larger animal groups.  
 
However, although the tumours grew well and light emission was easily 
quantified (figure 4.5), the relationship between tumour volume and light 
emission was questionable (figures 4.5 and 4.6). Data from a representative 
animal showed that between day 7 and 13 there was an increase in both 
measurements, however between day 13 and 20 the light emission gradually 
decreased, reaching its lowest at days 19 and 20 (tumours 1 and 2 
respectively), before climbing again at day 21/22, culminating in another 
decrease which lasted until termination of the experiment on day 26 (figure 4.5). 
The highest volumes that tumours 1 and 2 reached were 108 and 250mm3 
respectively.  
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Figure 4.4 – DLD-1/SVFluc s.c growth curves. A-B) Growth curves of DLD-1/SVFluc tumours 
measured by callipers and by BLI in two mice. Green arrows represent anomalous light 
emission values C) regression analysis (R
2
=0.41) to investigate the correlation between 
fluorescent output and tumour size (n=9 mice/ 18 tumours) and D) representative histology of a 
DLD-1/SVFluc subcutaneous tumour, which is clearly well vascularised throughout. Scale bar 
≈100µm 
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Figure 4.5 – An example of the erratic light emission readings from DLD-1/SVFluc s.c tumours. 
A) Graph to show the calliper versus BLI measurements in one animal over time. The solid lines 
represent the calliper measurements whilst the dotted lines represent light emission. Relative 
values are calculated by dividing values by the data obtained on the first day, in this case, day 
7. B) Representative images of one animal at days 7, 13, 19, 22 and 26 
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Figure 4.6 – DLD-1/SVFLuc s.c tumour regression analysis based on tumour size A) all tumours 
(n=60 data points) B) 9-50 mm
3
, n=14, C) 50-100 mm
3 
n=17, D) 100-200, n=17 and E) 
200+mm
3
, n=12. R
2
 values are 0.08, 0.61 (p<0.05), 0.15, 0.12 and 0.01 respectively. In all 
graphs y-axis = RLU, x = Tumour volume (mm
3
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To statistically analyse the correlation between tumour size and RLU values for 
different tumour sizes data from many DLD-1/SVFluc tumours was collated and 
regression analysis performed according to tumour volume (figure 4.6B-E). With 
the exception of tumours below 50mm3 (figure 4.6B), no correlation was seen 
between tumour size and RLUs in DLD-1/SVFluc s.c tumours.  
 
4.3.3.2 Monitoring the effect of cisplatin treatment on s.c DLD-1/SVFluc 
tumours 
In order to compare the effect of treatment on tumour volume and light emission 
relative changes in both parameters were calculated based on pre-treatment 
data. Mice were imaged prior to treatment and then at days 1, 2, 3, 4 and day 7.   
 
Cisplatin did appear to have an effect on the tumour growth (figure 4.7A), which 
was significantly slowed (p<0.05). With respect to relative counts (figure 4.7B), 
at day 1 there was a significant difference between the treated and the 
untreated group which had disappeared by the second day. Relative light 
emission signal for treated and control groups then increased until 6 days where 
there was a large drop in relative counts in both treatment and control groups. 
Overall light emission was variable shown by the large SEM bars (figure 4.7B).  
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Figure 4.7 – The effect of cisplatin on DLD-/SVFluc tumours A) Relative tumour volumes 
following treatment and B) relative counts following treatment. Each animal acted as its own 
control and averages were calculated for each group at each time point. n=3 mice / 6 tumours 
per group). Error bars represent SEM. * = p<0.05 when comparing the treatment and control 
groups 
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4.3.3.3 Characterisation of orthotopic DLD-1/SVFluc tumours  
The relationship between tumour growth and light emission of DLD-1/SVFluc 
cells was investigated in an orthotopic model.  
 
The tumours grew steadily until around day 36 where it became more of a 
plateau especially in mouse 2 (figure 4.8A and B). The experiment was 
terminated on day 70 and the primary tumour plus the peripheral organs were 
imaged ex vivo. None of the peripheral organs showed any sign of light 
emission, indicating that there had been no migration of tumour cells from the 
primary site. The primary tumour had invaded into the gut wall and this was 
shown by the small amount of light being emitted from this tissue (figure 4.8C) 
which was confirmed by histology (figure 4.8D).  
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Figure 4.8 – Orthotopic growth of DLD-1/SVFluc tumours A) Images of one representative 
animal over the time course of the experiment B) total count measurements recorded at each 
imaging session for two mice C) ex vivo imaging of the primary tumour and peripheral organs of 
the mouse shown in (A) indicating some invasion into the gut wall and D) conformational 
histology of the primary tumour (left) and the invasion into the gut wall (right). Similarly to the 
subcutaneous tumour using this cell line, vascularity is high. Scale bar ≈100µm 
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4.3.4 LS174T/SVFluc tumour models 
LS174T/SVFluc cells were used to establish xenografts in both flanks of nude 
mice that were treated with either cisplatin or doxorubicin. Tumours from 
untreated control mice were used to set up orthotopic tumours. Intrasplenic 
injections were performed to establish liver metastasis.  
4.3.4.1 Characterisation of subcutaneous tumours  
A pilot study that involved 3 mice was initially undertaken to ensure that this cell 
line was suitable for in vivo BLI. Calliper and light emission were recorded and 
compared to analyse the relationship between the two parameters. A pre-
palpable tumour mass can be detected using BLI before it is possible to obtain 
calliper measurements (figure 4.9A and B).  
 
With the exception of one tumour (tumour 2, figure 4.9A) all LS174T/SVFluc s.c 
tumours grow steadily across the time course of the experiment and light 
emission increased with tumour volume. Regression analysis using all data 
available for s.c tumours of this cell type (figure 4.10) led to a higher correlation 
than when pilot data alone was used (figure 4.9C) although both were 
significant. The histology (figure 4.9D) indicated that LS174T/SVFluc tumours 
were well vascularised. Overall BLI data was more correlated to tumour volume 
in this cell line (figure 4.10) than seen in the DLD-1/SVFluc tumours (figure 
4.6A).  
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Figure 4.9 – LS174T/SVFluc s.c pilot study. A & B) representative calliper and total counts of 
tumours in 2 mice (error bars = SEM), C) Regression analysis of all data points in the pilot study 
(n=16 tumours, p<0.05), D) representative histology indicates that LS174T/SVFluc tumours 
were well vascularised. Scale bar ≈100µm 
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Figure 4.10 – LS174T/SVFluc regression analysis to compare tumour volume and light 
emission. All LS174T/SVFluc control tumours were for analysis (R
2
 = 0.5, p≤0.01, n=124 data 
points). 
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Figure 4.11 – The effect of cisplatin on LS174T/SVFluc s.c tumours. A) Relative tumour 
volumes as measured by calliper and B) relative RLU values. Mice were imaged pre-treatment 
and then on day 1, 2, 3 and 6 days post-treatment (n= 22 tumours, error bars = SEM) 
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4.3.4.2 Monitoring the effects of cisplatin treatment on s.c LS174T/SVFluc 
tumours  
The effect of cisplatin treatment in this cell line was investigated to see whether 
the light emission remained correlated to tumour volume. All mice were imaged 
before treatment and subsequently at 2, 3 and 6 days.  
 
Cisplatin appeared to exert no inhibitory growth effect on this tumour type as 
measured by calliper (figure 4.11A), where both tumours showed an increase in 
volume of approximately 4-fold over the 6 days of the experiment. 
Concordantly, average light emission between the groups was not significantly 
different (figure 4.11B), the largest apparent difference (albeit not statistically 
significant) being seen at day 2. The fold increase of light emission at day 6 was 
1.5 for treated tumours and 2.5 for untreated, which was lower than that seen 
for the equivalent relative increases in calliper measurements.  
 
4.3.4.3 Monitoring the effect of doxorubicin treatment on LS174T/SVFluc 
tumours 
Following the investigation into the effects of cisplatin on LS174T/SVFluc 
xenografts, doxorubicin was similarly investigated. Doxorubicin appeared to 
have more of an effect than cisplatin on this cell line in vivo, with the difference 
between tumour volumes being statistically significance at days 3 and 6 post-
treatment (figure 4.12A). Average tumour volume in untreated animals 
increased to 5-fold higher than treated group by day 6. Although the change in 
light emission mirrored the change in tumour volume, the larger standard errors 
meant that statistical significance was not reached (figure 4.12B).  
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Figure 4.12 – The effect of doxorubicin on LS174T/SVFluc s.c tumours as measured by A) 
callipers and B) bioluminescent imaging (n = 6 mice per group, error bars = SEM, *= p<0.05 
between groups) 
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4.3.4.4 Characterisation of an orthotopic LS174T/SVFluc tumour model 
Intracaecal orthotopic tumours were established in nude mice as described 
previously. Mice were imaged over 120 days. Orthotopic tumour development 
was successful in 11 out of 12 animals. Representative traces of 4 animals 
show tumour growth as monitored by detected light emission are shown in 
figure 4.13.  
 
In all mice there is a sharp increase in signal between 15 and approximately 40 
days following tumour establishment, and here there appears to be a plateau in 
the light emission as measured by BLI (figure 4.13, mice 2-4). At day 68 (mice 2 
and 4), light emission begins to increase again until termination of the 
experiment at day 88. Mice 1 and 2 were sacrificed prior to this due to large 
tumour size. Mouse 1 developed a number of metastatic lesions as measured 
by noninvasive BLI (data present in section 4.3.4.7). 
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Figure 4.13 – Orthotopic growth of LS174T/SVFluc tumours in 4 untreated mice. Total count 
values increase with time but tend to plateau at higher values 
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4.3.4.5 The effect of cisplatin on LS174T/SVFluc intracaecal tumours  
Cisplatin (8mg/kg) was used to treat mice bearing intracaecal LS174T/SVFluc 
tumours to investigate whether any effect exerted on the tumour could be 
monitored by changes in light emission. As previously, mice were imaged 
before treatment and subsequently at day 2, 3, 4 and 7. Cisplatin appeared to 
have an effect on light emission from the tumours (figure 4.14) however the 
differences were not significant (p>0.05).  
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Figure 4.14– The effect of cisplatin on LS174T/SVFluc orthotopic tumours (n = 12, error 
bars=SEM) 
 
 
Interestingly 2 of the animals in the control group developed metastasis whilst 
none of the animals in the treated group showed any sign of tumour cell 
dissemination as shown by post mortem BLI imaging (data presented in section 
4.3.4.7). 
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4.3.4.6 The effect of doxorubicin on LS174T/SVFluc intracaecal tumours 
Doxorubicin (10mg/kg) was used to treat mice bearing intracaecal tumours. The 
drug appeared to have no effect on the tumours as growth (measured by BLI) 
increased similarly to untreated controls (figure 4.15A-E). One animal in the 
control group developed lung metastases whilst no treated mice developed 
metastatic lesions.  
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Figure 4.15 – The effect of doxorubicin on 
LS174T/SVFluc orthotopic tumours. Y-
axis = RLU, x-axis = Day, error bars = 
SEM. A-D) Plots of total count values 
from each treated animal in the 
experiment. Animals were treated on day 
46, indicated by the arrows. No 
metastases were seen in any of these 
animals. E-F) control animals. Metastasis 
was seen in the lungs of the animal 
represented in graph e (figure 3.18B). n = 
5.  
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4.3.4.7 Spontaneous metastatic tumour development from LS174T/SVFluc 
intracaecal tumours 
During the development of the LS174T/SVFluc tumour models, metastatic 
spread of the tumour occurred in 3 untreated animals (out of a total of 8). BLI 
data and images are presented in figures 4.16 and 4.17. Figure 4.16A tracks 
one animal (primary tumour growth in this animal is shown in figure 4.13, mouse 
1), where BLI indicated that tumour masses were growing at sites other than the 
primary tumour. In this figure, from day 36, it can be seen that more than one 
ROI is apparent. At termination of the animal on day 48 there are a number of 
ROIs that are clearly separate from the primary tumour mass at locations 
elsewhere in the peritoneum, the testes and potentially in locations higher up 
within the peritoneum that may be representative of the liver (figure 4.16A). 
Confirmation that these deposits were present was made post mortem when the 
animal was imaged following removal of the primary tumour. Ex vivo imaging of 
the peripheral tissue showing photon emission was also performed (figure 
4.16B) and metastases were confirmed with histology (figure 4.16C).  
 
The lesions in the two remaining animals presenting with metastases could not 
be indentified during routine imaging sessions and it was not until post-mortem 
analysis that lung metastases were discovered (figure 4.17). All peripheral 
organs including the liver were imaged ex vivo and lesions were only apparent 
in the lungs of both mice. There were also some small deposits elsewhere on 
the gut wall close to the primary tumour in one animal (figure 4.17B). Invasion 
into the peritoneal wall was not seen in any mice where the primary tumour had 
metastasised.  
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Figure 4.16 – The development of liver metastases in a nude mouse bearing an orthotopic 
LS174T/SVFluc tumour. A) BLI images over the course of the experiment B) BLI post 
mortem and ex vivo tissues including the liver and the diaphragm C) H&E sections to 
confirm the presence of metastases, Scale bar ≈ 100µm 
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Figure 4.17 – Detection of lung metastases in 2 nude mice (A and B) bearing orthotopic 
LS174T/SVFluc tumours was detected at post-mortem. A) from L-R, BL image, post-mortem 
BLI (primary tumour removed), ex vivo heart and lung and H&E section. B) (top) from L-R, 
BL image, ex vivo primary tumour, post-mortem BLI, heart and lungs, (middle) H&E section 
of primary tumour & lung metastasis (bottom) further confirmation of micrometastases (blue 
arrows). Scale bar ≈100µm 
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4.3.4.8 LS174T/SVFluc intrasplenic metastatic models 
Three mice were injected intrasplenically with LS174T/SVFluc cells and 
bioluminescent imaging performed regularly over a period of 100 days.  
 
Two of the three mice developed liver metastasis (figure 4.18A): ROIs started to 
develop in mouse 3 as early as day 10; whilst the tumour in mouse 2 did not 
demonstrate measurable amounts of light emission until day 28 (figure 4.18A). 
Ex vivo analysis at post mortem of mouse 2 confirmed the presence of two 
large liver deposits (figure 4.18D/E), which may represent the two ROIs seen 
when the mouse was imaged prone (figure 4.18C). When the animal was 
imaged supine only one ROI could be distinguished (figure 4.18B). Liver 
deposits were also confirmed in mouse 3 by BLI and ex vivo analysis (data not 
shown).  
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Figure 4.18 – LS174T/SVFluc 
Intrasplenic injection leading to 
formation of liver metastases. 
A) Light emission traces of the 
two animals that developed 
liver tumours, B) 
representative supine images 
of mouse 2 from day 28 – 73, 
C) prone images of the same 
mouse, D) bioluminescent 
image of the spleen and 
pancreas (red circle) and the 
liver (bottom) and a 
photograph of the liver (right) 
showing 2 large metastatic 
deposits (indicated) and E) 
H&E image of the liver 
metastasis. Scale bar ≈100µm 
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4.3.5 Colo205/SVFluc tumour models  
Similarly to the experiments performed with DLD-1 and LS174T/SVFluc tumour 
models, Colo205/SVFluc cells were used to establish subcutaneous xenografts, 
and orthotopic models.  
4.3.5.1 Subcutaneous tumour models   
Initial pilot study results confirmed that this cell line was suitable for in vivo 
bioluminescent imaging. Colo205/SVFluc tumours grew well in nude mice and 
in general tumour growth was accurately tracked by total count values (figure 
4.19A and B). When data from all Colo205/SVFluc tumours from a number of 
different studies was collated to investigate the overall correlation between 
tumour volume and photon emission the result was significant (figure 4.19D, 
p<0.05) and in fact of the three Fluc cell lines developed, Colo205/SVFluc 
showed the highest correlation when regression analysis was performed. 
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Figure 4.19 – Colo205/SVFluc s.c growth curves (A and C), B) representative images of the 
mouse in figure (A) and D) regression analysis of all (n=66 tumours) untreated Colo205/SVFluc 
tumours (R
2
=0.61, p<0.05, error bars = SEM)  
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4.3.5.2 The effect of cisplatin treatment on subcutaneous Colo2-5/SVFluc 
tumours  
As previously described for the DLD-1/ and LS174T/SVFluc s.c tumour models, 
mice were imaged prior to treatment with cisplatin and subsequently imaged on 
days 1, 2, 3 and 6. Animals were treated again on day 8 and subsequently 
imaged until day 11.  
 
Cisplatin inhibited the growth of Colo205/SVFluc tumours, which reached 
significance at day 6 post-treatment as compared to the control animals. 
Following a second round of treatment the difference between the two groups 
was maintained until termination of the experiment at day 11 (figure 4.20A). The 
total count values mirrored the relative tumour volumes (figure 4.20B), which 
similarly reached statistical significance. The relative increase in total counts 
from tumours of control animals was almost 10-fold higher between pre-
treatment and day 11 readings. The relative increase in tumour volume for the 
same group was 3.5-fold.  
 
In treated animals the relative increase in tumour volume across the time 
course of the experiment was extremely low, mirrored in the low relative 
increase in total counts measured from the tumours, of around 2-fold. 
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Figure 4.20 – The effect of cisplatin on Colo2-5/SVFluc s.c tumours. A) Changes in light 
emission and B) tumour volume (n= 3 mice (6 tumours) per group). Mice were treated at day 0 
(pre) and day 8 (arrowed). Error bars = SEM, * = p<0.05 between groups. 
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4.3.5.3 Characterisation of orthotopic Colo205/SVFluc tumour models  
Orthotopic intracaecal models were set up as before. Although some tumours 
did establish from Colo205/SVFluc donor pieces placed onto the caecal wall 
(figure 4.21A), the take rate was lower than for that of the other two cell types 
and it was common for the tumours to begin to grow, only to show decreased 
total count values after 3-4 weeks (figure 4.21B). Overall the number of mice 
that developed primary orthotopic tumours using this model was approximate 
50%. In those tumours that did develop, the histology confirmed that there was 
local invasion into the gut wall (figure 4.21C) but that no distant metastases 
occurred.  
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Figure 4.21 – Colo205/SVFluc intracaecal tumour growth tracked by BLI. In some cases 
tumours did grow well (A), however there were issues with tumours appearing to show 
signs of growth initially, but losing signal by day 30 (C). D) Representative histology of a 
tumour that grew successfully. Scale bar ≈100µm, n=4 (2 animals represented here) 
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4.3.5.4 The effect of cisplatin treatment on the growth of Colo205/SVFluc 
orthotopic tumours  
The take rate in this experiment was 50% so analyses of any drug effect is 
difficult, however following treatment with cisplatin there did appear to be a 
small effect when compared the average relative light emission from the two 
control tumours (figure 4.22). Due to the low number of animals (n = 3), 
statistical tests could not be performed. There was a huge difference between 
the two treated animals on day 7 indicated by the very large standard error 
bars.  
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Figure 4.22 – The effect of cisplatin on light emission from Colo205/SVFluc intracaecal tumour 
bearing animals (n= 3 animals (6 tumours) per group)  
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4.3.6 HT29-CMVLuc tumour models 
4.3.6.1 Characterisation of HT29-CMVLuc subcutaneous xenografts 
To determine whether the correlation between light emission and tumour 
volume seen above was similar to that seen in commercially available cell lines 
s.c tumours were established in nude mice using HT29-CMVLuc (from Caliper 
LS). This cell line was readily detectable in nude mice and grew well. A lack of 
consistency was observed between calliper-determined tumour volume and 
light emission, with some tumours showing good correlation (figure 4.23A) and 
others showing erratic emission (figure 4.23B). Overall when the regression 
between tumour volume and total count values was analysed the correlation 
was low but significant (R2=0.3, p<0.05, figure 4.23C). 
 
In comparison to the cell lines developed during this project, the correlation 
between HT29-CMVLuc tumour volume and the light emission (R2=0.3, figure 
4.23C) was better than that seen in DLD-1/SVFluc tumours (R2=0.08, figure 
4.6A), but lower than in Colo205/SVFluc (R2=0.61, figure 4.19B) and 
LS174T/SVFluc (R2=0.5, figure 4.10).  
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Figure 4.23 – Subcutaneous growth of HT29-CMVLuc cells in 2 mice; A) indicates a growth 
curve where light emission traced the calliper measurements well, whilst B) shows poor tracking 
of calliper measurements by BLI, especially tumour one (red) and C) shows the regression 
analysis for this cells line using data from untreated control animals (R
2
=0.3, p<0.05, error bars 
= SEM) n=6 mice 
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4.3.6.2 The effect of cisplatin treatment on HT29-CMVLuc s.c tumours 
Treatment of HT29-CMVLuc s.c tumour bearing mice with cisplatin lead to a 
small growth delay but this did not reach statistical significance (figure 4.24A). 
In untreated animals the average relative tumour volume increased 2-fold, 
whilst in treated animals no obvious increase was observed. There was no 
statistical difference between the change in light emission in treated compared 
to control animals (figure 4.24B) and both groups of animals showed a 
decrease in emitted light between pre-treatment and day 1 imaging sessions. 
The light emission from tumours of the treatment group decreased between day 
3 and day 7, but again this was not significant.  
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Figure 4.24 – The effect of cisplatin on the light emission from HT29-CMVLuc s.c tumours as 
measured by calliper (A) and BLI (B). n= 3 animals (6 tumours) per group. Error bars = SEM 
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4.3.7 DLD-1/SVRluc tumour models: Renilla luciferase 
4.3.7.1 Characterisation of DLD-1/SVRluc subcutaneous xenografts 
The DLD-1/SVRluc cells, expressing Renilla as opposed to Firefly luciferase 
were successfully imaged at the subcutaneous location following inoculation 
into nude mice. Tumours were monitored by regular calliper measurements and 
BLI.  
 
Overall DLD-1/SVRluc tumours showed poor correlation between light emission 
and tumour volume overall (figure 4.25C), although in some animals the light 
emission did increase according to tumour size (figure 4.25A). In some tumours 
there was an initial increase in light emission, which then tailed off, an example 
of this is shown in figure 4.25C. The light emitted from the Renilla expressing 
tumours was highly variable between imaging sessions even in those animals 
where the overall trend was to increase with volume. Tumour morphology was 
similar to that seen in the Fluc expressing tumours (figure 4.25E). 
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Figure 4.25 – DLD-1/SVRluc s.c tumour growth. A and C) Examples of growth curves that show 
total count values track tumour volume well (A) and poorly (C), B) representative images from 
the mouse in graph A, D) Regression analysis of tumour volume and total count values for 
xenografts of this tumour type (n= 70, R
2
=0.1). E) Representative histology. Scale bar ≈100µm 
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4.3.7.2 The effect of cisplatin on the growth of DLD-1/SVRluc xenografts  
Mice were imaged pre-treatment and for 4 weeks subsequently. Mice were 
retreated on day 21.   
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Figure 4.26 – The effect of cisplatin on DLD-1/SVRluc tumours A) calliper measurements and B) 
bioluminescent data. The arrows indicate treatment administration (n=6 tumours per group, 
error bars = SEM 
 
 
Although at days 1 and 3 there appeared to be small delay in tumour growth in 
those animals treated with cisplatin (figure 4.26A), this was not significant. 
Similarly for light emission there was again, a small difference at day 3, the 
large standard error seen in control animals deems this difference insignificant.  
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4.3.7.3 Characterisation of a DLD-1/SVRluc orthotopic tumour model 
DLD-1/SVRluc xenografts were used to establish orthotopic tumours on the 
caecum of 3 nude mice. The donor tumour pieces were taken from the indicated 
tumour of the mouse shown in figure 4.27A, where a light emission was 
detected on the day of transplantation. The animals bearing orthotopic tumours 
were imaged on day 13, 20, 27 and 41 however no signal was detected from 
any of the three animals (figure 4.27B).  
 
         
 
Figure 4.27 – DLD-1/SVRLuc orthotopic tumour growth. No orthotopic growth was seen in mice 
transplanted with DLD-1/SVRluc donor tumours (B – representative image). The donor tumour 
emitted a signal prior to being transplanted (A), suggesting that there was growth failure rather 
than inadequate detection.  
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4.3.8 LS174T/SVRluc tumour models 
4.3.8.1 Characterisation of LS174T/SVRluc subcutaneous xenografts  
In those animals where tumours became established light emission was readily 
detectable and there were many cases where light emission tracked tumour 
growth successfully (figure 4.28A). However, the number of tumours that 
successfully grew following injection of the cell suspension was low (50%). 
There were also instances where initially light emission increased, but then 
began to fall after a couple of imaging sessions (figure 4.28B). Using the data of 
tumours that grew successfully the overall correlation between tumour volume 
and light emission was significant (p<0.05, figure 4.28D).  
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Figure 4.28 – LS174T/SVRluc s.c tumour growth A) growth curve of two tumours (in two 
different mice), B) representative images from Mouse 1, C) Plot from a tumour that showed 
diminished light emission towards the end of the experiment and d) regression analysis of all 
LS174T/SVRluc control tumours (n=35, R
2
=0.4, p<0.05). Error bars = SEM. 
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4.3.8.2 The effect of cisplatin treatment on LS174T/SVRluc s.c xenografts  
Mice were imaged prior to treatment and subsequently at days 1, 3, 4, 9 and 11. 
Tumour growth in treated animals was not significantly different to growth of 
untreated tumours until 11 days following treatment where the tumour volume of 
control animals had increased by around 6-fold compared to 3.5-fold in treated 
tumours (figure 4.29A).  Total count values of the treated group stayed lower 
than those of the control group until day 11 and were significantly different at 
day 3 (figure 4.29B), however at day 11 the relative light emission from the 
control group fell back to pre-treatment values, which was not mirrored by the 
average tumour volumes that had continued to increase.   
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Figure 4.29 – The effect of cisplatin on LS174T/SVRluc tumour growth; A) Measured by 
callipers and b) bioluminescent output. n=3 mice (6 tumours) per group, error bars = SEM, * = 
p<0.05 between groups  
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4.3.8.3 Characterisation of an orthotopic LS174T/SVRluc tumour model 
Donor LS174T/SVRluc s.c tumours were used to set up intracaecal tumours in 
three nude mice. Similarly to results seen for DLD-1/Rluc the number of 
intracaecal tumours that grew was low; in 1 mouse a tumour could be 
successfully monitored using BLI until its sacrifice on day 38 (mouse 1, figure 
4.30). In another animal tumour growth was monitored until day 30 before light 
emission receded to background levels by day 40. Histological analysis 
comparing the tumours that were excised from these two animals following 
sacrifice confirm high levels of necrotic tissue in the tumour from mouse 2 
(figure 4.30C) compared to the presence of viable tissue in the tumour excised 
from mouse 1 (figure 4.30B). No metastases were seen in mice bearing 
LS174T/SVRluc tumours although local invasion into the gut wall was evident 
(figure 4.30B). In the third animal low levels of light emission were detected at 
days 16, 21 and 29 which then receded.  
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Figure 4.30 – Orthotopic growth of LS174T/SVRluc tumours as measured by BLI (A). Only 1 
mouse showed good tumour growth, where the presence of a large tumour meant the animal 
had to be sacrificed at day 38. B) Images of mice 1 and 2 at day 21, 29, 37 and 52 (mouse 2 
only. C) Histology from mouse 1 (L) and 2 (R) confirming extensive necrotic areas in mouse 2. 
Scale bars ≈100µm 
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4.3.9 Evaluation of cross reactivity between Firefly and Renilla substrates  
Mice bearing DLD-1/SVRluc, DLD-1/SVFluc and DLD-1/SVFR (mixed) 
subcutaneous tumours in three 3 locations (figure 4.31A) were injected with 
CET (0.35mg/kg, i.v) and imaged. After 4 hours the animals were injected with 
D-luciferin (150mg/kg, i.p) and imaged as usual. In imaging sessions following 
CET administration, light was emitted from tumours 2 and 3 (which were 
established using Rluc expressing cells). Conversely, following administration of 
D-luciferin tumours 1 and 3 (Fluc expressing) emitted light. The images in figure 
4.31 are representative of the same animal imaged after injection with CET and 
4 hours later following injection with D-luciferin. Neither of the substrates 
showed any cross-reactivity with the alternative luciferase enzyme and tumour 3 
(a mixture of both cell types) emitted a signal when both substrates were 
administered.  
 
                            
Figure 4.31 – DLD-1/SVFLuc, /SVRLuc and mixed tumours. A) Location of the three tumour 
types; 1 = DLD-1/SVFluc, 2 = DLD-1/SVRluc and 3 = a mixed population of both cell types B) 
Bioluminescent image following injection of CET C) The same animal imaged 4 hours later 
following injection with D-luciferin indicating no cross-reactivity between the substrates.  
 
C B A 
1 
3 
2 
186 
 
4.4 Discussion 
In the development of reporter cell lines for preclinical anticancer drug testing 
there are certain characteristics that must be exhibited by the cell line when 
they are used in various tumour models. Firstly, they must be detectable 
through the skin of the mouse, or from deeper anatomical locations if they are to 
be used as orthotopic or metastatic models. Secondly, if the efficacy of a 
cytotoxic drug is being investigated then there must be a relationship between 
the decreasing size of the tumour and a lower level of light emission as 
detected by BLI. If tumour growth is delayed or reversed by a compound then 
light emission must be similarly responsive to avoid false negative results for 
the drug. This is highly important for orthotopic and metastatic tumours as they 
are not measurable using callipers. As detailed in the introduction, orthotopic 
and metastatic models are superior to subcutaneous xenografts as they are 
more replicative of the human disease and should be used wherever possible, 
especially after initial drug-efficacy tests have been performed.  
 
In this chapter a panel of cell lines created in this project were tested for their 
ability to monitor tumour growth in vivo over time. Using cisplatin and 
doxorubicin they were also tested for their ability to monitor cytotoxic treatment 
effect at subcutaneous and orthotopic locations. The potential of developing 
new metastatic models for colorectal using these cell lines was also 
investigated.  
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There are certain advantages using fluorescent over bioluminescent cell lines, 
including the lack of requirement of an injected substrate; however this study 
demonstrated that although the pCMVdsRed protein is useful for tracking 
tumour growth at subcutaneous locations (figure 4.2) it is not suitable for use in 
orthotopic models (figure 4.3). In s.c models the correlation between the 
fluorescent signal and the tumour volume was better for smaller tumours 
(<200mm3) which is not unexpected in sight of the fact that attenuation of the 
fluorescent signal will be increased in cells farthest from the excitation source 
(Brindle, 2008; Lowik et al., 2009). Unfortunately orthotopic growth of this cell 
line could not be monitored non-invasively, likely due to due to tissue depth and 
light penetration limitations (Hall et al., 2011). Recently fluorescent proteins that 
emit light farther into the near infra-red spectrum (650-900 nm) have been 
engineered that show promise in orthotopic and metastatic models (Reddy et 
al., 2011). Far-red fluorophores are thought to be superior to other fluorescent 
proteins as longer excitation wavelengths entail less cytotoxicity to the cells and 
decreased autofluorescence and scattering of light as it travels through the 
tissue (Davidson and Campbell, 2009).   
 
It has been reported that high levels of Firefly luciferase expression may inhibit 
growth of the cell lines in vivo (Brutkiewicz et al., 2007). Conversely, several 
studies have confirmed that transfection using Firefly and Renilla luciferase 
does not negatively affect cell line growth in vitro (Tiffen et al., 2010). During 
this study initial comparisons between the growth of s.c DLD-1 w.t, DLD-
1/SVFluc and DLD-1/SVRluc doubling times (table 4.1) appeared to confirm that 
introduction of luciferase into cells does not affect their growth in vivo. At a later 
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stage in the project SVRluc-expressing cells showed less tumourgenicity than 
their SVFluc counterparts and this will discussed later.  
 
Among the Firefly luciferase expressing cell lines there were variable levels of 
correlation between the tumour volume and the levels of light emission. DLD-
1/SVFluc cell line gave the lowest correlation (figure 4.6A), followed by the 
commercially available HT29-CMVLuc cells (figure 4.23C). LS174T/SVFluc 
(figure 4.10) and Colo205/SVFluc (figure 4.19D) gave the highest correlation 
between light emission and tumour volume. Luciferase substrates are delivered 
to the tumour via the blood stream so it is possible that these correlations are 
due to differences in tumour vasculature. Histology of DLD-1/SVFluc tumours 
indicated a well vascularised tumour with uniform vessels (figure 4.4D). The 
LS174T/SVFluc tumours were well vascularised however there appeared to be 
less uniformity and vessel diameter was more variable (figure 4.9E), as 
previously reported (Laufer et al., 2011). Similarly the Colo205 tumour is known 
to be well vascularised (Shnyder et al., 2007). It may be that in tumours where 
vessel density is high and very uniform the influx and efflux of the substrate may 
be more fluctuating than in tumours such as LS174T where it may perhaps 
become trapped in regions that are less densely vascularised. Further work 
correlating the vascularity of the tumour with light emission kinetics is required 
to confirm this theory.  
 
Interestingly, the ability of BLI to accurately track the effect of exposure to 
cytotoxic drugs mirrored the overall correlations discussed above i.e. light 
emission from s.c DLD-1/SVFluc or HT29-CMVLuc tumours, following treatment 
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cisplatin, did not accurately mirror the effect of the drug as measured by calliper 
(figure 4.7). Conversely, measured light emission from s.c Colo205/SVFluc 
tumours following treatment with cisplatin, accurately tracked the tumour 
volume changes (figure 4.20). This was also seen in LS174T/SVFluc tumours 
treated with doxorubicin (where there was a growth inhibitory effect, figure 4.12) 
and with cisplatin (where no growth inhibition occurred, figure 4.11). It is 
important to note that with the exception of doxorubicin treatment on 
LS174T/SVFluc s.c xenografts (figure 4.12, n=22 tumours), the maximum 
number of animals used per experiment was 6. Although increasing the number 
of animals may lead to improved data sets and improved statistical analyses, 
with regards to the overall aims of this project using more animals is less 
appropriate when the 3Rs are being considered. Therefore a balance has to be 
made between using a larger data set for greater statistical analyses and a 
smaller set for animal reduction and study refinement.  
 
The growth of Fluc-expressing orthotopic tumours was monitored successfully 
using all three transfected cell lines, where light emission increased over time. 
Although impossible to confirm precisely whether the increase in light emission 
was matched by similar increases in tumour volume, it was possible to palpate 
the tumour manually when they reached larger sizes thus confirming volume 
increase to an extent. Although the correlation between the tumour volumes  
and light emission  was poor in some cases, as long as appropriate precautions 
were taken with regards to data and imaging, BLI could be used to successfully 
monitor tumour growth.  
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In orthotopic models, cisplatin showed a possible effect on the growth of 
Colo205/SVFluc and LS174T/SVFluc tumours; however the sample size was 
too small for satisfactory statistical analyses. In contrast, treatment with 
doxorubicin did not appear to affect the growth rates of orthotopic 
LS174T/SVFluc intracaecal tumours (figure 4.15). Interestingly, in untreated 
mice, metastasis was observed in 3 out of 8 animals bearing orthotopic 
LS174T/SVFluc intracaecal tumours. In one animal metastatic deposits were 
detectable using noninvasive BLI (figure 4.16), whereas in the other 2 animals 
the deposits were discovered at post-mortem (figure 4.17). In these latter two 
animals metastatic deposits were found only in the lungs, whilst the other 
mouse presented with deposits in a variety of anatomical locations including the 
liver, gut wall and diaphragm.  Although other cell lines, most notably HCT-116, 
has been shown to disseminate to the lung and liver (Guo et al., 2007; Holgren 
et al., 2010; Rajput et al., 2008; Wang et al., 2009b), no study has previously 
reported metastatic dissemination of LS174T from a clinically relevant 
intracaecal orthotopic site. Furthermore the dissemination pattern of LS174T 
appears to recapitulate the clinical situation, which means that this model could 
potentially be used for testing novel agents against disseminated colorectal 
cancer in a noninvasive manner.  
 
Further work would be required to increase the percentage of mice presenting 
with metastatic disease, which could be done by passaging the primary tumours 
of animals that developed metastases or by passaging the metastatic tumours 
themselves. Interestingly during this project the liver metastasis that developed 
during intrasplenic injection (figure 4.18) was used to establish xenografts and 
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orthotopic models. Surprisingly none of the mice developed intracaecal tumours 
and only one tumour (out of 12) grew at the s.c location after 64 days (data not 
shown).  
 
Imaging metastatic deposits is also hindered by the limits of detection using BLI. 
Intracaecal orthotopic models are, by their nature, deep in the tissue which 
leads to higher levels of light attenuation and measuring light emission from 
very small metastatic deposits (like those seen in the lungs) is difficult. 
Additionally, quenching effects, where a dominant signal from the primary 
tumour mass masks the light emitted from a smaller mass was clearly seen and 
this has also been reported elsewhere (Yurek et al., 2011). Because the 
majority of dissemination from intracaecal tumours is within the peritoneal 
cavity, it is hard to distinguish which organ a ROI is being emitted from. This 
has been seen here using BLI (figure 4.16), and in other reports using a GFP 
labelled colorectal cell line (Rajput et al., 2008; Wang et al., 2009b). BLI has 
been used successfully to track metastases in a range of different tumour 
models including fibrosarcoma, lung, renal, prostate, breast and colorectal 
cancer (Drake et al., 2010; Nogawa et al., 2005; Takahashi et al., 2010; Zhang 
et al., 2010). However, all of these models were established directly at the site 
of metastasis, so no primary tumour was present. Removal of the primary 
tumour mass may be an option to study the development of metastases in 
distant anatomical locations more closely and this would mimic the treatment 
regime in the clinic. This method has been developed for prostate, breast 
(Corey et al., 2003; Vantyghem et al., 2005) and colorectal orthotopic models 
(Kojima et al., 2010; Tanaka et al., 2001).  
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Local invasion but no dissemination from DLD-1/ or Colo205/SVFluc intracaecal 
was seen in this project. In one study it was reported that DLD-1 can 
metastasise to the lungs (Seiden-Long et al., 2008), although the majority of 
studies that have used this cell line for SOI implantation on the caecum have 
not led to the formation of metastases (Tsutsumi et al., 2009). There are no 
reports of Colo205 being used to establish orthotopic models using SOI 
however, only a 50% of the transplanted tumours grew and more should be set 
up in order to fully characterise the orthotopic growth of this cell line.  
 
Injection of LS174T/SVFluc tumour cells into the spleens of nude mice led to 
the development of liver metastases in 2/3 animals, the growth of which could 
be tracked using BLI. Similarly to other groups that have used this cell line, liver 
metastases did not occur in 100% of animals injected (Hamada et al., 2008) 
and a plateau of light emission was reached at later stages of the experiment 
(Zabala et al., 2009). The reasons for this are yet unknown, but may reflect 
either differential metastatic spread observed with orthotopic tumours, 
described above, coupled to tissue restricted tumour development. Despite the 
lower development rate, this model gives a further dimension for evaluating 
novel agents against dissemination to the liver, the primary metastatic site for 
colorectal cancer.  
 
As discussed previously the use of Renilla expressing cell lines led to the 
development of fewer tumours both at the s.c and orthotopic sites when 
compared to their Firefly expressing counterparts. The effect of expression of 
Rluc has not been investigated specifically, however early in vitro 
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characterisation of the Rluc cell lines did not suggest any negative effect on the 
growth of the tumour cell lines (chapter 2). In orthotopic models the take rate of 
Rluc expressing cells was much lower than that seen for Firefly expressing 
tumours. Intracaecal tumour growth as detected by light emission was only 
detected in 1/3 LS174T/SVRluc tumours and in 0/3 DLD-1/SVRluc tumours. 
This is not due to the higher levels of light attenuation seen in Rluc-expressing 
tumours, confirmed by the lack of a palpable tumour mass and no visible 
primary tumour at post-mortem. In previous studies Rluc expressing cells have 
been used successfully to monitor orthotopic tumour growth over time when 
imaging was done every 2-5 days (Dobrenkov et al., 2008; Shah et al., 2008), 
however in both cases the experiments were shorter and the primary tumour 
was created using cell suspensions, rather than SOI. It could be possible that 
inclusion of the SVRluc vector lead to a decrease in the tumourgenicity of the 
cell line, although this did not affect cell proliferation in vitro. Another possibility 
is that exposure of the donor s.c tumour to CET in imaging sessions prior to 
being transplanted into the caecum may have affected its carcinogenic 
potential. Elsewhere it has been reported that pre-expansion of s.c tumours 
prior to their use as donors may alter their growth and dissemination capacities 
(Farre et al., 2002), although compared to SVFluc expressing tumours there is 
no reason why the SVRluc tumours should behave differently. In both the 
LS174T/ and DLD-1/SVRluc orthotopic experiments only 3 mice were used 
which is low considering the take rate may only be around 50%. It was also 
common to see tumours begin to grow but then recede, as seen in figure 4.25A 
and 4.30, which illustrates this in subcutaneous and orthotopic models 
respectively.  
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In some cases the Rluc expressing- tumour did grow, but the signal appeared to 
decline after a number of imaging sessions evidenced in figure 4.25A/B (DLD-
1/SVRluc) and figure 4.28C (LS174T/SVRluc) where the last data points for 
both tumours had decreased significantly despite the tumour volume increasing. 
Conversely it was also noted that occasionally there was a decrease in tumour 
volume towards the end of an experiment concordantly with the decrease in 
light emission (figure 4.25C). The decrease in light emission was observed prior 
to the decrease in tumour volume, suggesting that the reaction between Rluc 
and CET may in itself lead to negative effects on the tumour cells. Although this 
has not been previously reported in Rluc-expressing tumours a similar 
phenomenon has been reported for the Fluc/D-luciferin where expression in 
itself did not affect cell growth or light emission, but that repeated imaging 
sessions led to a decrease in signal and tumour growth (Brutkiewicz et al., 
2007).  
 
Of note, as well as being the substrate for Renilla luciferase, CET has been 
shown to be transported by the P-gp transporter (Pichler et al., 2004), a 
transmembrane protein encoded by the multi-drug resistance (MDR-1) gene 
(Ambudkar et al., 1999). This phenomenon is due to the chemical structure of 
CET, which shares physiochemical features of may substrates of the ATP-
binding cassette transporter superfamily, especially those of P-gp (Pichler et al., 
2004). Colorectal cancer has been estimated as one of the tumours having the 
highest level expression of MDR1 and P-gp (Polimeni et al., 2011; Shen et al., 
2005) and of the cell lines being used, DLD-1 has been reported to show 
moderate expression of P-gp (Iwahashi et al., 1993) while LS174T appears to 
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have low baseline P-gp expression. Upregulation of the P-gp has been 
demonstrated using various agents such as rifampicin (Kota et al., 2010) and  
persistent use of CET may have a similar effect, although this relationship has 
not been investigated. Any upregulation would increase the speed at which CET 
is removed from the tumours, potentially leading to a lower signal being 
achieved. The relationship between the exposure of tumours to CET and their 
expression levels of both MDR1 and P-gp would be very interesting to 
investigate and may help to explain some of the unexpected light emission 
decreases. The use of Rluc in in vivo systems where P-gp status is unknown or 
may be affected by the experimental conditions should therefore be cautious 
(Pichler et al., 2004). 
 
Another explanation that may account for the decreased light emission seen 
when Rluc expressing tumours grew larger are the reaction kinetics: Very little 
is known on the kinetics of the CET/Renilla reaction, but has been reported that 
one molecule of the Rluc enzyme can turn over up to 100 molecules of native 
CET (Woo and von Arnim, 2008). Secondly, Both Firefly and Renilla luciferase 
enzymes follow Michaelis–Menten kinetics, by which maximum light output is 
not achieved unless substrates and co-factors are present in excess (MIP, 
2008). Both of these factors may have an impact on the light output of larger 
Rluc-expressing tumours where the amount of CET present could have been 
below that required to allow the reaction to emit the maximum light output. D-
luciferin is injected at a much higher concentration and thus would not lead to 
the same problems. The lower injection concentrations of CET may also be 
affected by the high interstitial pressures and poor vasculature that are 
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commonly present in the centre of larger tumours (Tredan et al., 2007). 
Elsewhere, higher doses of coelenterazine were required for Rluc-expressing 
cells from deeper tissues as compared with superficial tissues (Bhaumik and 
Gambhir, 2002), so in retrospect using a higher concentration of CET may have 
improved bioluminescence. However, a higher concentration may be 
counterproductive based on its potential effects upon P-gp.  
 
Ultimately dual-imaging tumour models would be of much interest for preclinical 
drug development as specific interactions could be individually imaged. Dual 
luciferase reporter systems are generally used to track tumour cells expressing 
one type of luciferase and using the other to track either other cell types, such 
as mesenchymal stem cells (Kidd et al., 2010) or to monitor gene delivery 
(Shah et al., 2003) for example. The potential of using the two luciferase 
enzymes in one system is indicated here by the lack of cross-reactivity seen 
between the substrates and the alternative luciferase enzymes (figure 4.31). 
Clearly the emission from the two reactions was indistinguishable in the tumour 
type that consisted of a mix of Fluc and Rluc expressing cells and if dual 
reporting from the same tumour was required imaging sessions using the two 
substrates would have to be separated by approximately 3 hours. 
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4.5 Conclusions 
A panel of luciferase expressing cell lines were characterised for their capacity 
to successfully monitor tumour growth and drug efficacy in a variety of tumour 
models. Although there were some limitations regarding the ability of certain cell 
lines to show a correlation between tumour volume and light emission (most 
notably DLD-1/SVFluc) the remainder of the Fluc-expressing cell lines showed 
excellent potential in subcutaneous xenografts. With regards to the Rluc 
expressing cell lines, although there were instances where tumour growth was 
accurately tracked, further work needs to be carried out with regards to 
improving the apparently low tumourgenicity of these cells and confirmation of 
the involvement of P-gp expression over multiple imaging sessions. Although 
the pCMVdsRed expressing cell line gave excellent results regarding correlation 
between tumour volume and light emission it was unsuitable for use in 
orthotopic models. 
 
Importantly for this project, the LS174T/SVFluc cell line led to the development 
of novel clinically relevant tumour models; the development of spontaneous 
metastases to the lungs, liver, diaphragm and elsewhere in the peritoneum was 
seen, which are similar to that seen in clinical metastatic presentation. Further 
development of both the methods used and the cell line itself would be required 
prior to this model being used routinely for preclinical testing of novel agents.  
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5 Investigation of the utilisation of bioluminescent imaging to 
evaluate agents that target the tumour vasculature  
5.1 Introduction 
As discussed previously, noninvasive bioluminescent imaging has been 
assessed for its use in monitoring the relationship between tumour volume and 
light emission and its ability to track treatment efficacy. Although BLI is 
commonly used for these purposes by a large number of research groups, its 
utility extends to other fields that are more pharmacodynamic in nature. One 
such area in which BLI has not extensively been utilised is that of investigating 
the effects of vascular disrupting agents. In this chapter BLI as a method to 
report vascular shutdown in response to treatment with drugs that affect the 
tumour vasculature is validated.  
5.1.1 The tumour vasculature  
More than 90% of all cancers present as solid tumours (Siemann et al., 2005) 
and in order to develop beyond 1-2mm3 in size they must support a functional 
vasculature (Folkman, 1972). Interruption of the tumour blood supply can lead 
to death of tumour cells and tumour shrinkage (Denekamp et al., 1983). There 
are various differences between tumour and normal vasculature  including 
absent or abnormal perivascular cells, high vascular permeability and chaotic 
and disorganised vessel architecture (Carmeliet and Jain, 2000; Denekamp, 
1982; McDonald and Baluk, 2002). Figure 5.1 illustrates the variety of 
differences seen between normal and tumour vasculature. Due to these 
differences there are a number of drugs that have been developed to 
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specifically target the immature, irregular vasculature of the tumour (Siemann, 
2011). Targeting the colorectal tumour vasculature has previously been shown 
to be an important therapeutic target (Baker et al., 2008). The cell lines 
developed in this project are therefore of translational importance for use in 
such models, although all solid tumours are potentially targetable by this 
strategy. 
 
 
 
Figure 5.1 – The tumour vasculature. A) Normal tissue and B) solid tumour vasculature. Green 
represents lymphatics, blue represents poorly oxygenated blood and red represents well 
oxygenated blood (Adapted from (Tredan et al., 2007) 
 
5.1.2 Vascular Targeting Agents 
In the development of drugs against the tumour vasculature there are two 
approaches: Firstly they can be developed to target angiogenesis, which was 
first  proposed as a method to treat tumours in the early 1970s (Folkman, 1972) 
and has been in development since. Secondly they can target the pre-existing 
vasculature, first suggested in the 1980s (Denekamp, 1982).  
 
A B 
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Drugs that target angiogenesis are usually involved in the inhibition of 
angiogenic growth factors, modulation of the extra-cellular matrix, or targeting of 
cell surface adhesion molecules (Chan et al., 2008; Thorpe, 2004). 
Bevacizumab and erlotinib are examples of antiangiogenic drugs currently in 
clinical trials that target the vascular endothelial growth factor and the epidermal 
growth factor-tyrosine kinase receptor respectively (Chan et al., 2008).  
 
Vascular disrupting agents (VDAs) are a large group of chemicals that 
specifically target the endothelial cells and pericytes of the tumour vasculature 
in existing tumours (Chan et al., 2008; Hinnen and Eskens, 2007), exploiting  
the immature and rapidly developing tumour vasculature, which is dependent on 
the tubulin cytoskeleton to maintain cell shape (Siemann, 2011). Treatment with 
such agents leads to rapid and massive collapse of the tumour vasculature, 
within 1-6 hours of administration (Tozer et al., 2008). This leads to secondary 
neoplastic death (Siemann et al., 2002). Advantages of VDAs over cytotoxic 
drugs include a decreased chance of acquired drug resistance because the 
drugs are targeting the normal endothelium rather than the malignant cells 
themselves. There is also increased effectiveness in drug delivery due to the 
cells being more easily accessible and the number of tumour cells that can be 
killed is high as thousands are dependent upon one vessel (Bloemendal et al., 
1999; Chaplin and Hill, 2002; Kerbel, 1997).  
 
There are two types of VDA; biological (or ligand-directed) and small molecule 
VDAs. Ligand-directed VDAs use target molecules such as antibodies or growth 
factors that selectively travel to tumour endothelium, which have a toxin or pro-
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coagulant attached (Gaya and Rustin, 2005). The clinical efficacy of these 
biological VDAs appears to be limited due to cost issues and a lack of specificity 
and toxicity (Chan et al., 2008). The small molecule VDAs are further divided 
into flavonoids and tubulin binding agents.  
5.1.2.1 The Flavonoids  
These molecules have a tubulin-independent mechanism of action  (Chan et al., 
2008; McKeage and Baguley, 2010) and are derivatives of flavone acetic acid 
(FAA). The compound DMXAA is a more powerful analogue of FAA that was 
developed in the early 1990s (Rewcastle et al., 1991). Its exact mechanism is 
unknown but it works by damaging the tumour vascular endothelium, leading to 
DNA strand breaks and apoptosis, thought be via the production of TNF and 
other cytokines as a result of the upregulation of nuclear transcription factor 
NFκB (Baguley et al., 1997). In the clinic DMXAA is currently in stage III trials in 
combination with carboplatin and paclitaxel, however for the treatment of 
NSCLC it did not provide additional benefits compared to cytotoxic treatment 
alone (Lara et al., 2011). Other phase III studies are however ongoing 
(McKeage and Baguley, 2010). 
5.1.2.2 Tubulin-binging agents 
Tubulin binding agents act as vascular disrupting agents due to the high 
dependence of unstable tumour vasculature on microtubules to maintain their 
structure (Chan et al., 2008; Thorpe, 2004). Some tubulin binding agents, such 
as the combretastatins, work by binding at or near the colchicine site on the β-
subunit of endothelial cell tubulin. This leads to depolymerisation of 
microtubules and disorganisation of actin and tubulin cytoskeletons within the 
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tumour endothelial cells (EC) (Gaya and Rustin, 2005). Subsequent disruption 
of the formation of the mitotic spindle during mitosis as well as alterations in cell 
shape then occur (Chan et al., 2008). Rapid changes in cell shape lead to 
micro-vessel blockage and loss of flow as well as disruption of the EC layer 
leading to exposure of the basement membrane and increased permeability 
(Gaya and Rustin, 2005). The high interstitial pressures and vessel congestion 
lead to further loss of blood flow in the tumour and there may also be induction 
of the coagulation cascade and local thrombus formation (Gaya and Rustin, 
2005). The mechanism of action that follows after the drugs have bound to the 
microtubules is not fully understood however it is thought that the 
depolymerisation of microtubules leads to the release of microtubule-associated 
proteins, activating RhoA and its downstream effectors such as RhoA kinase 
that causes cytoskeletal rearrangements and rapid vascular shutdown (Lippert, 
2007) as shown in figure 5.2. 
 
The leading compound in this class of agents is combretastatin A-4 phosphate 
(CA4P) (Pettit et al., 1995), a combretastatin A-4 pro-drug that binds to tubulin 
at the same site as colchicine but with a much higher affinity (McGown and Fox, 
1989; Pettit et al., 1989). It has been shown to produce vascular shutdown in 
s.c tumours at doses one tenth of the MTD (Dark et al., 1997) and leads to a 
reduction of blood flow in the tumour and haemorrhagic necrosis (Grosios et al., 
1999). CA4P is in clinical trials to be used in conjunction with a variety of other 
compounds such as paclitaxel and carboplatin (Bilenker et al., 2005; Rustin et 
al., 2010) and various antibodies including the carcinoembryonic antigen, CEA  
(Meyer et al., 2009). 
203 
 
The vinca-alkaloids are another group of tubulin binding agents that include 
vinblastine, vincristine and the cytotoxic pentapeptide dolastatin-10 and its 
derivatives (Lippert, 2007). These drugs all bind to the vinca-alkaloid site of β-
tubulin. At high concentrations vinca alkaloids inhibit microtubule polymerisation 
(Bai et al., 1990a) which disrupts formation of the microtubules during mitosis, 
thus arresting cell division and leading to cell death (Jordan et al., 1991), 
whereas at low concentrations a more subtle action on microtubules is exerted 
which does not significantly inhibit polymerisation but appear to block mitosis by 
activation of the metaphase-anaphase checkpoint (Ngan et al., 2000). 
Dolastatin-10 initially showed promise in vivo (Bai et al., 1990b) but lacked 
efficacy in clinical trials for treatment of a range of cancer types including 
advanced colorectal (Saad et al., 2002) and breast cancer (Perez et al., 2005) 
however its derivatives such as auristatin-PYE has shown promise in vivo 
(Shnyder et al., 2007). TZT1027, another synthetic derivative of dolastatin-10 
leads to the collapse of tumour vasculature as well as DNA fragmentation and 
tumour cell cycle arrest (de Jonge et al., 2005; Natsume et al., 2003; Watanabe 
et al., 2000). 
 
The original drugs that showed potential as vascular disrupting agents, such as 
colchicine, vincristine and vinblastine had to be given at doses that were close 
to the MTD before any therapeutic effect was achieved (Hill et al., 1993; 
Thorpe, 2004). More recently analogues of these drugs have been developed 
that have a wider therapeutic index and exert their effect at doses much lower 
than the MTD. There are now a number of colchicine analogues that have 
progressed to clinical trials such as combretastatin A-4 phosphate (CA4P), and 
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combretastatin A-1 phosphate (CA1P/Oxi4503) and ZD6126 (Monk et al., 2006; 
Pettit and Lippert, 2000).  
 
  
Figure 5.2 – An overview of the mechanisms of action of tubulin-binding VDAs. (VE: vascular 
endothelial; EC: endothelial cell) Adapted from (Wang et al., 2011) 
 
 
5.1.3 Potential problems and issues surrounding VDA treatment  
There are a number of issues surrounding the use of VDAs in the treatment of 
solid tumours which means that they are unlikely ever to be used as single 
agents. Firstly, although VDAs cause tumour vascular shutdown, a “viable rim” 
of tumour cells are left at the periphery of the tumour (Rice et al., 2010) that get 
their oxygen and nutrient supply from normal tissue blood vessels. These cells 
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on the edge of the tumour mass have proven difficult to eradicate and they lead 
to tumour re-growth (Tozer et al., 2008). Secondly, issues surrounding the 
generation of a VDA induced central necrotic and hypoxic region of a solid 
tumour (Davis et al., 2002) may have implications regarding upregulation of 
pathways that lead to increased angiogenesis (Rey and Semenza, 2010; Simon 
et al., 2008). In many studies investigating vascular shutdown by VDAs 
repopulation of the tumour vascular is apparent after 24 hours (Salmon and 
Siemann, 2006; Siemann et al., 2002; Wankhede et al., 2010). Finally, as well 
as driving neoangiogenesis, the appearance of hypoxia in tumours can lead to 
pro-survival changes in gene expression (that suppresses apoptosis), 
autophagy and an anabolic switch in the metabolism of the tumour cells 
(Martinez-Outschoorn et al., 2010; Wilson and Hay, 2011) that can lead to a 
more aggressive phenotype (Vigneswaran et al., 2011). This has recently been 
reviewed with regards to treatment with antiangiogenic compounds, but the 
same issues are applicable for treatment with VDAs (De Bock et al., 2011).  
 
To overcome these three issues, VDAs have been used with various other 
agents such as cytotoxics (Bilenker et al., 2005; Rustin et al., 2010; Thorpe, 
2004), antiangiogenic therapies (Tozer et al., 1999) and drugs that specifically 
target hypoxic cells (Wilson and Hay, 2011) and it may be that treatment 
combinations of such drugs with VDAs will be effective treatment strategies.   
 
Another issue associated with VDAs in the clinic is that their associated 
cardiotoxicity, which has limited the progression of some VDAs through trials 
(LoRusso et al., 2008; Tozer et al., 2005). It is therefore important to develop 
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new VDAs and to test them in combination with a variety of other agents. 
Improving preclinical testing of VDAs both alone and in combination is important 
to help improve understanding of the mechanisms of action and help to facilitate 
the optimisation of therapeutic combinations (Zhao et al., 2008). Improved 
preclinical studies in the development of this class of agent will undoubtedly 
lead to improved efficacy in the clinic. 
5.1.4 Measuring vascular shutdown in preclinical in vivo models 
As with the development of all anticancer agents the development processes for 
vascular disrupting agents shows a large attrition rate as they progress through 
preclinical and early clinical trials when the efficacy fades or dose-limiting side 
effects become apparent. With regards to the development of vascular 
shutdown agents it is important to show a rapid, extensive collapse of the 
tumour vasculature in good pre-clinical models so that the mechanism of action 
is better understood before a drug goes through into early clinical trials. To 
effectively monitor the effect of a VDA the specific vascular shutdown event 
must be monitored, as oppose to measuring tumour shrinkage or growth delay, 
which are both used as an endpoint markers in many preclinical anticancer drug 
testing (Suggitt and Bibby, 2005).  
 
The most commonly used method is to visualise the functional tumour 
vasculature using a fluorescent dye in histological sections of tumours. Hoechst 
33342, a dye that emits blue fluorescence when excited by ultra-violet light 
(Smith et al., 1988) has been used most commonly to measure the effects of 
vascular disrupting agents in vivo (Davis et al., 2002; Grosios et al., 1999; 
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Shnyder et al., 2007). The dye is injected via the tail vein into a mouse 1 minute 
prior to sacrifice allowing the dye to bind to DNA in the first structures it comes 
to; in this case the endothelium of the vasculature, including that of the tumour. 
The tumours are then removed and snap frozen in liquid nitrogen before being 
sectioned using a cryostat and viewed under a microscope. The dye cannot 
reach endothelial cells in those vessels that collapse following treatment and 
this can be seen when sections of the tumour are viewed under a UV light-
microscope and Hoechst 33342 staining manually quantified (Shnyder et al., 
2007). As with any method that is undertaken manually, there is risk of human 
error and bias. Additionally only a finite number of sections (usually 5) can be 
analysed and quantified and although the sections are spread throughout the 
tumour it means that the whole tumour vasculature cannot be examined. 
5.1.5 Non-invasive imaging of vascular shutdown 
Vascular shutdown is a dynamic process that begins within minutes (Wang et 
al., 2011) and can be monitored anytime between a couple of hours following of 
administration of the VDA (Holwell et al., 2002) and up to 24 hours later (Zhao 
et al., 2008). When methods such as Hoechst 33342 are used to assess the 
functional vasculature only single time point measurements for each animal can 
be achieved (Davis et al., 2002). In the development of vascular disrupting 
agents being able to image the same group of animals prior to and 
during/following treatment with a drug is extremely beneficial, allowing real 
changes in vasculature to be measured. This prevents the necessity of control 
versus treatment groups, as required when Hoechst 33342 is used. Non-
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invasive imaging methods would allow such dynamic assessment to be made 
and a variety of techniques have been utilised for VDA development. 
5.1.5.1 MRI for the assessment of vascular shutdown 
MRI has been used to evaluate the effects of VDAs and has various 
characteristics that make it suitable for this application. It has excellent spatial 
and temporal resolution, it can image in arbitrary planes, no ionising radiation is 
used and it can give information regarding morphological, functional and 
metabolic information (Wang et al., 2011). MRI can be applied in both 
preclinical and clinical settings and thus one drug can be investigated 
throughout its later development using the same technology.  
 
DCE-MRI is a quantitative method of investigating the structure and function of 
tumour microvasculature and microcirculation that assess changes in tumour 
blood perfusion by tracking the pharmacokinetic uptake and wash-out of low-
molecular weight contrast agents within the extracellular space of tumours and 
can give values regarding vascular permeability as well as correlating with 
tumour perfusion and angiogenesis (Ali et al., 2010) and to this end can show 
efficacy of VDAs. It was utilised in the phase I clinical trials of CA4P (Rustin et 
al., 2010; Stevenson et al., 2003) and has also successfully been used to 
demonstrate vascular shutdown following administration of VDAs in preclinical 
models (Beauregard et al., 2002; Galbraith et al., 2003; Robinson et al., 2003; 
Salmon and Siemann, 2006) and give provides information regarding tumour 
blood flow and vascular permeability (Zhao et al., 2008).  
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As discussed in section 1.11.1.1, MRI has low sensitivity and a relatively long 
acquisition time as well as having a high associated cost making the technique 
unsuitable for small laboratories.  
5.1.5.2 Positron emission tomography assessment of the effects of VDAs 
PET can be used to monitor physiological and metabolic processes in vivo and 
methods of monitoring tissue perfusion using 15O-labelled tracers have been 
validated in the brain and myocardium and the data corresponds well to 
measurements obtained in cerebral, pancreatic and hepatic tumours using other 
methods (Anderson and Price, 2002; Gaya and Rustin, 2005).  
 
Although PET has not been used to measure the effect on tumour perfusion of 
VDAs in preclinical work directly it has successfully shown dynamic vascular 
shutdown in vivo as a result of treatment using photodynamic therapy (Berard et 
al., 2006a; Berard et al., 2006b). It was used in the phase I clinical trials of 
CA4P to measure tumour and normal tissue perfusion (Anderson et al., 2003).  
 
Similarly to MRI, PET is also an expensive technology for preclinical imaging 
and the majority of small laboratories where preclinical testing is performed do 
not have access to this equipment. The technique also requires the use a 
radioisotopes which are difficult and potentially hazardous to work with (Brindle, 
2008). 
5.1.5.3 Other techniques  
Other non-invasive imaging techniques that have been used in preclinical 
testing to monitor vascular shutdown are laser Doppler flowmetry (Burns et al., 
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2009; Ley et al., 2007), magnetic resonance spectroscopy (Bohndiek et al., 
2010) and spectral imaging (Wankhede et al., 2010), which utilises a dorsal 
skin-fold window chamber and is therefore not truly non-invasive.  
5.1.5.4 Bioluminescent imaging 
As previously discussed, BLI requires the modification of tumour cell lines to 
express a luciferase gene which are then used to establish tumours in mice.  
When the substrate, D-luciferin in the case of Fluc expressing cells, is injected 
intraperitoneally it is absorbed into the blood and delivered to tumour cells 
where the enzymatic reaction results in the emission of photons, the intensity of 
which can be measured using a cooled charge couple device camera. The 
hypothesis is that if tumour blood flow is restricted by VDAs the amount of D-
luciferin that can reach the tumour cells is limited, fewer enzymatic reactions 
can occur and thus the number of photons emitted from the tumour decreases. 
As tumour vasculature recovers photon signal will increase respectively.  
 
211 
 
5.1.6 Aims and Objectives  
The aim of the work carried out in this chapter was to validate BLI as a method 
to quantitate vascular shutdown in response to a known VDA, 
azademethylcolchicine (ICT-2552), a colchicine derivative characterised in 
house and known to produce a vascular shutdown effect in a very short time 
period (Atkinson et al., 2010). Initially the technique was performed in parallel 
with Hoechst 33342 staining, which is currently used in the majority of 
preclinical studies to assess vascular shutdown. Further validation of the 
technique was performed by using another Fluc expressing cell line as well as 
investigating the effect of alternative common cytotoxic agents on BLI over the 
same time period. Finally a fluorescent tumour model was used to further 
confirm that the decrease in light emission was due to shutdown of the 
vasculature rather than potential cytotoxicity caused by the VDA. Ultimately if 
BLI could be further validated as a proof-of-principle method to show vascular 
shutdown it would improve data sets whilst adhering to the 3Rs principles.  
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5.2 Materials and Methods 
5.2.1 Compounds 
Doxorubicin, 5-Fluorouracil, cis-Diammineplatinum (II) dichloride (Cisplatin), 
paclitaxel, Hoechst 33342 (bizBenzimide) and Chremophor EL were obtained 
from Sigma, Poole, UK. Azademethylcolchicine (ICT-2552) was prepared in 
house as previously described (Atkinson et al., 2010) . Drugs were reconstituted 
and injected as follows: 5-FU (75mg/kg), and doxorubicin and cisplatin 
(10mg/kg) in sterile physiological saline, paclitaxel (20mg/kg) in 10% 
DMSO/10% Chremophor EL/80% sterile physiological saline and ICT-2552 in 
10% DMSO/oil at 60 or 30 mg/kg. All drugs were injected intraperitoneally (i.p), 
except Doxorubicin which was injected intravenously (i.v) via the tail vein. 
Hoechst 33342 was dissolved in saline and injected i.v at 40mg/kg. All doses 
were below those previously shown to be lower than the MTD. D-luciferin was 
made up at 30mg/ml in sterile dH2O before being diluted further in cell culture 
medium prior to injection to a final concentration of 15mg/ml (150mg/kg).  
5.2.2 Animals and tumour systems 
Refer to Chapter 3, section 3.2.2 
5.2.3 Cell lines 
The DLD-1/SVFluc, DLD-1/pCMVdsRed and Colo205/SVFluc cell lines, 
engineered as described in Chapter 2 were used to set up the subcutaneous 
xenografts used for these experiments. Cells were maintained as previously 
described (section 2.2.3.3).   
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5.2.4 In vivo bioluminescent imaging 
In vivo BLI was performed using a cooled charge coupled device camera 
system (IVIS imaging system 50, Xenogen/Calliper Life Sciences, Alameda, 
CA). Tumour bearing mice were injected i.p with D-luciferin (150mg/kg) before 
being anaesthetised using 2.5% isoflurane/O2. Anaesthesia was maintained at 
the same level throughout the imaging procedure. When in the dark chamber of 
the IVIS 50 system mice were kept under anaesthetic via connection to the 
nose cones. Imaging was performed across a range of times points (12-20 
minutes) following injection of D-luciferin, and signal intensity calculated as the 
total photon count within a region of interest around the tumour, placed during 
data analysis following imaging of the animal (refer to sections 2.2.7 and 2.2.8). 
5.2.5 In vivo fluorescent imaging 
FLI was also performed using the IVIS 50 system. Animals were anaesthetised 
as previously, and placed into the light-tight chamber where anaesthesia was 
maintained. Images were acquired over 1 minute using excitation/emission 
wavelengths of 558/583nm respectively to image the fluorophore.  
5.2.6 Assessment of vascular shutdown using noninvasive imaging 
All mice were imaged at day -1 to gain a baseline signal intensity reading for 
each tumour. Mice were split into groups and treated at time 0/day 0. Mice were 
imaged at 1 and either 4/6 hours (day 0) and 24 hours (day 1) with injection of 
D-luciferin prior to each imaging session for the Fluc expressing models.  
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5.2.7 Assessment of vascular shutdown using Hoechst 33342 
Animals were injected with Hoechst 33342 at 40mg/kg 1 minute prior to 
sacrifice by cervical dislocation. Tumours were removed and snap frozen in 
liquid nitrogen and stored at -80°C until required. Tumours were sectioned using 
a cryostat; 10μm sections were taken from each tumour with at least 100µm 
between each section, ensuring that the middle of the tumour mass was 
sampled. Analysis was performed using methods previously described 
(Shnyder et al., 2007). Briefly, 5 random fields from each of 10 random sections 
were examined for each tumour under UV illumination using a Leica DMRB 
microscope, with images captured digitally through a JCD 3-CCD camera and 
processed using AcQuis (Synoptics, Cambridge, UK) software. Functional 
vasculature was assessed by placing a cm2 grid over the captured digital image 
and counting the number of points on the grid which overlay fluorescent cells. 
Comparisons were made between percentage vasculature in control and 
treated tumours. 
5.2.8 Data analysis 
All post-treatment values (both Hoechst 33342 and BLI data) were normalised 
to pre-treatment values for individual mice and averaged across each treatment 
group. Significance between pre- and post-treatment readings was determined 
using the students t-test with a p<0.05 considered to be statistically significant. 
To establish whether BLI would be suitable to replace Hoechst 33342 as a 
method to indicate vascular shutdown the two methods were compared using 
ratios between pre- and post-treatment readings. 
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5.3 Results 
5.3.1 Investigating ideal time points for measuring vascular shutdown 
using BLI  
In this study it was established that photon output from the D-luciferin/luciferase 
reaction had ceased 3 hours following injection (Chapter 3, figure 3.4). This 
meant that the minimum time between imaging sessions to track vascular 
shutdown was 3 hours, as re-injection of the D-luciferin substrate before this 
time could lead to overestimation of the photon emission from the tumours.  
 
Initially four groups (n = 3 per group) of DLD-1/SV-Fluc s.c tumour bearing mice 
were injected with D-luciferin. Each group was imaged and treated (ICT-2552, 
60mg/kg i.v) as described in section 5.2.7.  
 
Evaluation of histological assessment and BLI demonstrated that both Hoechst 
33342 staining and light emission significantly drop after 1 hour, on observation 
which is maintained until 4 hours. Following 24 hours ICT-2552 exposure 
Hoechst staining was still low, whist light emission had increased to levels 
higher than the pre-treatment readings (figure 5.3). Overall this result suggests 
that imaging at either 1 or 4 hours following treatment would be sufficient to 
show vascular shutdown.  
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Figure 5.3 – The effect of treatment with ICT-2552 on the light emission and functional 
vasculature as measured by Hoechst 33342 and BLI A) representative pre- (left) and post- 
(right) treatment images at each time point, B) graph to compare Hoechst 33343 and BLI that 
demonstrates consistent decreases for post-treatment readings compared to pre-treatment for 
all tumours at the 1 and 4 hour time points (p<0.05) error bars = SEM. n=3 animals per group 
except the 24 hour group which contained only 2 mice. C) Hoechst stained tumour sections 
representing vascular shutdown at 1, 4 and 24 hours, and a control section. 
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5.3.2 The effects of cisplatin on light emission and functional vasculature  
Having demonstrated that imaging at 1 hour was appropriate for assessment of 
vascular shutdown, a further experiment was performed including the control 
agent cisplatin, which is not reported to be a VDA. Evaluation of shutdown was 
performed at 1 and 24 hours post-treatment. 
 
Similarly to previous observations (figure 5.3), both light emission and Hoechst 
staining showed a significant drop between pre-treatment and 1 hour post-
treatment (figure 5.4, p<0.01 for both methods) in animals treated with ICT-
2552. By 24 hours the values compared to controls for both Hoechst and ICT-
2552 had returned to around 90% of the control values. In animals treated with 
cisplatin there appeared to be no effect on the vasculature was observed by 
method; after one hour neither the Hoechst or total count values were 
significantly different from control values (p>0.05) or from each other (p=0.49). 
By 24 hours both methods indicated an increase in vascular density as 
compared to control, although again, values were not significant as compared to 
controls, or between methods (p>0.05).  
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Figure 5.4 – Analysis of treatment effects of ICT-2552 and cisplatin on DLD-1/SVFluc tumour 
vasculature using Hoechst 33342 and BLI A) representative images of mice from each time 
point (pre/post) B) graph comparing the two methods  as Hoechst 33342 and BLI imaging are 
not significantly different. n=30 (** p<0.01, error bars = SEM)  
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5.3.3 Validating the use of BLI to measure vascular shutdown over time 
in the same animal  
As previously indicated changes in light emission, as a result of treatment with 
ICT-2552, correlated highly with histological assessment of the actual tumour 
vasculature as shown by Hoechst 33342 data. This demonstrates that BLI could 
be reliably used to measure vascular shutdown.  
 
With regards to a time course for vascular shutdown mice treated with ICT-2552 
showed a significant decrease in total count values 1 hour following treatment 
and a further decrease by 6 hours, before returning to pre-treatment values by 
24 hours (figure 5.5A and B, p<0.05). In tumours treated with non-VDAs, 
despite small increases being observed compared to the pre-treatment values 
none of these changes reached significance (figure 5.5A and B).   
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5.3.4 Validation of BLI to measure vascular shutdown using a second 
colorectal model 
To confirm that BLI was a suitable technique for monitoring vascular shutdown 
in more than one tumour type, similar experiments were performed using 
another colorectal cell line, Colo205/SVFluc that had been characterised 
previously (Chapter 2).  The results in figure 5.6 confirm that vascular shutdown 
as a result of ICT-2552 was also measurable using BLI in another colorectal cell 
line, Colo205. Tumours treated with ICT-2552 showed a significant decrease in 
light emission 6 hours following treatment. No significant change was observed 
in control mice (figure 5.6B).  
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5.3.5 Investigating whether the decrease in light emission was 
associated to cytotoxicity of ICT-2552 
To further confirm that the decrease in light emission in tumours following 
treatment with ICT-2552 was as a result of the vascular shutdown effect rather 
than any cytotoxicity, similar experiments were performed on animals bearing 
tumours composed of a mix of bioluminescent and fluorescent cells; DLD-
1/SVFluc and DLD-1/pCMVdsRed. As fluorescent cells do not rely on the 
delivery of an exogenous substrate light emission should be maintained despite 
treatment with ICT-2552.  
 
The fluorescent and bioluminescent data presented in figure 5.7 supports data 
obtained previously by using common cytotoxic drugs (figure 5.6), that the 
decrease in bioluminescent signal from SVFluc expressing tumour cells is as a 
result of the disruption of the tumour vasculature rather than cytotoxic effects. 
The fluorescent signal remains constant in both treated and untreated animals 
whilst the BLI signal shows a significant decrease at the 6 hour time point in 
those animals treated with ICT-2552 (figure 5.7B, p<0.05).  
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Figure 5.7 – Monitoring the effect of ICT-2552 on DLD-1/pCMVdsRed/SVFluc tumours using 
BLI. A) Representative images of treated animals, B) Group ratios of light emission compared to 
pre-treatment values. n= 6, * = p<0.05, error bars = SEM 
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5.4 Discussion 
In the development of vascular disrupting agents vascular shutdown must be 
monitored. This is commonly performed using a dye, Hoechst 33342, that labels 
the functional endothelial cells in the tumour blood vessels. Hoechst 33342 is 
used extensively to evaluate the effects of vascular shutdown agents 
(Bhattacharya et al., 2008; Davis et al., 2002; Grosios et al., 1999; Shnyder et 
al., 2007) as well as changes in the vasculature resulting from anti-angiogenic 
compounds (Cesca et al., 2009). The aim of the work in this chapter was to 
validate BLI imaging as a method to determine the effects of vascular disrupting 
agents on the tumour vasculature. ICT-2552 was chosen as a suitable agent 
that causes vascular collapse. This compound is a colchicine derivative which 
has previously demonstrated vascular disrupting capabilities (Atkinson et al., 
2010) soon after treatment. It was hypothesised that following treatment with 
ICT-2552 the vasculature within subcutaneous colorectal xenograft tumours 
would shut down. D-luciferin, the substrate for luciferase, is usually injected i.p 
and reaches the tumour through absorption into the abdominal vasculature. 
VDAs cause collapse of the tumour vasculature and therefore impede drug 
distribution and influx into the Fluc-expressing tumours. Ultimately this should 
lead to a decrease in the amount of light emitted from the tumour. Results 
presented here indicate that this is indeed the case and the comparability of BLI 
to Hoechst 33342 validates the noninvasive method as being suitable for 
monitoring vascular shutdown noninvasively in vivo.   
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Preliminary experiments using DLD-1/SVFluc tumours demonstrated that 
following treatment with ICT-2552, there was a decrease in light emission at 
both 1 and 4 hours (figure 5.3). Due to the comparability of light emission and 
the extent of functional vasculature measured by Hoechst 33342, the decrease 
in light emission was interpreted as being induced by vascular collapse caused 
by the agent. Concordant findings were reported in another study where similar 
time points were also used to analyse the effect of combretastatin A-4 
phosphate (CA4P) on tumour vasculature using BLI (Zhao et al., 2008). 
Vascular collapse is usually seen within the first 4 hours following treatment 
which lasts up to 24 hours, making these time points common for measuring the 
effect of VDAs (Grosios et al., 1999; Hori et al., 2002; Kanthou and Tozer, 2009; 
Lankester et al., 2007; Siemann et al., 2002; Zhao et al., 2008). Inconsistencies 
between the two methods seen in figure 5.3B can be partially explained by low 
animal number in the group; n=2, (one animal could not be included in post-
treatment measurements) and a large degree of variance between these two 
animals. It has also been reported elsewhere that individual light emission 
measurements could show discrepancies of up to 60%, however overall were 
<20% (Zhao et al., 2008). 
 
Extensive tumour necrosis is seen in histology following treatment with a range 
of VDAs after 24 hours (Dark et al., 1997; Davis et al., 2002; Grosios et al., 
1999; Siemann et al., 2002) and histology confirms that this was also the case 
in this study (figure 5.5C). Interestingly, and somewhat contrary, it is also the 
case that blood flow and vasculature begin to be re-established by 24 hours 
following treatment with VDAs including OXi4503 and CA4P (Salmon and 
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Siemann, 2006; Siemann et al., 2002; Wankhede et al., 2010), both colchicine 
derivatives (the parent molecule of ICT-2552). This revascularisation as 
determined by BLI was also seen in this study (figure 5.5B) where at the 24 
hour time point tumour vasculature had returned to 90% of the initial levels. Of 
note, in early studies it appeared that BLI provided a more sensitive 
methodology for determining the revascularisation as compared to Hoechst 
33342 (figure 5.3B).  
 
To confirm that shutdown as measured by BLI was a result of vascular collapse 
rather than associated cytotoxicity, a variety of cytotoxic drugs were included as 
controls. Experiments using cisplatin, doxorubicin, 5-FU and paclitaxel 
confirmed that any decrease in light emission was caused as a result of 
treatment with the VDA (figure 5.4 and 5.5). Treatment with cisplatin did not 
lead to a change in light emission or functional vasculature as measured by 
Hoechst 33342 at 1 or 24 hours (figure 5.4). Similarly, 5-FU, doxorubicin and 
paclitaxel led to an insignificant increase in the light emission of tumours at 1, 6 
and 24 hours (figure 5.5). This is supported by previous studies demonstrating 
that doxorubicin, cisplatin and 5-FU have no effect on tumour vascular perfusion 
as measured by Hoechst 33342 24 hours after treatment (Chaplin and Hill, 
2002). To further confirm that light emission decreased due to vascular collapse 
rather than cytotoxic events, animals bearing tumours made up of a mixed 
population of pCMVdsRed and SVFluc cells were treated with ICT-2552. This 
led to a significant decrease in the bioluminescent signal at 6 hours but not the 
fluorescent signal which remained constant throughout the 24 hours of the 
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experiment (figure 5.7). If cytotoxicity resulted from treatment a concurrent 
decrease in fluorescence emission would have been expected.  
 
The ultimate aim of using BLI instead of more invasive techniques is to 
minimise the numbers of animals being used whilst enabling animals to act as 
their own controls. Validation that BLI can successfully monitor vascular 
shutdown in one animal over time was therefore a necessary step in the 
development of the method. Following treatment with ICT-2552 a decrease in 
light emission was recorded between 1 and 6 hours, with recovery at 24 hours 
(figure 5.5). This mirrored data present earlier (figure 5.4B) where 90% recovery 
of the functional vasculature was observed at 24 hours, as measured by 
Hoechst 33342. 
 
After demonstrating that vascular shutdown could effectively be demonstrated 
using BLI, another colon cancer model was investigated; Colo205/SVFluc. This 
cell line had shown more consistent results regarding light emission/tumour size 
than DLD-1/SVFluc. Similarly to results seen in the DLD-1/SVFluc model, 
treatment of Colo205/SVFluc tumours led to a significant decrease in light 
emission 6 hours following treatment (figure 5.6), confirming the suitability of 
BLI for measuring vascular shutdown.  
 
Bioluminescent imaging and Hoechst 33342 both represent the same 
physiological effect in this study, however BLI has many benefits. Firstly it 
eliminates bias that may be introduced when using manual methods, such as to 
quantify Hoechst 33342 staining, including limited sampling of the tumour 
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vasculature. Secondly it means that the same group of animals can be used 
throughout one experiment and sacrifice at each time point is not required. 
Thirdly, it enables animals to act as their own controls; data from the same 
mouse gives both pre- (control) and post-treatment readings whilst a separate 
group of mice is left untreated to act as an extra control group ensuring that 
there are no issues with regards to variables other than those that are treatment 
related. This removes the possibility that a control group of mice may have 
higher levels of tumour vasculature than treatment groups, which could lead to 
false negative results during treatment analysis. A further benefit of using BLI is 
that it could be used to concurrently monitor drug dosing and efficacy: The 
effects of treatment with VDAs is known to be dependent on the administered 
dose as well as the tumour model (Kanthou and Tozer, 2009). Thus, higher 
doses of a drug may cause more disruption of the tumour vasculature when 
compared to lower does (as seen here where a 60mg/kg dose of ICT-2552 led 
to rapid shutdown at 1 hour (figures 5.3 and 5.4), whilst 30mg/kg led to 
shutdown at 6 hours (figure 5.5) in DLD-1/SVFluc tumours. A plateau of 
“maximal shutdown” may also be attained where further dose increases would 
have no additional benefit.  
 
Drawbacks to using BLI include issues with reproducibility; the use of small 
groups of animals means that if one animal cannot be used (which can be due 
to a variety of reasons including ineffective delivery of luciferin to the tumour or 
an unpleasant reaction to the drug requiring termination) there is a potentially 
huge percentage decrease in the number of tumours available for analysis. This 
is highlighted effectively by the 24 hour time point in figure 5.3B, where one 
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animal could not be included for post-treatment analysis and a large error was 
seen across the two remaining animals. Another drawback to using BLI is that 
the extent of the viable rim cannot be accurately assessed due to the low 
resolution of the technique.  
 
5.5 Conclusions  
In this study we have shown that BLI is a viable alternative to using Hoechst 
33342 in small animal studies investigating vascular shutdown. The effect of 
VDAs on different tumour types and at different sites, including orthotopic 
tumours, could also be investigated. BLI data could provide information 
regarding drug dosing strategies and efficacy of combination therapies. This is 
especially important considering that VDAs are highly unlikely to ever be used 
as single agents. Dual-reporter non-invasive FLI and BLI may also be of use as 
constitutive expression of a fluorescent protein could be used to asses tumour 
size whilst BLI could assess tumour shutdown if a VDA was given in parallel 
with a cytotoxic drug. Ultimately BLI can demonstrate proof-of-principle of novel 
antivascular compounds in early-phase preclinical drug development.  
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6 Evaluation of bioluminescent reporter models for 
pharmacodynamic proof-of-concept studies 
6.1 Introduction  
Bioluminescent imaging is most commonly used to track tumour growth in vivo 
and to monitor the efficacy of treatment on a variety of tumour models which 
can be measured by quantifying the light emitted from the tumour following 
injection of the appropriate luciferase substrate, discussed previously. In light of 
the evolution of molecular-targeted cancer therapeutics (section 1.7) and the 
need to extract as much information from in vivo studies as possible (section 
1.10), a significant advantage and potential of BLI is the assessment of 
molecular-target interactions and drug pharmacodynamics in vivo.  
 
There are now a large number of genes and transcription factors that have been 
successfully monitored in vitro using luciferase, including VEGF-A (Ellrichmann 
et al., 2010), p53 (Weiss et al., 2010), survivin (Sakoguchi-Okada et al., 2007)  
and AP-1 (Weiss et al., 2010) amongst others. When the luciferase gene is 
under control of a transcription factor upregulation leads to higher expression of 
the luciferase enzyme and thus a higher light emission on exposure to the 
luciferase substrate.  
6.1.1 Rationale for the development of in vivo BLI models for the 
detection of p53 and p21 gene responses to anticancer therapies  
As previously discussed in section 2.1.3, the tumour suppressor protein, p53, is 
usually maintained at low levels in the cell, regulated by the negative feedback 
loop with the MDM2 protein (Li et al., 2011). However there are various 
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instances that lead to stabilisation and accumulation of p53 including chemically 
induced DNA damage. The detection of an in vivo p53 response has been 
proposed as an evaluation tool for potentially useful cytotoxic anticancer agents 
(Briat and Vassaux, 2008).  
 
The p53 protein represents an important target for drug development because it 
provides a key difference between normal and tumour cells (Wang et al., 2006). 
Regarding the development of targeted therapy, drugs that obstruct the 
interaction between p53 and MDM2 were introduced in chapter 1: Nutlin, RITA 
and MI-219 that interrupt the MDM2-p53 interaction can reactivate p53 and lead 
to tumour regression in vivo (Vassilev et al., 2004). As more drugs are 
discovered that exert their effect by reactivation (e.g. Nutlin) or transcriptional 
upregulation (e.g. doxorubicin) of p53, a validated bioluminescent tumour model 
to indicate this noninvasively in vivo would be very valuable. 
 
Similarly, the development of a tumour model that could indicate the 
upregulation of p21 would also be of high interest. The activation of the p21 
gene and subsequent upregulation of the protein leads to cell-cycle arrest and 
potentially cell death as introduced previously (section 2.1.3). Activation of p21 
can be in a p53- dependent or –independent manner and apoptosis induced by 
treatment with various cytotoxic drugs leads to its upregulation via the p53 
pathway (el-Deiry et al., 1994). Conversely independent activation of p21 has 
been revealed as a mechanism by which some molecular targeted therapies 
exert their therapeutic effects (Archer et al., 1998; Sowa et al., 1999).  
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6.1.2 Measurement of p53 and p21 activation by bioluminescent imaging 
Normally the detection of a p53 or p21 response relies on ex vivo analysis of 
tissue samples. However, development of models in which luciferase 
expression was stimulated through p53 and p21 activation would allow non-
invasive imaging of such a response.  
 
There are a number of in vitro studies that use p21 or p53- driven cell reporter 
systems to monitor the transcriptional activity of the two genes. BLI has 
previously been validated in cell based screens for small molecules and other 
drugs that activate a p53 response (Wang et al., 2006; Weiss et al., 2010). 
Recently, novel polyoxometalate compounds that work through HDAC inhibition 
were identified using a p21-driven luciferase reporter cell based screen (Dong 
et al., 2011). There are many examples of other studies that use similar 
methods in vitro but do not extend to work in vivo (Hu et al., 2011a; Hu et al., 
2011b; Lin et al., 2011; Liu et al., 2011; Yoon et al., 2011).  
 
The development of an in vivo model would allow real-time quantitative 
assessment of gene activation and would require fewer animals than would be 
required for current ex vivo analysis. As discussed previously, each animal 
would also act as its own control, eliminating inter-mouse differences that may 
affect the significance of results. Although p53- and p21-luciferase models have 
only rarely been used, a limited number of studies have used knock-in and 
genetically modified mice to study both endogenous and treatment induced p21 
and p53 expression (Briat and Vassaux, 2008; Ohtani et al., 2007; Tinkum et 
al., 2011) using luciferase. Models that use knock-in p21Fluc enable the study 
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of p53-dependent and independent stress responses within the context of the 
whole animals (Tinkum et al., 2011). Other genes that have successfully been 
monitored in vivo using luciferase using transgenic mouse strains are Early 
growth response (EGR)-1 (Dussmann et al., 2011), E2F (Uhrbom et al., 2004) 
and NFκB (Robbins and Zhao, 2011). For small laboratories genetically 
modified animals are not economically viable, so a reporter cell line that could 
be used to establish tumour models could offer a practical alternative to monitor 
the upregulation of p53 and p21. 
6.1.3 Aims and objectives  
In vivo luciferase-reporter systems have the potential to monitor the 
pharmacodynamics of anticancer drugs in vivo, but they have been underused 
in this area so far. In this study, colorectal cancer cells were engineered to 
express luciferase under the control of the p53 and p21 gene promoters. In vitro 
characterisation of these cell lines was performed using doxorubicin and 
trichostatin A, as reported in chapter 2. Doxorubicin had been shown to 
upregulate both p53 and p21 and was therefore chosen as a common cytotoxic 
drug that could indicate proof-of-concept for this approach. Similarly, the HDAC-
inhibitor trichostatin A was chosen for its reported p53-independent activation of 
p21. In this chapter, the potential of this pharmacodynamic reporter approach 
was evaluated through establishment of these cell lines as xenografts in mice. 
Proof-of-concept for this approach and confirmation of translation from in vitro to 
in vivo was evaluated using doxorubicin and trichostatin A, for the reasons 
previously described. Such models have the potential to provide information on 
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both the toxicity and mechanisms of action of novel cytotoxic drugs as well as 
HDAC inhibitors that may independently upregulate p21.   
 
The use of p21-promoter driven Renilla luciferase and p53-promoter driven 
Firefly luciferase also enables the two cell lines to be used in conjunction as a 
dual-reporter model allowing even more information regarding the mechanism 
of action of various drugs to be studied simultaneously.  
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6.2 Materials and Methods 
6.2.1 Compounds 
Doxorubicin was obtained from Sigma, Poole, UK. For in vivo treatment 
doxorubicin was reconstituted at 2mg/ml in sterile physiological saline and 
injected i.v via the tail vein at a concentration of 10mg/kg or 1mg/kg (half-
volumes). D-luciferin was made up at 30mg/ml in sterile dH2O before being 
diluted further in cell culture medium prior to injection to a final concentration of 
15mg/ml (150mg/kg) as previously. A CET stock solution at 1mg/ml was further 
diluted to 0.07mg/ml and injected at 0.35mg/kg (half-volumes). 
6.2.2 Animals and tumour systems  
Refer to Chapter 3, section 3.2.2. 
6.2.3 Cell lines 
DLD-1/SVFluc, DLD-1/p53Fluc and DLD-1/p21Rluc were established as 
previously described in chapter 2 and used for the work in this chapter. 
6.2.4 Bioluminescent imaging  
Refer to Chapter 4, section 4.2.6. 
6.2.5 In vivo BLI to assess p53/p21 promoter upregulation 
All mice were imaged to obtain pre-treatment readings before being grouped so 
a range of tumour sizes and light emission values were included in each. 
Groups received either 10mg/ml or 1mg/ml of doxorubicin by i.v injection and 
the control group received no treatment. Imaging was performed 3, 7 and 24 
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hours following treatment. As it had previously been shown that there was no 
cross-reactivity between the luciferase substrates both were employed within 
the same imaging session at each time point. Mice were initially injected with D-
luciferin and after 10 minutes were anaesthetised before being injected i.v with 
CET. Images were obtained over an 8 minute period and averages calculated.  
6.2.6 Data analysis 
Light emission values from post-reading imaging sessions were normalised to 
data from the same animals‟ pre-treatment readings and averages were 
calculated across each group. Comparisons between groups were made using 
t-tests with p<0.05 accepted as statistically significant.  
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6.3 Results  
6.3.1 Characterisation of subcutaneous DLD-1/p53Fluc tumours   
Subcutaneous tumours were established from injection of DLD-1/p53Fluc cells, 
the growth of which was monitored using callipers and BLI. The DLD-1/p53Fluc 
cells grew well as subcutaneous xenografts (figure 6.1A) and the correlation 
between light emission and tumour volume was significant (figure 6.1C, 
p<0.05). Representative images (figure 6.1B) indicate that the p53Fluc tumour 
showed an increased light emission over time.  
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Figure 6.1 – DLD-1/p53Fluc s.c 
growth curves. A) Representative 
graph indicating calliper 
measurements and BLI data from 
one animal. B) Images of the animal 
presented in (A). C) DLD-1/p53Fluc 
tumours showed good correlation 
between volume and light emission: 
(n=22, R
2
 = 0.86, p<0.05).  
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6.3.2 The effect of doxorubicin treatment on p21- and p53-luciferase 
expressing tumours  
The p53- and p21- cell lines were used to establish subcutaneous tumours in 
nude mice, in order to investigate whether doxorubicin treatment would induce 
an increase in light emission. 
 
6.3.2.1 Doxorubicin induced luminescence in subcutaneous DLD-1/p53Fluc 
and p21Rluc xenografts  
Initially both the DLD-1/p21Rluc and DLD-1/p53Fluc cell lines were used to 
establish tumours in the same animal. In addition DLD-1/SVFluc tumours were 
included in the study to act as a control, as luminescence should not be induced 
as a consequence of doxorubicin treatment. The tumours were located as 
previously indicated in figure 4.36 (Chapter 4) in three positions on each mouse. 
In this case, cell lines were not mixed so each tumour contained only one cell 
type.  
 
As figure 6.2 indicates, the results were inconclusive. DLD-1/p53Fluc tumours 
(figure 6.2A) treated with 10mg/kg doxorubicin showed a non-significant 
decrease in light emission of approximately 50% after 3 hours, before returning 
to pre-treatment values at 7 hours. When the same tumour type was treated 
with 1mg/kg doxorubicin there was a slight increase at 3 hours, which reached 
significance by 7 hours and remained so at 24 hours, where the average 
increase in light emission was approximately 2.3-fold. However, control tumours 
showed a similarly significant increase in light emission at the 24 hour time 
point, which reached approximately 2-fold that of the pre-treatment values.  
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DLD-1/p21Rluc tumours (figure 6.2B) treated with 10mg/kg showed a significant 
decrease in light emission after 3 hours, which remained low until at least 7 
hours. A slight recovery toward control levels was observed at 24 hours post-
treatment. When this tumour model was exposed to 1mg/kg doxorubicin, light 
emission was maintained at 3 hours, but significantly dropped to approximately 
75% of pre-treatment emission at 7 hours, before recovering to almost 2-fold 
that of the pre-treatment values (figure 6.2B) at 24 hours. When DLD-1/p21Rluc 
tumours were not exposed to doxorubicin, light emission fluctuated but the 
differences were not statistically significant.   
 
No significant change in light emission from SVFluc tumours was observed 
although there were large fluctuations within each group (figure 6.2C).  
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Figure 6.2 – The effect of doxorubicin treatment on light emission from DLD-1/SVFluc, /p53Fluc 
and p21/Rluc s.c tumours. A) DLD-1/p53Fluc, B) DLD-1/p21Rluc and C) DLD-1/SVFluc tumour 
photon emission. n = 9 mice * p <0.05 compared to pre-treatment values, error bars = SEM. y 
axis =1 (black line) is representative of the pre-treatment light emission values.  
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6.3.2.2 Effect of doxorubicin treatment on DLD-1/p53 and /SVFluc 
subcutaneous tumours 
In order to confirm previous results regarding the p53-Fluc expressing tumours 
(figure 6.3A), the sample size of each treatment group was increased to 6 mice. 
In tumours exposed to 10mg/kg doxorubicin there were no significant increases 
in light emission. At 24 hours treatment there was a significant 30% reduction 
compared to pre-treatment values. In DLD-1/p53Fluc tumours treated with 1 
mg/kg there was a gradual increase in light emission which reached 
significance at 7 hours and remained raised at 24 hours. In control tumours no 
significant difference was seen.  
 
Light emission from DLD-1/SVFluc tumours (figure 6.3B) treated with 
doxorubicin increased at 3 and 7 hours before returning to pre-treatment levels 
by 24 hours. In untreated tumours the light emission increased at 3 hours 
before returning to values more similar to pre-treatment by 7 hours. Light 
emission from this tumour type showed large levels variation and none of the 
values reached significance.  
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Figure 6.3 – The effect of doxorubicin treatment on light emission from A) DLD-1/p53Fluc and 
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6.4 Discussion  
Anticancer drug development is evolving towards mechanism based 
approaches (section 1.8), thus preclinical validation of the pathways by which 
novel drugs work is important. In this study two cell lines, DLD-1/p53Fluc and 
DLD-1/p21Rluc, were used in an attempt to demonstrate their feasibility for use 
as tumour models to indicate proof-of-concept that novel therapeutic agents, 
namely those that target either the p53- the p21- or both genes, work via their 
expected mechanisms.  
 
Initial in vitro validation studies used both doxorubicin, a common cytotoxic 
agent that is known to upregulate both p53 and p21 and trichostatin A, a HDAC-
inhibitor that alters gene transcription and upregulates p21 by a p53-
independent mechanism (Chapter 2, figures 2.16-7). For in vivo validation of 
these tumour models doxorubicin alone was used for a variety of reasons. 
Firstly it is very well characterised in vivo and tolerated doses are established. 
Secondly it meant that both the p21-Rluc and p53-Fluc models could be 
evaluated in the same animal, as doxorubicin is known to induce both of these 
promoters.  
 
As discussed previously (Chapter 2, page 91) it is important that when 
luciferase is under control of a constitutive promoter, such as SV40, expression 
of these promoters is not upregulated as a result of treatment with cytotoxic 
drugs. Previous studies had suggested that the CMV promoter can be affected 
by a variety of cytotoxic agents (Svensson et al., 2007) whereas the SV40 
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promoter appears unaffected by extracellular processes. In particular, 
doxorubicin was shown to increase induction of the CMV promoter and thus of 
the luciferase gene under its control when normalised to tumour volume. 
Conversely no promoter activation was observed when SV40 was used 
(Svensson et al., 2007), an observation reinforced by in vitro studies within this 
project (Chapter 2, figure 2.16B). The lack of SV40 promoter modulation by 
doxorubicin was also translated into the in vivo situation (figures 6.2C and 6.3B) 
which supports previously reported data (Svensson et al., 2007).  
 
Clearly, the primary aim of the work presented here was to evaluate the 
feasibility of using the DLD-1/p53Fluc and /p21Rluc cells to establish tumour 
models that were responsive to treatment with doxorubicin. Preliminary 
experiments utilised p21Rluc and p53Fluc cells to establish separate tumours, 
but since they expressed different luciferase enzymes there was a potential for 
using them in a co-expressing model in the future. 
 
Initially increased light emission from DLD-1/p53Fluc tumours was observed 7 
and 24 hours following treatment with 1mg/kg doxorubicin (figure 6.2A, p<0.05). 
However, the same tumour model in untreated animals also showed a 
significant increase in light emission at 24 hours. In tumours exposed to 
10mg/kg doxorubicin no significant changes in light emission were detected 
during the experiment. Based on this preliminary study a further experiment was 
set up where the number of animals was increased in an attempt to improve the 
statistical power.  
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Crucially, in the second experiment (figure 6.3), results were similar to the pilot 
study data indicating reproducibility, essential in such models. A significant 
increase in light emission was seen after 7 and 24 hours following treatment 
with 1mg/kg (figure 6.3A, p<0.05) which reached a maximum of approximately 
1.8-fold. Importantly, on this occasion the control tumours did not emit 
significantly higher levels of light compared to their pre-treatment values. This 
result is similar to that seen elsewhere, where treatment of p53-luciferase 
expressing tumours with a similar concentration of doxorubicin (1.5 mg/kg) led 
to a 2.5-fold increase in light emission after 24 hours compared to pre-treatment 
readings (Briat and Vassaux, 2008).  
 
Surprisingly, light emission from DLD-1/p53Fluc tumours exposed to 10mg/kg 
doxorubicin at 24 hours post-treatment was lower than those treated with 
1mg/kg (figure 6.3B, p<0.05). This was not mirrored by a decrease in tumour 
volume. Previously it has been reported that cells with non-functional p53 enter 
senescence following treatment with doxorubicin whilst those expressing mutant 
p53 undergo apoptosis (Elmore et al., 2002). Additionally, low dose doxorubicin 
has been shown to induce a senescence-like phenotype, whilst treatment with 
high doses of the drug led to apoptosis (Eom et al., 2005). Here the mutant p53 
DLD-1/p53Fluc tumours were exposed to a high dose of doxorubicin, therefore 
it could be suggested that the decrease in light emission was due to apoptosis 
of cells in the tumour. Within a 24 hour time frame this would not lead to a 
decrease in overall volume. Further confirmation of tumour cell apoptosis would 
be required to confirm this theory. The decrease in light emission after exposure 
to 10 mg/kg doxorubicin for 24 hours was not mirrored in DLD-1/SVFluc 
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tumours. However, the signal intensity from the SVFluc tumours is much higher 
than that from p53Fluc tumours so a small decrease in light emission may not 
be detectable. Overall the data presented suggest that exposure of p53Fluc 
tumours to 1 mg/kg doxorubicin causes an increase in light emission as a result 
of p53 activation (figure 6.3A) but that treatment with a higher dose of 
doxorubicin does not lead to a similar increase in light emission, possibly due to 
its cytotoxic effect on the tumour cells.  
 
Of note, although significantly different from pre-treatment values, the increase 
in light emission from DLD-1/p53Fluc tumours treated with 1mg/kg was not 
significantly different from the increase in light emitted from untreated tumours 
of the same cell type (figure 6.3A). One reason for this may be that the inherent 
signal (figure 6.1) of the p53Fluc expressing cell line masks small increases in 
drug related increases. Alternatively, DLD-1 cells express mutated p53 so a 
potential issue regarding transactivation of p53 is whether any of the upstream 
elements of the pathway are mutated. It has been reported that in cells 
expressing high levels of mutated p53, MDM2 is stabilised by interaction with 
p53 resulting in accumulation of the protein in tumour cells (Peng et al., 2001). 
MDM2 is a negative regulator of p53 so increased accumulation would lead to a 
decrease in the transcription of p53 (Harris and Levine, 2005). Potentially this 
could have affected the luciferase expression in the p53Fluc cell lines. To 
overcome this problem models using p53+/+ cells may be advantageous: 
Previously when HCT116-/- and +/+ cells lines transfected with p53-response 
element-luciferase (p53-RE-luc) were compared, the p53 positive tumours 
showed a marked increase in signal intensity when treated with doxorubicin and 
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this was significantly higher than light emission from control tumours (Briat and 
Vassaux, 2008), which was not repeated here. However, ultimately these 
results indicate that the DLD-1/p53Fluc cell line has the potential to be used to 
develop in vivo models to investigate p53 activation induced by novel agents. 
 
There was no additional increase in light emission from DLD-1/p21Rluc tumours 
treated with doxorubicin compared to untreated controls (figure 6.2B). 
Conversely, treatment with 1 and 10 mg/kg actually led to a decrease in light 
emission by 7 and 3/7 hours respectively (p<0.05). Again, although this could 
potentially be explained as a result of cell death, the decrease was not matched 
by a decrease in volume at 24 hours. Also a similar decrease in light emission 
was not seen from the p53- or SVFluc- tumours present in the same animal. 
The p21 promoter used to create the p21Rluc reporter in this study was that 
used by El-Deiry et al (el-Deiry et al., 1993). The promoter includes a p53 
binding site that confers p53-dependent induciblity upon the reporter gene, 
Renilla luciferase in this case. As previously discussed, DLD-1 cells express a 
mutant p53 protein which may hinder the expression of p21 in the reporter 
system leading to lower than expected transcription of luciferase following 
exposure to doxorubicin. In vitro small increases in photon emission can be 
detected as there are no confounding factors, however as discussed with 
regard to the p53 system, very small increases in photon emission in animal 
models are not distinguishable from the generic error seen for this technique. 
Again, due to the link between a functional p53 and p21 upregulation using this 
reporter, a cell line such as HCT116+/+ may have been a more suitable model.  
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HDAC-inhibitors have been shown to upregulate p21 independently to p53, so it 
would clearly be of interest to develop this experiment by testing the effect of 
various HDAC-inhibitors in vivo. Initial in vitro results indicated that there was an 
increase in luciferase expression as the concentration of the HDAC inhibitor 
trichostatin A increased (figure 4.17B) but this was not evaluated in vivo in this 
study.   
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6.5 Conclusions  
Whilst there was a varying degree of success with regards to the 
responsiveness of both cell lines, the experiments presented confirm the 
feasibility of using a dual reporter model in the same mouse.   
 
The in vitro potential of the p53Fluc cell line translated to the in vivo setting, 
where treatment with 1mg/kg led to a significant increase in light emission from 
tumours at 7 hours, which remained elevated at 24 hours. Although higher 
doses of the drug led to somewhat detrimental effects of the tumour cells, 
ultimately these results indicate that the DLD-1/p53Fluc cell line has the 
potential to be used to develop in vivo models to investigate p53 activation 
induced by novel agents.  
 
Unfortunately promising results in vitro that showed an increase in light 
emission from the p21Rluc reporter cell line exposed to increasing 
concentrations of doxorubicin did not translate into the in vivo model. Potentially 
the mutation status of p53 in the DLD-1 cell line may have led to decreased 
transactivation of the p21Rluc reporter (which is p53-dependent). This could 
possibly be overcome by using a cell line such as HCT116+/+ that is known to 
express wild type p53.  
 
Although further validation of the p53Fluc model would be required before it 
could be used to evaluate the pharmacodynamics of novel agents, some very 
promising results have been presented in this chapter.  
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7 Overall summary 
Despite significant advances in cancer treatment, clinical response remains 
suboptimal and there is a continued requirement for improved 
chemotherapeutics. The attrition rate for new therapies is high, due principally 
to lack of in vivo efficacy and poor pharmacodynamics. Consequently better 
systems are required to determine in vivo preclinical efficiency and drug-target 
interactions. 
 
The main aims of this project were to develop in vivo colorectal tumour models 
with the ability to demonstrate drug pharmacodynamics and report drug target 
interactions non-invasively. To achieve these aims a panel of reporter cell lines 
was successfully engineered which contained both constitutive and gene-driven 
luciferase protein expression reporter DNA. Several of the created cell lines, 
most notably DLD-1/SVFluc but also HT-29-luc, a commercially available cell 
line, showed poor correlation when light emission and tumour volume were 
compared. Similarly there were issues regarding the use of the Rluc expressing 
cell lines which showed lower tumourgenicity in both subcutaneous and 
orthotopic models. This deemed them unsuitable for the establishment of 
models to measure the efficacy of novel cytotoxic compounds that lead to 
tumour growth attenuation. However, in this study a new in vivo model of 
spontaneous colorectal cancer (LS174T/SVFluc) was developed. This model 
was demonstrated to be valuable for the preclinical evaluation of cancer 
therapeutics in a clinically relevant model of human colorectal cancer. Another 
important finding in this study was the lack of cross-reactivity between the two 
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luciferase genes and their respective substrates was confirmed in vivo, meaning 
that dual reporter systems could be a viable option for simultaneous 
measurements of two reporter parameters.  
 
Successful validation of BLI as a method to demonstrate vascular shutdown as 
a result of treatment with ICT-2552 was demonstrated. This model was further 
validated using Colo205/SVFluc and using a range of cytotoxic drugs that did 
not result in decreased light emission.  
 
Finally, the p53- and p21-driven luciferase cell lines were tested for their ability 
to monitor drug-target interactions. This was done by treating animals bearing 
p53Fluc and p53Rluc tumours with doxorubicin at varying doses and measuring 
the effect on light emission from the tumours over time. In vitro tests using the 
cell lines had shown positive results and the DLD-1/p53Fluc cell line went on to 
show promising results in vivo. However, DLD-1/p21Rluc in vivo data did not 
replicate promising in vitro data. Conversely, doxorubicin appeared to bring 
about a decrease in light emission. Currently this data means that a dual-
imaging model that could provide information on both p21 and p53 transcription 
concurrently is not feasible, however DLD-1/p53Fluc tumours do have the 
potential to be used in the preclinical development of drugs that target the p53 
pathway.  
 
As with many other investigations where BLI is used, large degrees of 
fluctuation were seen with regards to the light emission, and time to peak light 
emission was highly variable. Judging the best time to image is therefore 
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difficult. To try and elucidate the nature of this variability, pharmacokinetic 
analysis of D-luciferin was undertaken. This led to similarly variable results 
despite analyses that normalised the concentration of D-luciferin to tumour 
volume. This suggests that delivery of the substrate to the tumour and its 
fluctuating levels within the tumours are reasons for the variation in light 
emission from tumours. Previously tumour size and location have been 
suggested for the variability (Cho and Yoon, 2007; Sim et al., 2011), however 
this cannot account for the lack of reproducibility of measurements in the same 
animal. Unfortunately due to the unstable nature of the Renilla substrate, 
coelenterazine, HPLC could not be performed on this molecule. The more 
stable synthetic molecules in development (e.g. ViviRen™ and EnduRen™ 
(Promega, Madison, WI) may be suitable for such analysis.  
 
As a result of the research performed in this project, further studies can be 
proposed which would strengthen the promising findings seen here.  
1) Further development of the LS174T/SVFluc intracaecal model: 
 To further characterise and improve the reproducibility of the 
spontaneous metastatic LS174T/SVFluc model by passaging either the 
primary tumour or metastatic deposits into new mice to try and increase 
the aggressiveness of the model 
 Develop a method to remove the primary tumour burden in the 
LS174T/SVFluc model which would allow metastases to be imaged non-
invasively. Removal of the primary tumour has been shown to increase 
the size and number of metastatic lesions in other studies (Kojima et al., 
2010; Tanaka et al., 2001) 
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2) Regarding the Rluc expressing cell lines it is important to investigate the fall 
in emission seen over multiple imaging sessions by: 
 Investigating MDR1 and P-gp expression in tumours exposed to CET  
 Investigating whether a higher injection volume of CET would be more 
appropriate for larger tumours 
3) Regarding pharmacokinetic analysis of the luciferase substrates: 
 Repeating the same experiments using both Colo205/SVFluc and 
LS174T/SVFluc tumour models to determine whether the cell type 
affected the distribution of the substrate 
 Performing the same analysis on orthotopic tumours to indicated whether 
substrate delivery is an issue in more clinically relevant sites 
4) Regarding the use of BLI to monitor vascular shutdown: 
 Further development of this technique would be to validate the model 
using LS174T/SVFluc tumour cell lines, which showed improved 
characteristics over the DLD-1/SVFluc cell in earlier experiments 
 Validate the model in orthotopic tumours 
 Extend the model further to allow dual-imaging (for example indicated in 
this project with pCMVdsRed and SVFluc) which could test the efficacy 
of VDAs in conjunction with other cytotoxic agents 
 Use of this model for preclinical evaluation of novel VDAs 
5) Regarding the gene-driven cell lines: 
 Evaluate whether the p21Rluc cell line responds in vivo with increased 
light emission to treatment with a HDAC-inhibitors such as trichostatin A, 
which activates the pathway independently of p53 light emission 
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 Use another colorectal cell line known to express w.t p53 (such as HCT-
116) to develop a dual-reporter model where analysis of p53 and p21 
activation could be monitored simultaneously in vivo 
 
7.1.1 Conclusions  
In conclusion a panel of luciferase-expressing colon carcinoma cell lines have 
been created that may help to improve pre-clinical cancer drug testing. 
Importantly, a Fluc-expressing intracaecal orthotopic model that developed 
spontaneous metastasis at clinically relevant sites was successfully established. 
This is important due to the invaluable nature of better in vivo models that mimic 
the human disease. Moreover, this model enables noninvasive imaging of the 
efficacy of novel agents that target this disease. Validation of BLI as a method 
to evaluate the efficacy of VDAs noninvasively in vivo is also a very important 
result. Similarly the development of a new tumour model that can reveal p53 
transactivation in living mice is significant. Overall, the models developed here 
could help to improve preclinical cancer drug discovery, whilst reducing and 
refining the use of animals in research, thus conforming to the 3Rs principles. 
255 
 
List of references 
Ahlgren, S., Wallberg, H., Tran, T.A., Widstrom, C., Hjertman, M., Abrahmsen, L., Berndorff, D., 
Dinkelborg, L.M., Cyr, J.E., Feldwisch, J., et al. (2009). Targeting of HER2-expressing tumors 
with a site-specifically 99mTc-labeled recombinant affibody molecule, ZHER2:2395, with C-
terminally engineered cysteine. J Nucl Med 50, 781-789. 
Ali, M.M., Janic, B., Babajani-Feremi, A., Varma, N.R., Iskander, A.S., Anagli, J., and Arbab, 
A.S. (2010). Changes in vascular permeability and expression of different angiogenic factors 
following anti-angiogenic treatment in rat glioma. PloS One 5, e8727. 
Ambudkar, S.V., Dey, S., Hrycyna, C.A., Ramachandra, M., Pastan, I., and Gottesman, M.M. 
(1999). Biochemical, cellular, and pharmacological aspects of the multidrug transporter. Annu 
Rev Pharmacol Toxicol 39, 361-398. 
Amoh, Y., Nagakura, C., Maitra, A., Moossa, A.R., Katsuoka, K., Hoffman, R.M., and Bouvet, M. 
(2006). Dual-color imaging of nascent angiogenesis and its inhibition in liver metastases of 
pancreatic cancer. Anticancer Res 26, 3237-3242. 
Anderson, C.R., Hu, X., Zhang, H., Tlaxca, J., Decleves, A.E., Houghtaling, R., Sharma, K., 
Lawrence, M., Ferrara, K.W., and Rychak, J.J. (2011). Ultrasound molecular imaging of tumor 
angiogenesis with an integrin targeted microbubble contrast agent. Invest Radiol 46, 215-224. 
Anderson, H., and Price, P. (2002). Clinical measurement of blood flow in tumours using 
positron emission tomography: a review. Nucl Med Commun 23, 131-138. 
Anderson, H.L., Yap, J.T., Miller, M.P., Robbins, A., Jones, T., and Price, P.M. (2003). 
Assessment of pharmacodynamic vascular response in a phase I trial of combretastatin A4 
phosphate. J Clin Oncol 21, 2823-2830. 
Archer, S.Y., Meng, S., Shei, A., and Hodin, R.A. (1998). p21(WAF1) is required for butyrate-
mediated growth inhibition of human colon cancer cells. Proc Natl Acad Sci USA 95, 6791-
6796. 
Arwert, E., Hingtgen, S., Figueiredo, J.L., Bergquist, H., Mahmood, U., Weissleder, R., and 
Shah, K. (2007). Visualizing the dynamics of EGFR activity and antiglioma therapies in vivo. 
Cancer Res 67, 7335-7342. 
Atkinson, J.M., Falconer, R.A., Edwards, D.R., Pennington, C.J., Siller, C.S., Shnyder, S.D., 
Bibby, M.C., Patterson, L.H., Loadman, P.M., and Gill, J.H. (2010). Development of a novel 
tumor-targeted vascular disrupting agent activated by membrane-type matrix 
metalloproteinases. Cancer Res 70, 6902-6912. 
Attia, S., Eickhoff, J., Wilding, G., McNeel, D., Blank, J., Ahuja, H., Jumonville, A., Eastman, M., 
Shevrin, D., Glode, M., et al. (2008). Randomized, double-blinded phase II evaluation of 
docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent 
prostate cancer. Clin Cancer Res 14, 2437-2443. 
Avril, N., and Propper, D. (2007). Functional PET imaging in cancer drug development. Future 
Oncol 3, 215-228. 
Baboi, L., Pilleul, F., Milot, L., Lartizien, C., Poncet, G., Roche, C., Scoazec, J.Y., and Beuf, O. 
(2010). Magnetic resonance imaging follow-up of liver growth of neuroendocrine tumors in an 
experimental mouse model. Magn Reson Imaging 28, 264-272. 
Bading, J.R., Horling, M., Williams, L.E., Colcher, D., Raubitschek, A., and Strand, S.E. (2008). 
Quantitative serial imaging of an 124I anti-CEA monoclonal antibody in tumor-bearing mice. 
Cancer Biother Radiopharm 23, 399-409. 
256 
 
Baguley, B.C., Zhuang, L., and Kestell, P. (1997). Increased plasma serotonin following 
treatment with flavone-8-acetic acid, 5,6-dimethylxanthenone-4-acetic acid, vinblastine, and 
colchicine: relation to vascular effects. Oncol Res 9, 55-60. 
Bai, R., Pettit, G.R., and Hamel, E. (1990a). Dolastatin 10, a powerful cytostatic peptide derived 
from a marine animal. Inhibition of tubulin polymerization mediated through the vinca alkaloid 
binding domain. Biochem Pharmacol 39, 1941-1949. 
Bai, R.L., Pettit, G.R., and Hamel, E. (1990b). Binding of dolastatin 10 to tubulin at a distinct site 
for peptide antimitotic agents near the exchangeable nucleotide and vinca alkaloid sites.  J Biol 
Chem 265, 17141-17149. 
Baker, J.H., Lam, J., Kyle, A.H., Sy, J., Oliver, T., Co, S.J., Dragowska, W.H., Ramsay, E., 
Anantha, M., Ruth, T.J., et al. (2008). Irinophore C, a novel nanoformulation of irinotecan, alters 
tumor vascular function and enhances the distribution of 5-fluorouracil and doxorubicin. Clin 
Cancer Res 14, 7260-7271. 
Ballas, M.S., and Chachoua, A. (2011). Rationale for targeting VEGF, FGF, and PDGF for the 
treatment of NSCLC. Onco Targets Ther 4, 43-58. 
Bandapalli, O.R., Dihlmann, S., Helwa, R., Macher-Goeppinger, S., Weitz, J., Schirmacher, P., 
and Brand, K. (2009). Transcriptional activation of the beta-catenin gene at the invasion front of 
colorectal liver metastases. J Pathol 218, 370-379. 
Baselga, J., Norton, L., Albanell, J., Kim, Y.M., and Mendelsohn, J. (1998). Recombinant 
humanized anti-HER2 antibody (Herceptin) enhances the antitumor activity of paclitaxel and 
doxorubicin against HER2/neu overexpressing human breast cancer xenografts. Cancer Res 
58, 2825-2831. 
Beauregard, D.A., Pedley, R.B., Hill, S.A., and Brindle, K.M. (2002). Differential sensitivity of two 
adenocarcinoma xenografts to the anti-vascular drugs combretastatin A4 phosphate and 5,6-
dimethylxanthenone-4-acetic acid, assessed using MRI and MRS. NMR Biomed 15, 99-105. 
Berard, V., Lecomte, R., and van Lier, J.E. (2006a). Positron emission tomography imaging of 
tumor response after photodynamic therapy. J Environ Pathol Toxicol Oncol 25, 239-249. 
Berard, V., Rousseau, J.A., Cadorette, J., Hubert, L., Bentourkia, M., van Lier, J.E., and 
Lecomte, R. (2006b). Dynamic imaging of transient metabolic processes by small-animal PET 
for the evaluation of photosensitizers in photodynamic therapy of cancer. J Nucl Med 47, 1119-
1126. 
Berger, F., Paulmurugan, R., Bhaumik, S., and Gambhir, S.S. (2008). Uptake kinetics and 
biodistribution of 14C-D-luciferin--a radiolabeled substrate for the firefly luciferase catalyzed 
bioluminescence reaction: impact on bioluminescence based reporter gene imaging. Eur J Nucl 
Med Mol Imaging 35, 2275-2285. 
Bessard, A., Sole, V., Bouchaud, G., Quemener, A., and Jacques, Y. (2009). High antitumor 
activity of RLI, an interleukin-15 (IL-15)-IL-15 receptor alpha fusion protein, in metastatic 
melanoma and colorectal cancer. Mol Cancer Ther 8, 2736-2745. 
Bhattacharya, A., Seshadri, M., Oven, S.D., Toth, K., Vaughan, M.M., and Rustum, Y.M. (2008). 
Tumor vascular maturation and improved drug delivery induced by methylselenocysteine leads 
to therapeutic synergy with anticancer drugs. Clin Cancer Res 14, 3926-3932. 
Bhaumik, S., and Gambhir, S.S. (2002). Optical imaging of Renilla luciferase reporter gene 
expression in living mice. Proc Natl Acad Sci USA 99, 377-382. 
257 
 
Bhaumik, S., Lewis, X.Z., and Gambhir, S.S. (2004). Optical imaging of Renilla luciferase, 
synthetic Renilla luciferase, and firefly luciferase reporter gene expression in living mice. J 
Biomed Opt 9, 578-586. 
Bhullar, J.S., Subhas, G., Silberberg, B., Tilak, J., Andrus, L., Decker, M., and Mittal, V.K. 
(2011). A Novel Nonoperative Orthotopic Colorectal Cancer Murine Model Using 
Electrocoagulation. J Am Coll Surg 213, 54-60. 
Bibby, M.C. (2004). Orthotopic models of cancer for preclinical drug evaluation: advantages and 
disadvantages. Eur J Cancer 40, 852-857. 
Bilenker, J.H., Flaherty, K.T., Rosen, M., Davis, L., Gallagher, M., Stevenson, J.P., Sun, W., 
Vaughn, D., Giantonio, B., Zimmer, R., et al. (2005). Phase I trial of combretastatin a-4 
phosphate with carboplatin. Clin Cancer Res 11, 1527-1533. 
Bloemendal, H.J., Logtenberg, T., and Voest, E.E. (1999). New strategies in anti-vascular 
cancer therapy. Eur J Clin Invest 29, 802-809. 
Blumenthal, R.D., Osorio, L., Hayes, M.K., Horak, I.D., Hansen, H.J., and Goldenberg, D.M. 
(2005). Carcinoembryonic antigen antibody inhibits lung metastasis and augments 
chemotherapy in a human colonic carcinoma xenograft. Cancer Immunol Immunother 54, 315-
327. 
Bohndiek, S.E., Kettunen, M.I., Hu, D.E., Witney, T.H., Kennedy, B.W., Gallagher, F.A., and 
Brindle, K.M. (2010). Detection of tumor response to a vascular disrupting agent by 
hyperpolarized 13C magnetic resonance spectroscopy. Mol Cancer Ther 9, 3278-3288. 
Briat, A., and Vassaux, G. (2008). A new transgenic mouse line to image chemically induced 
p53 activation in vivo. Cancer Sci 99, 683-688. 
Brindle, K. (2008). New approaches for imaging tumour responses to treatment. Nat Rev 
Cancer 8, 94-107. 
Brutkiewicz, S., Mendonca, M., Stantz, K., Comerford, K., Bigsby, R., Hutchins, G., Goebl, M., 
and Harrington, M. (2007). The expression level of luciferase within tumour cells can alter 
tumour growth upon in vivo bioluminescence imaging. Luminescence 22, 221-228. 
Bug, M., and Dobbelstein, M. (2011). Anthracyclines induce the accumulation of mutant p53 
through E2F1-dependent and -independent mechanisms. Oncogene 30, 3612-3624. 
Burgos, J.S., Rosol, M., Moats, R.A., Khankaldyyan, V., Kohn, D.B., Nelson, M.D., Jr., and 
Laug, W.E. (2003). Time course of bioluminescent signal in orthotopic and heterotopic brain 
tumors in nude mice. BioTechniques 34, 1184-1188. 
Burns, C.J., Fantino, E., Phillips, I.D., Su, S., Harte, M.F., Bukczynska, P.E., Frazzetto, M., 
Joffe, M., Kruszelnicki, I., Wang, B., et al. (2009). CYT997: a novel orally active tubulin 
polymerization inhibitor with potent cytotoxic and vascular disrupting activity in vitro and in vivo. 
Mol Cancer Ther 8, 3036-3045. 
Cai, W., Rao, J., Gambhir, S.S., and Chen, X. (2006). How molecular imaging is speeding up 
antiangiogenic drug development. Mol Cancer Ther 5, 2624-2633. 
CaliperLS (2011). HT-29-luc-D6 Bioware® Cell Line In Products and contract services 
(Runcorn, Cheshire). http://www.caliperls.com/products/ht29lucd6-biowarereg-cell-line-pn-
119264.htm 
Camporeale, J. (2008). Basics of radiation treatment. Clin J Oncol Nurs 12, 193-195. 
258 
 
CancerResearchUK (2009). Our progress and achievements in the 2000s, CRUK, ed. 
http://info.cancerresearchuk.org/cancerandresearch/progress/a-century-of-progress/2000s/ 
Carmeliet, P., and Jain, R.K. (2000). Angiogenesis in cancer and other diseases. Nature 407, 
249-257. 
Carmichael, J., DeGraff, W.G., Gazdar, A.F., Minna, J.D., and Mitchell, J.B. (1987). Evaluation 
of a tetrazolium-based semiautomated colorimetric assay: assessment of chemosensitivity 
testing. Cancer Res 47, 936-942. 
Cesca, M., Frapolli, R., Berndt, A., Scarlato, V., Richter, P., Kosmehl, H., D'Incalci, M., Ryan, 
A.J., and Giavazzi, R. (2009). The effects of vandetanib on paclitaxel tumor distribution and 
antitumor activity in a xenograft model of human ovarian carcinoma. Neoplasia 11, 1155-1164. 
Cespedes, M.V., Espina, C., Garcia-Cabezas, M.A., Trias, M., Boluda, A., Gomez del Pulgar, 
M.T., Sancho, F.J., Nistal, M., Lacal, J.C., and Mangues, R. (2007). Orthotopic microinjection of 
human colon cancer cells in nude mice induces tumor foci in all clinically relevant metastatic 
sites. Am J Pathol 170, 1077-1085. 
Chan, L.S., Daruwalla, J., and Christophi, C. (2008). Selective targeting of the tumour 
vasculature. ANZ J Surg 78, 955-967. 
Chaplin, D.J., and Hill, S.A. (2002). The development of combretastatin A4 phosphate as a 
vascular targeting agent. Int J Radiat Oncol Biol Phys 54, 1491-1496. 
ChemBlink (2011). Doxorubicin Hydrochloride. In Chemical Listing, ChemBlink, ed. 
http://www.chemblink.com/products/25316-40-9.htm 
Chen, W., Delaloye, S., Silverman, D.H., Geist, C., Czernin, J., Sayre, J., Satyamurthy, N., 
Pope, W., Lai, A., Phelps, M.E., et al. (2007). Predicting treatment response of malignant 
gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine 
positron emission tomography: a pilot study. J Clin Oncol 25, 4714-4721. 
Chen, Z.Y., Liang, K., and Qiu, R.X. (2010). Targeted gene delivery in tumor xenografts by the 
combination of ultrasound-targeted microbubble destruction and polyethylenimine to inhibit 
survivin gene expression and induce apoptosis. J Exp Clin Cancer Res 29, 152. 
Cho, K.R. (2009). Ovarian cancer update: lessons from morphology, molecules, and mice. Arch 
Pathol Lab Med 133, 1775-1781. 
Cho, M., and Yoon, J. (2007). The application of bioluminescence assay with culturing for 
evaluating quantitative disinfection performance. Water Res 41, 741-746. 
Condeelis, J., and Pollard, J.W. (2006). Macrophages: obligate partners for tumor cell migration, 
invasion, and metastasis. Cell 124, 263-266. 
Contag, C.H., and Ross, B.D. (2002). It's not just about anatomy: in vivo bioluminescence 
imaging as an eyepiece into biology. J Magn Reson Imaging 16, 378-387. 
Contero, A., Richer, E., Gondim, A., and Mason, R.P. (2009). High-throughput quantitative 
bioluminescence imaging for assessing tumor burden. Methods Mol Biol (Clifton, NJ 574, 37-45. 
Contessa, J.N., Bhojani, M.S., Freeze, H.H., Ross, B.D., Rehemtulla, A., and Lawrence, T.S. 
(2010). Molecular imaging of N-linked glycosylation suggests glycan biosynthesis is a novel 
target for cancer therapy. Clin Cancer Res 16, 3205-3214. 
Coppola, J.M., Ross, B.D., and Rehemtulla, A. (2008). Noninvasive imaging of apoptosis and its 
application in cancer therapeutics. Clin Cancer Res 14, 2492-2501. 
259 
 
Cordero, A.B., Kwon, Y., Hua, X., and Godwin, A.K. (2010). In vivo imaging and therapeutic 
treatments in an orthotopic mouse model of ovarian cancer. J Vis Exp 42, pii 2125 
Corey, E., Quinn, J.E., and Vessella, R.L. (2003). A novel method of generating prostate cancer 
metastases from orthotopic implants. Prostate 56, 110-114. 
Cowen, S.E., Bibby, M.C., and Double, J.A. (1995). Characterisation of the vasculature within a 
murine adenocarcinoma growing in different sites to evaluate the potential of vascular therapies. 
Acta Oncol 34, 357-360. 
Crawford, L.V., Pim, D.C., Gurney, E.G., Goodfellow, P., and Taylor-Papadimitriou, J. (1981). 
Detection of a common feature in several human tumor cell lines--a 53,000-dalton protein. Proc 
Natl Acad Sci USA 78, 41-45. 
CRUK (2008). CancerStats Key Facts All Cancers, pp. Risk Factors. 
http://info.cancerresearchuk.org/cancerstats/incidence/?a=5441#riskfactors 
CRUK (2011). Doxorubicin. In CancerHelp UK, CRUK, ed. 
http://cancerhelp.cancerresearchuk.org/about-cancer/treatment/cancer-drugs/doxorubicin 
Cui, K., Xu, X., Zhao, H., and Wong, S.T. (2008). A quantitative study of factors affecting in vivo 
bioluminescence imaging. Luminescence 23, 292-295. 
Czarnota, G.J., Kolios, M.C., Abraham, J., Portnoy, M., Ottensmeyer, F.P., Hunt, J.W., and 
Sherar, M.D. (1999). Ultrasound imaging of apoptosis: high-resolution non-invasive monitoring 
of programmed cell death in vitro, in situ and in vivo. BR J CANCER 81, 520-527. 
Czernin, J., Weber, W.A., and Herschman, H.R. (2006). Molecular imaging in the development 
of cancer therapeutics. Annu Rev Med 57, 99-118. 
Damia, G., Filiberti, L., Vikhanskaya, F., Carrassa, L., Taya, Y., D'Incalci, M., and Broggini, M. 
(2001). Cisplatinum and taxol induce different patterns of p53 phosphorylation. Neoplasia 3, 10-
16. 
Dark, G.G., Hill, S.A., Prise, V.E., Tozer, G.M., Pettit, G.R., and Chaplin, D.J. (1997). 
Combretastatin A-4, an agent that displays potent and selective toxicity toward tumor 
vasculature. Cancer Res 57, 1829-1834. 
Datto, M.B., Li, Y., Panus, J.F., Howe, D.J., Xiong, Y., and Wang, X.F. (1995). Transforming 
growth factor beta induces the cyclin-dependent kinase inhibitor p21 through a p53-independent 
mechanism. Proc Natl Acad Sci USA 92, 5545-5549. 
Davidson, M.W., and Campbell, R.E. (2009). Engineered fluorescent proteins: innovations and 
applications. Nat Methods 6, 713-717. 
Davis, P.D., Dougherty, G.J., Blakey, D.C., Galbraith, S.M., Tozer, G.M., Holder, A.L., Naylor, 
M.A., Nolan, J., Stratford, M.R., Chaplin, D.J., et al. (2002). ZD6126: a novel vascular-targeting 
agent that causes selective destruction of tumor vasculature. Cancer Res 62, 7247-7253. 
De Bock, K., Mazzone, M., and Carmeliet, P. (2011). Antiangiogenic therapy, hypoxia, and 
metastasis: risky liaisons, or not? Nat Rev Clin Oncol 8, 393-404. 
de Jong, M., and Maina, T. (2010). Of mice and humans: are they the same?--Implications in 
cancer translational research. J Nucl Med 51, 501-504. 
de Jonge, M.J., van der Gaast, A., Planting, A.S., van Doorn, L., Lems, A., Boot, I., Wanders, J., 
Satomi, M., and Verweij, J. (2005). Phase I and pharmacokinetic study of the dolastatin 10 
260 
 
analogue TZT-1027, given on days 1 and 8 of a 3-week cycle in patients with advanced solid 
tumors. Clin Cancer Res 11, 3806-3813. 
Dearling, J.L., Flynn, A.A., Qureshi, U., Whiting, S., Boxer, G.M., Green, A., Begent, R.H., and 
Pedley, R.B. (2009). Localization of radiolabeled anti-CEA antibody in subcutaneous and 
intrahepatic colorectal xenografts: influence of tumor size and location within host organ on 
antibody uptake. Nucl Med Biol 36, 883-894. 
Denekamp, J. (1982). Endothelial cell proliferation as a novel approach to targeting tumour 
therapy. BR J CANCER 45, 136-139. 
Denekamp, J., Hill, S.A., and Hobson, B. (1983). Vascular occlusion and tumour cell death. Eur 
J Cancer Clin Oncol 19, 271-275. 
Deshpande, N., Ren, Y., Foygel, K., Rosenberg, J., and Willmann, J.K. (2011). Tumor 
angiogenic marker expression levels during tumor growth: longitudinal assessment with 
molecularly targeted microbubbles and US imaging. Radiology 258, 804-811. 
DeVita, V., and Chu, E. (2001). Physicians' Cancer Chemotherapy Drug Manual 2001 (Sudbury, 
Massachusetts, Jones and Bartlett Publishers).  
Dexter, D.L., Barbosa, J.A., and Calabresi, P. (1979). N,N-dimethylformamide-induced 
alteration of cell culture characteristics and loss of tumorigenicity in cultured human colon 
carcinoma cells. Cancer Res 39, 1020-1025. 
Dexter, D.L., Spremulli, E.N., Fligiel, Z., Barbosa, J.A., Vogel, R., VanVoorhees, A., and 
Calabresi, P. (1981). Heterogeneity of cancer cells from a single human colon carcinoma. Am J 
Med 71, 949-956. 
Diaz, R., Nguewa, P.A., Parrondo, R., Perez-Stable, C., Manrique, I., Redrado, M., Catena, R., 
Collantes, M., Penuelas, I., Diaz-Gonzalez, J.A., et al. (2010). Antitumor and antiangiogenic 
effect of the dual EGFR and HER-2 tyrosine kinase inhibitor lapatinib in a lung cancer model. 
BMC cancer 10, 188. 
Dickson, P.V., Hamner, B., Ng, C.Y., Hall, M.M., Zhou, J., Hargrove, P.W., McCarville, M.B., 
and Davidoff, A.M. (2007). In vivo bioluminescence imaging for early detection and monitoring 
of disease progression in a murine model of neuroblastoma. J Pediatr Surg 42, 1172-1179. 
Dobrenkov, K., Olszewska, M., Likar, Y., Shenker, L., Gunset, G., Cai, S., Pillarsetty, N., Hricak, 
H., Sadelain, M., and Ponomarev, V. (2008). Monitoring the efficacy of adoptively transferred 
prostate cancer-targeted human T lymphocytes with PET and bioluminescence imaging. J Nucl 
Med 49, 1162-1170. 
Dong, Z., Tan, R., Cao, J., Yang, Y., Kong, C., Du, J., Zhu, S., Zhang, Y., Lu, J., Huang, B., et 
al. (2011). Discovery of polyoxometalate-based HDAC inhibitors with profound anticancer 
activity in vitro and in vivo. Eur J Med Chem 46, 2477-2484. 
Dothager, R.S., Flentie, K., Moss, B., Pan, M.H., Kesarwala, A., and Piwnica-Worms, D. (2009). 
Advances in bioluminescence imaging of live animal models. Curr Opin Biotechnol 20, 45-53. 
Drake, J.M., Danke, J.R., and Henry, M.D. (2010). Bone-specific growth inhibition of prostate 
cancer metastasis by atrasentan. Cancer Biol Ther 9, 607-614. 
DTP/NCI (2008). Developmental Therapeutics Programme (NCI/NIH). 
http://www.dtp.nci.nih.gov/screening.html 
261 
 
Dunphy, M.P., Entenberg, D., Toledo-Crow, R., and Larson, S.M. (2009). In vivo 
microcartography and subcellular imaging of tumor angiogenesis: a novel platform for 
translational angiogenesis research. Microvasc Res 78, 51-56. 
Dussmann, P., Pagel, J.I., Vogel, S., Magnusson, T., Zimmermann, R., Wagner, E., Schaper, 
W., Ogris, M., and Deindl, E. (2011). Live in vivo imaging of Egr-1 promoter activity during 
neonatal development, liver regeneration and wound healing. BMC Dev Biol 11, 28. 
el-Deiry, W.S., Harper, J.W., O'Connor, P.M., Velculescu, V.E., Canman, C.E., Jackman, J., 
Pietenpol, J.A., Burrell, M., Hill, D.E., Wang, Y., et al. (1994). WAF1/CIP1 is induced in p53-
mediated G1 arrest and apoptosis. Cancer Res 54, 1169-1174. 
el-Deiry, W.S., Tokino, T., Velculescu, V.E., Levy, D.B., Parsons, R., Trent, J.M., Lin, D., 
Mercer, W.E., Kinzler, K.W., and Vogelstein, B. (1993). WAF1, a potential mediator of p53 
tumor suppression. Cell 75, 817-825. 
Elbendary, A., Berchuck, A., Davis, P., Havrilesky, L., Bast, R.C., Jr., Iglehart, J.D., and Marks, 
J.R. (1994). Transforming growth factor beta 1 can induce CIP1/WAF1 expression independent 
of the p53 pathway in ovarian cancer cells. Cell Growth Differ 5, 1301-1307. 
Ellrichmann, M., Ritter, P.R., Schrader, H., Schmidt, W.E., Meier, J.J., and Schmitz, F. (2010). 
Gastrin stimulates the VEGF-A promotor in a human colon cancer cell line. Regul Pept 165, 
146-150. 
Elmore, L.W., Rehder, C.W., Di, X., McChesney, P.A., Jackson-Cook, C.K., Gewirtz, D.A., and 
Holt, S.E. (2002). Adriamycin-induced senescence in breast tumor cells involves functional p53 
and telomere dysfunction. J Biol Chem 277, 35509-35515. 
Emonds, E., Fitzner, B., and Jaster, R. (2010). Molecular determinants of the antitumor effects 
of trichostatin A in pancreatic cancer cells. World J Gastroenterol 16, 1970-1978. 
Eom, Y.W., Kim, M.A., Park, S.S., Goo, M.J., Kwon, H.J., Sohn, S., Kim, W.H., Yoon, G., and 
Choi, K.S. (2005). Two distinct modes of cell death induced by doxorubicin: apoptosis and cell 
death through mitotic catastrophe accompanied by senescence-like phenotype. Oncogene 24, 
4765-4777. 
Fan, S., el-Deiry, W.S., Bae, I., Freeman, J., Jondle, D., Bhatia, K., Fornace, A.J., Jr., Magrath, 
I., Kohn, K.W., and O'Connor, P.M. (1994). p53 gene mutations are associated with decreased 
sensitivity of human lymphoma cells to DNA damaging agents. Cancer Res 54, 5824-5830. 
Farre, L., Casanova, I., Guerrero, S., Trias, M., Capella, G., and Mangues, R. (2002). 
Heterotopic implantation alters the regulation of apoptosis and the cell cycle and generates a 
new metastatic site in a human pancreatic tumor xenograft model. FASEB J 16, 975-982. 
Fei, B., Wang, H., Meyers, J.D., Feyes, D.K., Oleinick, N.L., and Duerk, J.L. (2007). High-field 
magnetic resonance imaging of the response of human prostate cancer to Pc 4-based 
photodynamic therapy in an animal model. Lasers Surg Med 39, 723-730. 
Ferlay, J., Autier, P., Boniol, M., Heanue, M., Colombet, M., and Boyle, P. (2007). Estimates of 
the cancer incidence and mortality in Europe in 2006. Ann Oncol 18, 581-592. 
Fermentas (2009). Considerations for transfection with ExGen 500. In Support: Transfection 
Reagents, ThermoScientific, ed. 
http://www.fermentas.com/techinfo/transfection/considerations.htm 
Fidarova, E.F., El-Emir, E., Boxer, G.M., Qureshi, U., Dearling, J.L., Robson, M.P., Begent, 
R.H., Trott, K.R., and Pedley, R.B. (2008). Microdistribution of targeted, fluorescently labeled 
262 
 
anti-carcinoembryonic antigen antibody in metastatic colorectal cancer: implications for 
radioimmunotherapy. Clin Cancer Res 14, 2639-2646. 
Fidler, I.J., Naito, S., and Pathak, S. (1990). Orthotopic implantation is essential for the 
selection, growth and metastasis of human renal cell cancer in nude mice [corrected]. Cancer 
Metastasis Rev 9, 149-165. 
Fidler, I.J., Wilmanns, C., Staroselsky, A., Radinsky, R., Dong, Z., and Fan, D. (1994). 
Modulation of tumor cell response to chemotherapy by the organ environment. Cancer 
Metastasis Rev 13, 209-222. 
Flecknell, P. (2002). Replacement, reduction and refinement. Altex 19, 73-78. 
Folkman, J. (1972). Anti-angiogenesis: new concept for therapy of solid tumors. Ann Surg 175, 
409-416. 
Fomchenko, E.I., and Holland, E.C. (2006). Mouse models of brain tumors and their 
applications in preclinical trials. Clin Cancer Res 12, 5288-5297. 
Fonken, L.K., Workman, J.L., Walton, J.C., Weil, Z.M., Morris, J.S., Haim, A., and Nelson, R.J. 
(2010). Light at night increases body mass by shifting the time of food intake. Proc Natl Acad 
Sci USA 107, 18664-18669. 
Fontes, R., Ortiz, B., de Diego, A., Sillero, A., and Gunther Sillero, M.A. (1998). 
Dehydroluciferyl-AMP is the main intermediate in the luciferin dependent synthesis of Ap4A 
catalyzed by firefly luciferase. FEBS Lett 438, 190-194. 
Fusi, F., Saponara, S., Valoti, M., Dragoni, S., D'Elia, P., Sgaragli, T., Alderighi, D., Kawase, M., 
Shah, A., Motohashi, N., et al. (2006). Cancer cell permeability-glycoprotein as a target of MDR 
reverters: possible role of novel dihydropyridine derivatives. Curr Drug Targets 7, 949-959. 
Galbraith, S.M., Maxwell, R.J., Lodge, M.A., Tozer, G.M., Wilson, J., Taylor, N.J., Stirling, J.J., 
Sena, L., Padhani, A.R., and Rustin, G.J. (2003). Combretastatin A4 phosphate has tumor 
antivascular activity in rat and man as demonstrated by dynamic magnetic resonance imaging. 
J Clin Oncol 21, 2831-2842. 
Gaya, A.M., and Rustin, G.J. (2005). Vascular disrupting agents: a new class of drug in cancer 
therapy. Clin Oncol (R Coll Radiol) 17, 277-290. 
Gewirtz, D.A. (1999). A critical evaluation of the mechanisms of action proposed for the 
antitumor effects of the anthracycline antibiotics adriamycin and daunorubicin. Biochem 
Pharmacol 57, 727-741. 
Gheysens, O., and Mottaghy, F.M. (2009). Method of bioluminescence imaging for molecular 
imaging of physiological and pathological processes. Methods 48, 139-145. 
Ghoul, A., Serova, M., Astorgues-Xerri, L., Bieche, I., Bousquet, G., Varna, M., Vidaud, M., 
Phillips, E., Weill, S., Benhadji, K.A., et al. (2009). Epithelial-to-mesenchymal transition and 
resistance to ingenol 3-angelate, a novel protein kinase C modulator, in colon cancer cells. 
Cancer Res 69, 4260-4269. 
Golas, J.M., Lucas, J., Etienne, C., Golas, J., Discafani, C., Sridharan, L., Boghaert, E., Arndt, 
K., Ye, F., Boschelli, D.H., et al. (2005). SKI-606, a Src/Abl inhibitor with in vivo activity in colon 
tumor xenograft models. Cancer Res 65, 5358-5364. 
Gomi, K., and Kajiyama, N. (2001). Oxyluciferin, a luminescence product of firefly luciferase, is 
enzymatically regenerated into luciferin. J Biol Chem 276, 36508-36513. 
263 
 
Gould, S.J., and Subramani, S. (1988). Firefly luciferase as a tool in molecular and cell biology. 
Anal Biochem 175, 5-13. 
Grosios, K., Holwell, S.E., McGown, A.T., Pettit, G.R., and Bibby, M.C. (1999). In vivo and in 
vitro evaluation of combretastatin A-4 and its sodium phosphate prodrug. BR J CANCER 81, 
1318-1327. 
Grozio, A., Paleari, L., Catassi, A., Servent, D., Cilli, M., Piccardi, F., Paganuzzi, M., Cesario, A., 
Granone, P., Mourier, G., et al. (2007). Natural agents targeting the alpha7-nicotinic-receptor in 
NSCLC: A promising prospective in anti-cancer drug development. Int J Cancer 122, 1911-
1915. 
Guo, X.N., Rajput, A., Rose, R., Hauser, J., Beko, A., Kuropatwinski, K., LeVea, C., Hoffman, 
R.M., Brattain, M.G., and Wang, J. (2007). Mutant PIK3CA-bearing colon cancer cells display 
increased metastasis in an orthotopic model. Cancer Res 67, 5851-5858. 
Gwyther, S.J., and Schwartz, L.H. (2008). How to assess anti-tumour efficacy by imaging 
techniques. Eur J Cancer 44, 39-45. 
Hadaschik, B.A., Jackson, J., Fazli, L., Zoubeidi, A., Burt, H.M., Gleave, M.E., and So, A.I. 
(2008). Intravesically administered antisense oligonucleotides targeting heat-shock protein-27 
inhibit the growth of non-muscle-invasive bladder cancer. BJU international 102, 610-616. 
Hall, M.A., Kwon, S., Robinson, H., Lachance, P.A., Azhdarinia, A., Ranganathan, R., Price, 
R.E., Chan, W., and Sevick-Muraca, E.M. (2011). Imaging prostate cancer lymph node 
metastases with a multimodality contrast agent. Prostate [Epub ahead of print] 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_ui
ds=21538422 
Hamada, K., Monnai, M., Kawai, K., Nishime, C., Kito, C., Miyazaki, N., Ohnishi, Y., Nakamura, 
M., and Suemizu, H. (2008). Liver metastasis models of colon cancer for evaluation of drug 
efficacy using NOD/Shi-scid IL2Rgammanull (NOG) mice. Int J Oncol 32, 153-159. 
Hanahan, D., and Weinberg, R.A. (2000). The hallmarks of cancer. Cell 100, 57-70. 
Hanahan, D., and Weinberg, R.A. (2011). Hallmarks of cancer: the next generation. Cell 144, 
646-674. 
Harper, J.W., Adami, G.R., Wei, N., Keyomarsi, K., and Elledge, S.J. (1993). The p21 Cdk-
interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell 75, 805-816. 
Harrington, W., Bond, V., Huang, M.B., Powell, M., Lillard, J., Manne, U., and Bumpers, H. 
(2009). HIV Nef-M1 Effects on Colorectal Cancer Growth in Tumor-induced Spleens and 
Hepatic Metastasis. Mol Cell Pharmacol 1, 85-91. 
Harris, S.L., and Levine, A.J. (2005). The p53 pathway: positive and negative feedback loops. 
Oncogene 24, 2899-2908. 
Hawes, J.J., and Reilly, K.M. (2010). Bioluminescent approaches for measuring tumor growth in 
a mouse model of neurofibromatosis. Toxicol Pathol 38, 123-130. 
Heikkila, J.E., Vaha-Koskela, M.J., Ruotsalainen, J.J., Martikainen, M.W., Stanford, M.M., 
McCart, J.A., Bell, J.C., and Hinkkanen, A.E. (2010). Intravenously administered alphavirus 
vector VA7 eradicates orthotopic human glioma xenografts in nude mice. PloS one 5, e8603. 
Hill, S.A., Lonergan, S.J., Denekamp, J., and Chaplin, D.J. (1993). Vinca alkaloids: anti-vascular 
effects in a murine tumour. Eur J Cancer 29A, 1320-1324. 
264 
 
Hinnen, P., and Eskens, F.A. (2007). Vascular disrupting agents in clinical development. BR J 
CANCER 96, 1159-1165. 
Hoffman, R.M. (2009). Imaging cancer dynamics in vivo at the tumor and cellular level with 
fluorescent proteins. Clin Exp Metastasis 26, 345-355. 
Holgren, C., Dougherty, U., Edwin, F., Cerasi, D., Taylor, I., Fichera, A., Joseph, L., 
Bissonnette, M., and Khare, S. (2010). Sprouty-2 controls c-Met expression and metastatic 
potential of colon cancer cells: sprouty/c-Met upregulation in human colonic adenocarcinomas. 
Oncogene 29, 5241-5253. 
Holwell, S.E., Cooper, P.A., Thompson, M.J., Pettit, G.R., Lippert, L.W., 3rd, Martin, S.W., and 
Bibby, M.C. (2002). Anti-tumor and anti-vascular effects of the novel tubulin-binding agent 
combretastatin A-1 phosphate. Anticancer Res 22, 3933-3940. 
Holzmuller, R., Mantwill, K., Haczek, C., Rognoni, E., Anton, M., Kasajima, A., Weichert, W., 
Treue, D., Lage, H., Schuster, T., et al. (2010). YB-1 dependent virotherapy in combination with 
temozolomide as a multimodal therapy approach to eradicate malignant glioma. Int J Cancer 
129, 1265-1276. 
HomeOffice (2008). Research and Testing using animals. In Science and Research. 
http://www.homeoffice.gov.uk/science-research/animal-testing/ 
Hori, K., Saito, S., and Kubota, K. (2002). A novel combretastatin A-4 derivative, AC7700, 
strongly stanches tumour blood flow and inhibits growth of tumours developing in various 
tissues and organs. British journal of cancer 86, 1604-1614. 
Horowitz, M.E., Etcubanas, E., Christensen, M.L., Houghton, J.A., George, S.L., Green, A.A., 
and Houghton, P.J. (1988). Phase II testing of melphalan in children with newly diagnosed 
rhabdomyosarcoma: a model for anticancer drug development. J Clin Oncol 6, 308-314. 
Howlader, N., Noone, A.M., Krapcho, M., Neyman, N., Aminou, R., Waldron, W., Altekruse, 
S.F., Kosary, C., Rhul, J., Tatalovich, Z., et al. (2011). SEER Cancer Statistics Review, 1995-
2008, NCI, ed. (Bethesda, MD). 
Hu, S., Dong, T.S., Dalal, S.R., Wu, F., Bissonnette, M., Kwon, J.H., and Chang, E.B. (2011a). 
The microbe-derived short chain fatty acid butyrate targets miRNA-dependent p21 gene 
expression in human colon cancer. PloS one 6, e16221. 
Hu, X., Wang, L., Sun, W., Xiao, L., Wu, Y., Zhuo, Y., Nie, D., Zhou, J., and Zhang, J. (2011b). 
AP-2beta enhances p53-mediated transcription of the alphaB-crystallin gene through stabilizing 
p53. Mol Biol Rep. [Epub ahead of print] 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list
_uids=21556774 
Huang, L. (2006). Targeting histone deacetylases for the treatment of cancer and inflammatory 
diseases. J Cell Physiol 209, 611-616. 
Huang, S., Armstrong, E.A., Benavente, S., Chinnaiyan, P., and Harari, P.M. (2004). Dual-agent 
molecular targeting of the epidermal growth factor receptor (EGFR): combining anti-EGFR 
antibody with tyrosine kinase inhibitor. Cancer Res 64, 5355-5362. 
Hunter, T. (1993). Braking the cycle. Cell 75, 839-841. 
Huynh, A.S., Abrahams, D.F., Torres, M.S., Baldwin, M.K., Gillies, R.J., and Morse, D.L. (2011). 
Development of an orthotopic human pancreatic cancer xenograft model using ultrasound 
guided injection of cells. PLoS One 6, e20330. 
265 
 
Iwahashi, T., Okochi, E., Ariyoshi, K., Watabe, H., Amann, E., Mori, S., Tsuruo, T., and Ono, K. 
(1993). Specific targeting and killing activities of anti-P-glycoprotein monoclonal antibody 
MRK16 directed against intrinsically multidrug-resistant human colorectal carcinoma cell lines in 
the nude mouse model. Cancer Res 53, 5475-5482. 
Jabbar, S.A., Twentyman, P.R., and Watson, J.V. (1989). The MTT assay underestimates the 
growth inhibitory effects of interferons. BR J CANCER 60, 523-528. 
Jackson, T.L. (2003). Intracellular accumulation and mechanism of action of doxorubicin in a 
spatio-temporal tumor model. J Theor Biol 220, 201-213. 
Jeon, Y.H., Bae, S.A., Lee, Y.J., Lee, Y.L., Lee, S.W., Yoon, G.S., Ahn, B.C., Ha, J.H., and Lee, 
J. (2010). Evaluation of the reversal of multidrug resistance by MDR1 ribonucleic acid 
interference in a human colon cancer model using a Renilla luciferase reporter gene and 
coelenterazine. Molecular imaging 9, 343-350. 
Jia, D., Koonce, N.A., Halakatti, R., Li, X., Yaccoby, S., Swain, F.L., Suva, L.J., Hennings, L., 
Berridge, M.S., Apana, S.M., et al. (2010). Repression of multiple myeloma growth and 
preservation of bone with combined radiotherapy and anti-angiogenic agent. Radiat Res 173, 
809-817. 
Jiang, L., Lai, Y.K., Zhang, J., Wang, H., Lin, M.C., He, M.L., and Kung, H.F. (2011). Targeting 
S100P inhibits colon cancer growth and metastasis by lentivirus-mediated RNA interference 
and proteomic analysis. Mol Med 17, 709-716 
Johnson, M., Dimitrov, D., Vojta, P.J., Barrett, J.C., Noda, A., Pereira-Smith, O.M., and Smith, 
J.R. (1994). Evidence for a p53-independent pathway for upregulation of SDI1/CIP1/WAF1/p21 
RNA in human cells. Mol Carcinog 11, 59-64. 
Jones, L.R., Goun, E.A., Shinde, R., Rothbard, J.B., Contag, C.H., and Wender, P.A. (2006). 
Releasable luciferin-transporter conjugates: tools for the real-time analysis of cellular uptake 
and release. J Am Chem Soc 128, 6526-6527. 
Jordan, M.A., Thrower, D., and Wilson, L. (1991). Mechanism of inhibition of cell proliferation by 
Vinca alkaloids. Cancer Res 51, 2212-2222. 
Jordan, M.A., and Wilson, L. (2004). Microtubules as a target for anticancer drugs. Nat Rev 
Cancer 4, 253-265. 
Joyce, J.A., and Pollard, J.W. (2009). Microenvironmental regulation of metastasis. Nat Rev 
Cancer 9, 239-252. 
Ju, J.S., Miller, S.E., Jackson, E., Cadwell, K., Piwnica-Worms, D., and Weihl, C.C. (2009). 
Quantitation of selective autophagic protein aggregate degradation in vitro and in vivo using 
luciferase reporters. Autophagy 5, 511-519. 
Jung, I.D., Lee, J.S., Yun, S.Y., Park, C.G., Han, J.W., Lee, H.W., and Lee, H.Y. (2002). 
Doxorubicin inhibits the production of nitric oxide by colorectal cancer cells. Arch Pharm Res 25, 
691-696. 
Jurczok, A., Fornara, P., and Soling, A. (2008). Bioluminescence imaging to monitor bladder 
cancer cell adhesion in vivo: a new approach to optimize a syngeneic, orthotopic, murine 
bladder cancer model. BJU international 101, 120-124. 
Kalber, T.L., Waterton, J.C., Griffiths, J.R., Ryan, A.J., and Robinson, S.P. (2008). Longitudinal 
in vivo susceptibility contrast MRI measurements of LS174T colorectal liver metastasis in nude 
mice. J Magn Reson Imaging 28, 1451-1458. 
266 
 
Kamensek, U., Sersa, G., Vidic, S., Tevz, G., Kranjc, S., and Cemazar, M. (2011). Irradiation, 
cisplatin, and 5-azacytidine upregulate cytomegalovirus promoter in tumors and muscles: 
implementation of non-invasive fluorescence imaging. Mol Imaging Biol 13, 43-52. 
Kanthou, C., and Tozer, G.M. (2002). The tumor vascular targeting agent combretastatin A-4-
phosphate induces reorganization of the actin cytoskeleton and early membrane blebbing in 
human endothelial cells. Blood 99, 2060-2069. 
Kanthou, C., and Tozer, G.M. (2009). Microtubule depolymerizing vascular disrupting agents: 
novel therapeutic agents for oncology and other pathologies. Int J Exp Pathol 90, 284-294. 
Kassouf, W., Brown, G.A., Shetty, A., Hazle, J.D., Stafford, R.J., Rosser, C.J., Stephens, C., 
Tinkey, P.T., and Pisters, L.L. (2007). An in vivo orthotopic canine model to evaluate distribution 
of intraprostatic injectate: implications for gene therapy and drug delivery for prostate cancer. 
Urology 70, 822-825. 
Kato, H., Semba, S., Miskad, U.A., Seo, Y., Kasuga, M., and Yokozaki, H. (2004). High 
expression of PRL-3 promotes cancer cell motility and liver metastasis in human colorectal 
cancer: a predictive molecular marker of metachronous liver and lung metastases. Clin Cancer 
Res 10, 7318-7328. 
Kelly, K.J., Woo, Y., Brader, P., Yu, Z., Riedl, C., Lin, S.F., Chen, N., Yu, Y.A., Rusch, V.W., 
Szalay, A.A., et al. (2008). Novel oncolytic agent GLV-1h68 is effective against malignant 
pleural mesothelioma. Hum Gene Ther 19, 774-782. 
Kelly, W.K., Richon, V.M., O'Connor, O., Curley, T., MacGregor-Curtelli, B., Tong, W., Klang, 
M., Schwartz, L., Richardson, S., Rosa, E., et al. (2003). Phase I clinical trial of histone 
deacetylase inhibitor: suberoylanilide hydroxamic acid administered intravenously. Clin Cancer 
Res 9, 3578-3588. 
Kemper, E.M., Leenders, W., Kusters, B., Lyons, S., Buckle, T., Heerschap, A., Boogerd, W., 
Beijnen, J.H., and van Tellingen, O. (2006). Development of luciferase tagged brain tumour 
models in mice for chemotherapy intervention studies. Eur J Cancer 42, 3294-3303. 
Kerbel, R.S. (1997). A cancer therapy resistant to resistance. Nature 390, 335-336. 
Keyaerts, M., Heneweer, C., Gainkam, L.O., Caveliers, V., Beattie, B.J., Martens, G.A., 
Vanhove, C., Bossuyt, A., Blasberg, R.G., and Lahoutte, T. (2011). Plasma protein binding of 
luciferase substrates influences sensitivity and accuracy of bioluminescence imaging. Mol 
Imaging Biol 13, 59-66. 
Khan, O.A., Ranson, M., Michael, M., Olver, I., Levitt, N.C., Mortimer, P., Watson, A.J., 
Margison, G.P., Midgley, R., and Middleton, M.R. (2008). A phase II trial of lomeguatrib and 
temozolomide in metastatic colorectal cancer. BR J CANCER 98, 1614-1618. 
Kidd, S., Caldwell, L., Dietrich, M., Samudio, I., Spaeth, E.L., Watson, K., Shi, Y., Abbruzzese, 
J., Konopleva, M., Andreeff, M., et al. (2010). Mesenchymal stromal cells alone or expressing 
interferon-beta suppress pancreatic tumors in vivo, an effect countered by anti-inflammatory 
treatment. Cytotherapy 12, 615-625. 
Kim, T.J., Ravoori, M., Landen, C.N., Kamat, A.A., Han, L.Y., Lu, C., Lin, Y.G., Merritt, W.M., 
Jennings, N., Spannuth, W.A., et al. (2007). Antitumor and antivascular effects of AVE8062 in 
ovarian carcinoma. Cancer Res 67, 9337-9345. 
Klopp, A.H., Spaeth, E.L., Dembinski, J.L., Woodward, W.A., Munshi, A., Meyn, R.E., Cox, J.D., 
Andreeff, M., and Marini, F.C. (2007). Tumor irradiation increases the recruitment of circulating 
mesenchymal stem cells into the tumor microenvironment. Cancer Res 67, 11687-11695. 
267 
 
Kojima, T., Watanabe, Y., Hashimoto, Y., Kuroda, S., Yamasaki, Y., Yano, S., Ouchi, M., 
Tazawa, H., Uno, F., Kagawa, S., et al. (2010). In vivo biological purging for lymph node 
metastasis of human colorectal cancer by telomerase-specific oncolytic virotherapy. Ann Surg 
251, 1079-1086. 
Kong, W., Jiang, X., and Mercer, W.E. (2009). Downregulation of Wip-1 phosphatase 
expression in MCF-7 breast cancer cells enhances doxorubicin-induced apoptosis through p53-
mediated transcriptional activation of Bax. Cancer biology & therapy 8. [Epub ahead of print] 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_ui
ds=19242108 
Kota, B.P., Tran, V.H., Allen, J., Bebawy, M., and Roufogalis, B.D. (2010). Characterization of 
PXR mediated P-glycoprotein regulation in intestinal LS174T cells. Pharmacol Res 62, 426-431. 
Lage, H. (2008). An overview of cancer multidrug resistance: a still unsolved problem. Cell Mol 
Life Sci 65, 3145-3167. 
Lankester, K.J., Maxwell, R.J., Pedley, R.B., Dearling, J.L., Qureshi, U.A., El-Emir, E., Hill, S.A., 
and Tozer, G.M. (2007). Combretastatin A-4-phosphate effectively increases tumor retention of 
the therapeutic antibody, 131I-A5B7, even at doses that are sub-optimal for vascular shut-down. 
Intl J Oncol 30, 453-460. 
Lara, P.N., Jr., Douillard, J.Y., Nakagawa, K., von Pawel, J., McKeage, M.J., Albert, I., 
Losonczy, G., Reck, M., Heo, D.S., Fan, X., et al. (2011). Randomized phase III placebo-
controlled trial of carboplatin and paclitaxel with or without the vascular disrupting agent 
vadimezan (ASA404) in advanced non-small-cell lung cancer. J Clin Oncol 29, 2965-2971. 
Laufer, J., Johnson, P., Zhang, E., Treeby, B., Cox, B., Pedley, B., and Beard, P. (2011). In vivo 
longitudinal photoacoustic imaging of subcutaneous tumours in mice. Paper presented at: 
Photons Plus Ultrasound: Imaging and Sensing 2011 (Proc. of SPIE). 
http://www.medphys.ucl.ac.uk/research/mle/pdf_files/BIOS2011_JL_manuscriptF.pdf 
Laxman, B., Hall, D.E., Bhojani, M.S., Hamstra, D.A., Chenevert, T.L., Ross, B.D., and 
Rehemtulla, A. (2002). Noninvasive real-time imaging of apoptosis. Proc Natl Acad Sci USA 99, 
16551-16555. 
Lee, I., and Shogen, K. (2008). Mechanisms of enhanced tumoricidal efficacy of multiple small 
dosages of ranpirnase, the novel cytotoxic ribonuclease, on lung cancer. Cancer Chemother 
Pharmacol 62, 337-346. 
Lee, K.C., Hamstra, D.A., Bhojani, M.S., Khan, A.P., Ross, B.D., and Rehemtulla, A. (2007). 
Noninvasive molecular imaging sheds light on the synergy between 5-fluorouracil and 
TRAIL/Apo2L for cancer therapy. Clin Cancer Res 13, 1839-1846. 
Lee, K.H., Byun, S.S., Paik, J.Y., Lee, S.Y., Song, S.H., Choe, Y.S., and Kim, B.T. (2003). Cell 
uptake and tissue distribution of radioiodine labelled D-luciferin: implications for luciferase 
based gene imaging. Nucl Med Comms 24, 1003-1009. 
Lehmann, S., Stiehl, D.P., Honer, M., Dominietto, M., Keist, R., Kotevic, I., Wollenick, K., 
Ametamey, S., Wenger, R.H., and Rudin, M. (2009). Longitudinal and multimodal in vivo 
imaging of tumor hypoxia and its downstream molecular events. Proc Natl Acad Sci USA 106, 
14004-14009. 
Ley, C.D., Horsman, M.R., and Kristjansen, P.E. (2007). Early effects of combretastatin-A4 
disodium phosphate on tumor perfusion and interstitial fluid pressure. Neoplasia NY 9, 108-112. 
Leyton, J., Alao, J.P., Da Costa, M., Stavropoulou, A.V., Latigo, J.R., Perumal, M., Pillai, R., He, 
Q., Atadja, P., Lam, E.W., et al. (2006). In vivo biological activity of the histone deacetylase 
268 
 
inhibitor LAQ824 is detectable with 3'-deoxy-3'-[18F]fluorothymidine positron emission 
tomography. Cancer Res 66, 7621-7629. 
LGC/ATCC (2011). Cell lines and hybridomas, LCGStandards, ed. http://www.lgcstandards-
atcc.org/LGCAdvancedCatalogueSearch/tabid/961/Default.aspx?CollectionID=106 
Li, J., Zhang, S., Gao, L., Chen, Y., and Xie, X. (2011). A cell-based high-throughput assay for 
the screening of small-molecule inhibitors of p53-MDM2 interaction. J Biomol Screen 16, 450-
456. 
Li, Y., Jenkins, C.W., Nichols, M.A., and Xiong, Y. (1994). Cell cycle expression and p53 
regulation of the cyclin-dependent kinase inhibitor p21. Oncogene 9, 2261-2268. 
Liao, C.P., Zhong, C., Saribekyan, G., Bading, J., Park, R., Conti, P.S., Moats, R., Berns, A., 
Shi, W., Zhou, Z., et al. (2007). Mouse models of prostate adenocarcinoma with the capacity to 
monitor spontaneous carcinogenesis by bioluminescence or fluorescence. Cancer Res 67, 
7525-7533. 
Lim, E., Modi, K.D., and Kim, J. (2009). In vivo bioluminescent imaging of mammary tumors 
using IVIS spectrum. J Vis Exp. 26 pii 1210 
Lin, M.L., Lu, Y.C., Su, H.L., Lin, H.T., Lee, C.C., Kang, S.E., Lai, T.C., Chung, J.G., and Chen, 
S.S. (2011). Destabilization of CARP mRNAs by aloe-emodin contributes to caspase-8-
mediated p53-independent apoptosis of human carcinoma cells. J Cell Biochem 112, 1176-
1191. 
Lippert, J.W., 3rd (2007). Vascular disrupting agents. Bioorganic & medicinal chemistry 15, 605-
615. 
Lisy, M.R., Goermar, A., Thomas, C., Pauli, J., Resch-Genger, U., Kaiser, W.A., and Hilger, I. 
(2008). In vivo near-infrared fluorescence imaging of carcinoembryonic antigen-expressing 
tumor cells in mice. Radiology 247, 779-787. 
Liu, T., Ding, Y., Xie, W., Li, Z., Bai, X., Li, X., Fang, W., Ren, C., Wang, S., Hoffman, R.M., et 
al. (2007). An imageable metastatic treatment model of nasopharyngeal carcinoma. Clin Cancer 
Res 13, 3960-3967. 
Liu, W., Li, X., Chu, E.S., Go, M.Y., Xu, L., Zhao, G., Li, L., Dai, N., Si, J., Tao, Q., et al. (2011). 
Paired box gene 5 is a novel tumor suppressor in hepatocellular carcinoma through interaction 
with p53 signaling pathway. Hepatology 53, 843-853. 
LoRusso, P.M., Gadgeel, S.M., Wozniak, A., Barge, A.J., Jones, H.K., DelProposto, Z.S., 
DeLuca, P.A., Evelhoch, J.L., Boerner, S.A., and Wheeler, C. (2008). Phase I clinical evaluation 
of ZD6126, a novel vascular-targeting agent, in patients with solid tumors. Invest New Drugs 26, 
159-167. 
Loveless, M.E., Li, X., Huamani, J., Lyshchik, A., Dawant, B., Hallahan, D., Gore, J.C., and 
Yankeelov, T.E. (2008). A method for assessing the microvasculature in a murine tumor model 
using contrast-enhanced ultrasonography. J Ultrasound Med 27, 1699-1709. 
Lowik, C.W., Kaijzel, E., Que, I., Vahrmeijer, A., Kuppen, P., Mieog, J., and Van de Velde, C. 
(2009). Whole body optical imaging in small animals and its translation to the clinic: intra-
operative optical imaging guided surgery. Eur J Cancer 45 Suppl 1, 391-393. 
Luker, G.D., and Luker, K.E. (2008). Optical imaging: current applications and future directions. 
J Nucl Med 49, 1-4. 
Lyons, S.K. (2005). Advances in imaging mouse tumour models in vivo. J Pathol 205, 194-205. 
269 
 
Mallidi, S., Luke, G.P., and Emelianov, S. (2011). Photoacoustic imaging in cancer detection, 
diagnosis, and treatment guidance. Trends Biotechnol 29, 213-221. 
Manna, S.K., Gangadharan, C., Edupalli, D., Raviprakash, N., Navneetha, T., Mahali, S., and 
Thoh, M. (2011). Ras puts the brake on doxorubicin-mediated cell death in p53-expressing 
cells. J Biol Chem 286, 7339-7347. 
Marchenko, N.D., Zaika, A., and Moll, U.M. (2000). Death signal-induced localization of p53 
protein to mitochondria. A potential role in apoptotic signaling. J Biol Chem 275, 16202-16212. 
Marks, P.A., and Breslow, R. (2007). Dimethyl sulfoxide to vorinostat: development of this 
histone deacetylase inhibitor as an anticancer drug. Nat Biotechnol 25, 84-90. 
Martinez-Outschoorn, U.E., Trimmer, C., Lin, Z., Whitaker-Menezes, D., Chiavarina, B., Zhou, 
J., Wang, C., Pavlides, S., Martinez-Cantarin, M.P., Capozza, F., et al. (2010). Autophagy in 
cancer associated fibroblasts promotes tumor cell survival: Role of hypoxia, HIF1 induction and 
NFkappaB activation in the tumor stromal microenvironment. Cell cycle 9, 3515-3533. 
Massoud, T.F., and Gambhir, S.S. (2003). Molecular imaging in living subjects: seeing 
fundamental biological processes in a new light. Genes Dev 17, 545-580. 
Massoud, T.F., and Gambhir, S.S. (2007). Integrating noninvasive molecular imaging into 
molecular medicine: an evolving paradigm. Trends Mol Med 13, 183-191. 
McDonald, D.M., and Baluk, P. (2002). Significance of blood vessel leakiness in cancer. Cancer 
Res 62, 5381-5385. 
McGown, A.T., and Fox, B.W. (1989). Structural and biochemical comparison of the anti-mitotic 
agents colchicine, combretastatin A4 and amphethinile. Anticancer Drug Des 3, 249-254. 
McKeage, M.J., and Baguley, B.C. (2010). Disrupting established tumor blood vessels: an 
emerging therapeutic strategy for cancer. Cancer 116, 1859-1871. 
McNally, L.R., Welch, D.R., Beck, B.H., Stafford, L.J., Long, J.W., Sellers, J.C., Huang, Z.Q., 
Grizzle, W.E., Stockard, C.R., Nash, K.T., et al. (2010 ). KISS1 over-expression suppresses 
metastasis of pancreatic adenocarcinoma in a xenograft mouse model. Clin Exp Metastasis 27, 
591-600. 
Meyer, T., Gaya, A.M., Dancey, G., Stratford, M.R., Othman, S., Sharma, S.K., Wellsted, D., 
Taylor, N.J., Stirling, J.J., Poupard, L., et al. (2009). A phase I trial of radioimmunotherapy with 
131I-A5B7 anti-CEA antibody in combination with combretastatin-A4-phosphate in advanced 
gastrointestinal carcinomas. Clin Cancer Res 15, 4484-4492. 
Michieli, P., Chedid, M., Lin, D., Pierce, J.H., Mercer, W.E., and Givol, D. (1994). Induction of 
WAF1/CIP1 by a p53-independent pathway. Cancer Res 54, 3391-3395. 
MIP (2008). Firefly & Renilla Luciferase Assay Kit. In Assays and Reagents, M.i.p. company, ed. 
(Bend, OR). http://www.mipcompany.com/lucifer_kits.html 
Miretti, S., Roato, I., Taulli, R., Ponzetto, C., Cilli, M., Olivero, M., Di Renzo, M.F., Godio, L., 
Albini, A., Buracco, P., et al. (2008). A mouse model of pulmonary metastasis from spontaneous 
osteosarcoma monitored in vivo by Luciferase imaging. PLoS One 3, e1828. 
Monk, K.A., Siles, R., Hadimani, M.B., Mugabe, B.E., Ackley, J.F., Studerus, S.W., Edvardsen, 
K., Trawick, M.L., Garner, C.M., Rhodes, M.R., et al. (2006). Design, synthesis, and biological 
evaluation of combretastatin nitrogen-containing derivatives as inhibitors of tubulin assembly 
and vascular disrupting agents. Bioorg Med Chem 14, 3231-3244. 
270 
 
Moriyama, E.H., Niedre, M.J., Jarvi, M.T., Mocanu, J.D., Moriyama, Y., Subarsky, P., Li, B., 
Lilge, L.D., and Wilson, B.C. (2008). The influence of hypoxia on bioluminescence in luciferase-
transfected gliosarcoma tumor cells in vitro. Photochem Photobiol Sci 7, 675-680. 
Morse, D.L., Raghunand, N., Sadarangani, P., Murthi, S., Job, C., Day, S., Howison, C., and 
Gillies, R.J. (2007). Response of choline metabolites to docetaxel therapy is quantified in vivo 
by localized (31)P MRS of human breast cancer xenografts and in vitro by high-resolution (31)P 
NMR spectroscopy of cell extracts. Magn Reson Med 58, 270-280. 
Motani, K., Kawase, K., Imamura, R., Kinoshita, T., Kushiyama, H., and Suda, T. (2010). 
Activation of ASC induces apoptosis or necrosis, depending on the cell type, and causes tumor 
eradication. Cancer Sci 101, 1822-1827. 
Nakatsu, T., Ichiyama, S., Hiratake, J., Saldanha, A., Kobashi, N., Sakata, K., and Kato, H. 
(2006). Structural basis for the spectral difference in luciferase bioluminescence. Nature 440, 
372-376. 
Natsume, T., Watanabe, J., Koh, Y., Fujio, N., Ohe, Y., Horiuchi, T., Saijo, N., Nishio, K., and 
Kobayashi, M. (2003). Antitumor activity of TZT-1027 (Soblidotin) against vascular endothelial 
growth factor-secreting human lung cancer in vivo. Cancer Sci 94, 826-833. 
NC3Rs (2011). What are the 3Rs? (London, UK). http://www.nc3rs.org.uk/page.asp?id=7 
NCI (2011). Metastatic Cancer. In NCI Factsheet, N.C. Institute, ed. 
http://www.cancer.gov/cancertopics/factsheet/Sites-Types/metastatic 
Ngan, V.K., Bellman, K., Panda, D., Hill, B.T., Jordan, M.A., and Wilson, L. (2000). Novel 
actions of the antitumor drugs vinflunine and vinorelbine on microtubules. Cancer Res 60, 5045-
5051. 
Nogawa, M., Yuasa, T., Kimura, S., Kuroda, J., Sato, K., Segawa, H., Yokota, A., and 
Maekawa, T. (2005). Monitoring luciferase-labeled cancer cell growth and metastasis in 
different in vivo models. Cancer Lett 217, 243-253. 
O'Connor, P.M., Jackman, J., Bae, I., Myers, T.G., Fan, S., Mutoh, M., Scudiero, D.A., Monks, 
A., Sausville, E.A., Weinstein, J.N., et al. (1997). Characterization of the p53 tumor suppressor 
pathway in cell lines of the National Cancer Institute anticancer drug screen and correlations 
with the growth-inhibitory potency of 123 anticancer agents. Cancer Res 57, 4285-4300. 
Oba, Y., Shintani, T., Nakamura, T., Ojika, M., and Inouye, S. (2008). Determination of the 
luciferin contents in luminous and non-luminous beetles. Biosci Biotechnol Biochem 72, 1384-
1387. 
Ohta, S., Lai, E.W., Morris, J.C., Bakan, D.A., Klaunberg, B., Cleary, S., Powers, J.F., Tischler, 
A.S., Abu-Asab, M., Schimel, D., et al. (2006). MicroCT for high-resolution imaging of ectopic 
pheochromocytoma tumors in the liver of nude mice. Int J Cancer 119, 2236-2241. 
Ohtani, N., Imamura, Y., Yamakoshi, K., Hirota, F., Nakayama, R., Kubo, Y., Ishimaru, N., 
Takahashi, A., Hirao, A., Shimizu, T., et al. (2007). Visualizing the dynamics of p21(Waf1/Cip1) 
cyclin-dependent kinase inhibitor expression in living animals. Proc Natl Acad Sci USA 104, 
15034-15039. 
OpenBiosystems (2011). Puromycin Kill Curve and Puromycin Selection, T. Scientific, ed. 
(Thermo Scientific). 
http://www.openbiosystems.com/OpenAccessPortal/Content/pdf/Selecting%20cells%20with%2
0Puromycin.pdf  
271 
 
Ophardt, C.E. (2003). Anticancer Drugs. In Virtual Chembook, E. College, ed. (Chicago, IL). 
http://www.elmhurst.edu/~chm/vchembook/655cancer.html 
Otsuka, H., Morita, N., Yamashita, K., and Nishitani, H. (2007). FDG-PET/CT for cancer 
management. J Med Invest 54, 195-199. 
Otto-Duessel, M., Khankaldyyan, V., Gonzalez-Gomez, I., Jensen, M.C., Laug, W.E., and 
Rosol, M. (2006). In vivo testing of Renilla luciferase substrate analogs in an orthotopic murine 
model of human glioblastoma. Molecular imaging 5, 57-64. 
Ozawa, T., and James, C.D. (2010). Establishing intracranial brain tumor xenografts with 
subsequent analysis of tumor growth and response to therapy using bioluminescence imaging. 
J Vis Exp 41, pii 1986. 
Paroo, Z., Bollinger, R.A., Braasch, D.A., Richer, E., Corey, D.R., Antich, P.P., and Mason, R.P. 
(2004). Validating bioluminescence imaging as a high-throughput, quantitative modality for 
assessing tumor burden. Molecular imaging 3, 117-124. 
Pecorino, L. (2005). Molecular biology of cancer : mechanisms, targets and therapeutics 
(Oxford, Oxford University Press). 
Peng, Y., Chen, L., Li, C., Lu, W., Agrawal, S., and Chen, J. (2001). Stabilization of the MDM2 
oncoprotein by mutant p53. J Biol Chem 276, 6874-6878. 
Perez, E.A., Hillman, D.W., Fishkin, P.A., Krook, J.E., Tan, W.W., Kuriakose, P.A., Alberts, S.R., 
and Dakhil, S.R. (2005). Phase II trial of dolastatin-10 in patients with advanced breast cancer. 
Invest new drugs 23, 257-261. 
Pettit, G.R., and Lippert, J.W., 3rd (2000). Antineoplastic agents 429. Syntheses of the 
combretastatin A-1 and combretastatin B-1 prodrugs. Anticancer Drug Des 15, 203-216. 
Pettit, G.R., Singh, S.B., Hamel, E., Lin, C.M., Alberts, D.S., and Garcia-Kendall, D. (1989). 
Isolation and structure of the strong cell growth and tubulin inhibitor combretastatin A-4. 
Experientia 45, 209-211. 
Pettit, G.R., Temple, C., Jr., Narayanan, V.L., Varma, R., Simpson, M.J., Boyd, M.R., Rener, 
G.A., and Bansal, N. (1995). Antineoplastic agents 322. synthesis of combretastatin A-4 
prodrugs. Anticancer Drug Des 10, 299-309. 
Pichler, A., Prior, J.L., and Piwnica-Worms, D. (2004). Imaging reversal of multidrug resistance 
in living mice with bioluminescence: MDR1 P-glycoprotein transports coelenterazine. Proc Natl 
Acad Sci USA 101, 1702-1707. 
Pietsch, E.C., Sykes, S.M., McMahon, S.B., and Murphy, M.E. (2008). The p53 family and 
programmed cell death. Oncogene 27, 6507-6521. 
PMH (2011). Cancer Drug Development (Ontario, Canada). 
http://www.pmhf.ca/Pages/DonorImpact/Drug_Development_Story.aspx 
Polimeni, M., Voena, C., Kopecka, J., Riganti, C., Pescarmona, G., Bosia, A., and Ghigo, D. 
(2011). Modulation of doxorubicin resistance by the glucose 6-phosphate dehydrogenase 
activity. Biochem J 439, 141-149. 
Polyak, K., and Weinberg, R.A. (2009). Transitions between epithelial and mesenchymal states: 
acquisition of malignant and stem cell traits. Nat Rev Cancer 9, 265-273. 
Poulaki, V., Mitsiades, C.S., and Mitsiades, N. (2001). The role of Fas and FasL as mediators of 
anticancer chemotherapy. Drug Resist Updat 4, 233-242. 
272 
 
Promega (2011). Bioluminescent Reporters. In Protocols and applications guide, Promega, ed. 
http://www.promega.com/resources/product-guides-and-selectors/protocols-and-applications-
guide/bioluminescent-reporters/ 
Proschek, D., Mack, M.G., Kurth, A.A., Proschek, P., Martin, B., Hansmann, M.L., and Vogl, T.J. 
(2008). Radiofrequency ablation of experimental bone metastases in nude rats. Anticancer 
research 28, 879-885. 
Pysz, M.A., Foygel, K., Panje, C.M., Needles, A., Tian, L., and Willmann, J.K. (2011). 
Assessment and monitoring tumor vascularity with contrast-enhanced ultrasound maximum 
intensity persistence imaging. Invest Radiol 46, 187-195. 
Rajput, A., Dominguez San Martin, I., Rose, R., Beko, A., Levea, C., Sharratt, E., Mazurchuk, 
R., Hoffman, R.M., Brattain, M.G., and Wang, J. (2008). Characterization of HCT116 human 
colon cancer cells in an orthotopic model. J Surg Res 147, 276-281. 
Reddy, N.P., Miyamoto, S., Araki, K., Liu, T., Feldman, M., O'Malley, B.W., Jr., and Li, D. 
(2011). A novel orthotopic mouse model of head and neck cancer with molecular imaging. 
Laryngoscope 121, 1202-1207. 
Rewcastle, G.W., Atwell, G.J., Li, Z.A., Baguley, B.C., and Denny, W.A. (1991). Potential 
antitumor agents. 61. Structure-activity relationships for in vivo colon 38 activity among 
disubstituted 9-oxo-9H-xanthene-4-acetic acids. J Med Chem 34, 217-222. 
Rey, S., and Semenza, G.L. (2010). Hypoxia-inducible factor-1-dependent mechanisms of 
vascularization and vascular remodelling. Cardiovasc Res 86, 236-242. 
Rice, L., Pampo, C., Lepler, S., Rojiani, A.M., and Siemann, D.W. (2010). Support of a free 
radical mechanism for enhanced antitumor efficacy of the microtubule disruptor OXi4503. 
Microvasc Res 81, 44-51. 
Richon, V.M., Sandhoff, T.W., Rifkind, R.A., and Marks, P.A. (2000). Histone deacetylase 
inhibitor selectively induces p21WAF1 expression and gene-associated histone acetylation. 
Proc Natl Acad Sci USA 97, 10014-10019. 
Rini, B.I., and Small, E.J. (2005). Biology and clinical development of vascular endothelial 
growth factor-targeted therapy in renal cell carcinoma. J Clin Oncol 23, 1028-1043. 
Rivlin, N., Brosh, R., Oren, M., and Rotter, V. (2011). Mutations in the p53 Tumor Suppressor 
Gene: Important Milestones at the Various Steps of Tumorigenesis. Genes Cancer 2, 466-474. 
Robbins, D., and Zhao, Y. (2011). Imaging NF-kappaB signaling in mice for screening 
anticancer drugs. Methods Mol Biol 716, 169-177. 
Robinson, S.P., McIntyre, D.J., Checkley, D., Tessier, J.J., Howe, F.A., Griffiths, J.R., Ashton, 
S.E., Ryan, A.J., Blakey, D.C., and Waterton, J.C. (2003). Tumour dose response to the 
antivascular agent ZD6126 assessed by magnetic resonance imaging. BR J CANCER 88, 
1592-1597. 
Rousseau, J., Escriou, V., Perrot, P., Picarda, G., Charrier, C., Scherman, D., Heymann, D., 
Redini, F., and Trichet, V. (2010). Advantages of bioluminescence imaging to follow siRNA or 
chemotherapeutic treatments in osteosarcoma preclinical models. Cancer Gene Ther 17, 387-
397. 
Rudin, M. (2008). Noninvasive imaging of receptor function: signal transduction pathways and 
physiological readouts. Curr Opin Drug Discov Devel 11, 606-615. 
273 
 
Rudin, M. (2009). Noninvasive structural, functional, and molecular imaging in drug 
development. Curr Opin Chem Biol 13, 360-371. 
Russell, W.M.S., and Birch, R.L. (1959). The Principles of Humane Experimental Technique 
(John Hopkins Bloomberg School of Public Health ). 
Rustin, G.J., Shreeves, G., Nathan, P.D., Gaya, A., Ganesan, T.S., Wang, D., Boxall, J., 
Poupard, L., Chaplin, D.J., Stratford, M.R., et al. (2010). A Phase Ib trial of CA4P 
(combretastatin A-4 phosphate), carboplatin, and paclitaxel in patients with advanced cancer. 
BR J CANCER 102, 1355-1360. 
Rygaard, J., and Povlsen, C.O. (1969). Heterotransplantation of a human malignant tumour to 
"Nude" mice. Acta Pathol Microbiol Scand 77, 758-760. 
Saad, E.D., Kraut, E.H., Hoff, P.M., Moore, D.F., Jr., Jones, D., Pazdur, R., and Abbruzzese, 
J.L. (2002). Phase II study of dolastatin-10 as first-line treatment for advanced colorectal 
cancer. Am J Clin Oncol 25, 451-453. 
Sakoguchi-Okada, N., Takahashi-Yanaga, F., Fukada, K., Shiraishi, F., Taba, Y., Miwa, Y., 
Morimoto, S., Iida, M., and Sasaguri, T. (2007). Celecoxib inhibits the expression of survivin via 
the suppression of promoter activity in human colon cancer cells. Biochem Pharmacol 73, 1318-
1329. 
Sakuma, S., Yano, T., Masaoka, Y., Kataoka, M., Hiwatari, K., Tachikawa, H., Shoji, Y., Kimura, 
R., Ma, H., Yang, Z., et al. (2010). Detection of early colorectal cancer imaged with peanut 
agglutinin-immobilized fluorescent nanospheres having surface poly(N-vinylacetamide) chains. 
Eur J Pharm Biopharm 74, 451-460. 
Salmon, H.W., and Siemann, D.W. (2006). Effect of the second-generation vascular disrupting 
agent OXi4503 on tumor vascularity. Clin Cancer Res 12, 4090-4094. 
Samano, A.K., Ohshima-Hosoyama, S., Whitney, T.G., Prajapati, S.I., Kilcoyne, A., Taniguchi, 
E., Morgan, W.W., Nelon, L.D., Lin, A.L., Togao, O., et al. (2010). Functional evaluation of 
therapeutic response for a mouse model of medulloblastoma. Transgenic Res 19, 829-840. 
Sawada, R., Sun, S.M., Wu, X., Hong, F., Ragupathi, G., Livingston, P.O., and Scholz, W.W. 
(2011). Human monoclonal antibodies to sialyl-Lewisa (CA19.9) with potent CDC, ADCC, and 
antitumor activity. Clin Cancer Res 17, 1024-1032. 
Scabini, M., Stellari, F., Cappella, P., Rizzitano, S., Texido, G., and Pesenti, E. (2010). In vivo 
imaging of early stage apoptosis by measuring real-time caspase-3/7 activation. Apoptosis 16, 
198-207. 
Schmid, M.C., and Varner, J.A. (2010). Myeloid cells in the tumor microenvironment: modulation 
of tumor angiogenesis and tumor inflammation. J Oncol 2010, 201026. E-pub ahead of print 
http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&db=PubMed&dopt=Citation&list_ui
ds=20490273 
Schwartz, E.L. (2009). Antivascular actions of microtubule-binding drugs. Clin Cancer Res 15, 
2594-2601. 
Seiden-Long, I., Navab, R., Shih, W., Li, M., Chow, J., Zhu, C.Q., Radulovich, N., Saucier, C., 
and Tsao, M.S. (2008). Gab1 but not Grb2 mediates tumor progression in Met overexpressing 
colorectal cancer cells. Carcinogenesis 29, 647-655. 
Semple, T.U., Quinn, L.A., Woods, L.K., and Moore, G.E. (1978). Tumor and lymphoid cell lines 
from a patient with carcinoma of the colon for a cytotoxicity model. Cancer Res 38, 1345-1355. 
274 
 
Shah, K., Hingtgen, S., Kasmieh, R., Figueiredo, J.L., Garcia-Garcia, E., Martinez-Serrano, A., 
Breakefield, X., and Weissleder, R. (2008). Bimodal viral vectors and in vivo imaging reveal the 
fate of human neural stem cells in experimental glioma model. J Neurosci 28, 4406-4413. 
Shah, K., Tang, Y., Breakefield, X., and Weissleder, R. (2003). Real-time imaging of TRAIL-
induced apoptosis of glioma tumors in vivo. Oncogene 22, 6865-6872. 
Shah, R., and El-Deiry, W.S. (2004). p53-Dependent activation of a molecular beacon in tumor 
cells following exposure to doxorubicin chemotherapy. Cancer Biol Ther 3, 871-875. 
Shen, L.Z., Hua, Y.B., Yu, X.M., Xu, Q., Chen, T., Wang, J.H., and Wu, W.X. (2005). Tamoxifen 
can reverse multidrug resistance of colorectal carcinoma in vivo. World J Gastroenterol 11, 
1060-1064. 
Sheward, W.J., Naylor, E., Knowles-Barley, S., Armstrong, J.D., Brooker, G.A., Seckl, J.R., 
Turek, F.W., Holmes, M.C., Zee, P.C., and Harmar, A.J. (2010). Circadian control of mouse 
heart rate and blood pressure by the suprachiasmatic nuclei: behavioral effects are more 
significant than direct outputs. PLoS One 5, e9783. 
Shi, Y., Hollenstein, A., Felley-Bosco, E., Fraefel, C., Ackermann, M., Soltermann, A., Weder, 
W., Stahel, R., Pruschy, M., and Opitz, I. (2011). Bioluminescence imaging for in vivo monitoring 
of local recurrence mesothelioma model. Lung Cancer 71, 370-371. 
Shinde, R., Perkins, J., and Contag, C.H. (2006). Luciferin derivatives for enhanced in vitro and 
in vivo bioluminescence assays. Biochemistry 45, 11103-11112. 
Shnyder, S.D., Cooper, P.A., Millington, N.J., Pettit, G.R., and Bibby, M.C. (2007). Auristatin 
PYE, a novel synthetic derivative of dolastatin 10, is highly effective in human colon tumour 
models. Int J Oncol 31, 353-360. 
Shoemaker, R.H. (2006). The NCI60 human tumour cell line anticancer drug screen. Nat Rev 
Cancer 6, 813-823. 
Siddik, Z.H. (2003). Cisplatin: mode of cytotoxic action and molecular basis of resistance. 
Oncogene 22, 7265-7279. 
Siemann, D.W. (2011). The unique characteristics of tumor vasculature and preclinical evidence 
for its selective disruption by Tumor-Vascular Disrupting Agents. Cancer Treat Rev 37, 63-74. 
Siemann, D.W., Bibby, M.C., Dark, G.G., Dicker, A.P., Eskens, F.A., Horsman, M.R., Marme, 
D., and Lorusso, P.M. (2005). Differentiation and definition of vascular-targeted therapies. Clin 
Cancer Res 11, 416-420. 
Siemann, D.W., Mercer, E., Lepler, S., and Rojiani, A.M. (2002). Vascular targeting agents 
enhance chemotherapeutic agent activities in solid tumor therapy. Intl J Cancer 99, 1-6. 
Sim, H., Bibee, K., Wickline, S., and Sept, D. (2011). Pharmacokinetic modeling of tumor 
bioluminescence implicates efflux, and not influx, as the bigger hurdle in cancer drug therapy. 
Cancer Res 71, 686-692. 
Simon, M.P., Tournaire, R., and Pouyssegur, J. (2008). The angiopoietin-2 gene of endothelial 
cells is up-regulated in hypoxia by a HIF binding site located in its first intron and by the central 
factors GATA-2 and Ets-1. J Cell Physiol 217, 809-818. 
Smith, K.A., Hill, S.A., Begg, A.C., and Denekamp, J. (1988). Validation of the fluorescent dye 
Hoechst 33342 as a vascular space marker in tumours. Br J Cancer  57, 247-253. 
275 
 
Snoeks, T.J., Lowik, C.W., and Kaijzel, E.L. (2010). 'In vivo' optical approaches to angiogenesis 
imaging. Angiogenesis 13, 135-147. 
Sohn, T.A., Bansal, R., Su, G.H., Murphy, K.M., and Kern, S.E. (2002). High-throughput 
measurement of the Tp53 response to anticancer drugs and random compounds using a stably 
integrated Tp53-responsive luciferase reporter. Carcinogenesis 23, 949-957. 
Souhami, R., and Tobias, J. (2005). Cancer and its management, 5th Edition edn (Blackwell 
Publishing Ltd). 
Sowa, Y., Orita, T., Hiranabe-Minamikawa, S., Nakano, K., Mizuno, T., Nomura, H., and Sakai, 
T. (1999). Histone deacetylase inhibitor activates the p21/WAF1/Cip1 gene promoter through 
the Sp1 sites. Ann N Y Acad Sci 886, 195-199. 
SSOM, C. (2000). Transfection Of Mammalian Cells By Electroporation. In The Knight Lab; 
Protocols, L.U.C.S.S.o.M. (SSOM), ed. (Chicago). 
http://www.meddean.luc.edu/lumen/DeptWebs/microbio/knight/protoc/e_pore.php 
Steegmaier, M., Hoffmann, M., Baum, A., Lenart, P., Petronczki, M., Krssak, M., Gurtler, U., 
Garin-Chesa, P., Lieb, S., Quant, J., et al. (2007). BI 2536, a potent and selective inhibitor of 
polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol 17, 316-322. 
Stevenson, J.P., Rosen, M., Sun, W., Gallagher, M., Haller, D.G., Vaughn, D., Giantonio, B., 
Zimmer, R., Petros, W.P., Stratford, M., et al. (2003). Phase I trial of the antivascular agent 
combretastatin A4 phosphate on a 5-day schedule to patients with cancer: magnetic resonance 
imaging evidence for altered tumor blood flow. J Clin Oncol 21, 4428-4438. 
Strijkers, G.J., Kluza, E., Van Tilborg, G.A., van der Schaft, D.W., Griffioen, A.W., Mulder, W.J., 
and Nicolay, K. (2010). Paramagnetic and fluorescent liposomes for target-specific imaging and 
therapy of tumor angiogenesis. Angiogenesis 13, 161-173. 
Suggitt, M., and Bibby, M.C. (2005). 50 years of preclinical anticancer drug screening: empirical 
to target-driven approaches. Clin Cancer Res 11, 971-981. 
Svensson, R.U., Barnes, J.M., Rokhlin, O.W., Cohen, M.B., and Henry, M.D. (2007). 
Chemotherapeutic agents up-regulate the cytomegalovirus promoter: implications for 
bioluminescence imaging of tumor response to therapy. Cancer Res 67, 10445-10454. 
Takahashi, A., Ohkohchi, N., Yasunaga, M., Kuroda, J., Koga, Y., Kenmotsu, H., Kinoshita, T., 
and Matsumura, Y. (2010). Detailed distribution of NK012, an SN-38-incorporating micelle, in 
the liver and its potent antitumor effects in mice bearing liver metastases. Clin Cancer Res 16, 
4822-4831. 
Tan, M.H., Holyoke, E.D., and Goldrosen, M.H. (1977). Murine colon adenocarcinoma: 
syngeneic orthotopic transplantation and subsequent hepatic metastases. J Natl Cancer Inst 59, 
1537-1544. 
Tanaka, T., Konno, H., Baba, S., Kanai, T., Matsumoto, K., Matsuda, I., Ohba, K., Ohta, M., 
Kamiya, K., and Nakamura, S. (2001). Prevention of hepatic and peritoneal metastases by the 
angiogenesis inhibitor fr-118487 after removal of growing tumor in mice. Jpn J Cancer Res 92, 
88-94. 
Thorpe, P.E. (2004). Vascular targeting agents as cancer therapeutics. Clin Cancer Res 10, 
415-427. 
Tiffen, J.C., Bailey, C.G., Ng, C., Rasko, J.E., and Holst, J. (2010). Luciferase expression and 
bioluminescence does not affect tumor cell growth in vitro or in vivo. Mol Cancer 9, 299-307. 
276 
 
Tinkum, K.L., Marpegan, L., White, L.S., Sun, J., Herzog, E.D., Piwnica-Worms, D., and 
Piwnica-Worms, H. (2011). Bioluminescence Imaging Captures the Expression and Dynamics 
of Endogenous p21 Promoter Activity in Living Mice and Intact Cells. Mol Cell Biol 31, 3759-
3772. 
Tom, B.H., Rutzky, L.P., Jakstys, M.M., Oyasu, R., Kaye, C.I., and Kahan, B.D. (1976). Human 
colonic adenocarcinoma cells. I. Establishment and description of a new line. In Vitro 12, 180-
191. 
Torigian, D.A., Huang, S.S., Houseni, M., and Alavi, A. (2007). Functional imaging of cancer 
with emphasis on molecular techniques. CA Cancer J Clin 57, 206-224. 
Tozer, G.M., Kanthou, C., and Baguley, B.C. (2005). Disrupting tumour blood vessels. Nat Rev 
Cancer 5, 423-435. 
Tozer, G.M., Kanthou, C., Lewis, G., Prise, V.E., Vojnovic, B., and Hill, S.A. (2008). Tumour 
vascular disrupting agents: combating treatment resistance. Br J Radiol 81 Spec No 1, S12-20. 
Tozer, G.M., Prise, V.E., Wilson, J., Locke, R.J., Vojnovic, B., Stratford, M.R., Dennis, M.F., and 
Chaplin, D.J. (1999). Combretastatin A-4 phosphate as a tumor vascular-targeting agent: early 
effects in tumors and normal tissues. Cancer Res 59, 1626-1634. 
Tredan, O., Galmarini, C.M., Patel, K., and Tannock, I.F. (2007). Drug resistance and the solid 
tumor microenvironment. J Natl Cancer Inst 99, 1441-1454. 
Tsuiji, H., Hayashi, M., Wynn, D.M., and Irimura, T. (1998). Expression of mucin-associated 
sulfo-Lea carbohydrate epitopes on human colon carcinoma cells. Jpn J Cancer Res 89, 1267-
1275. 
Tsutsumi, S., Fukasawa, T., Yamauchi, H., Kato, T., Kigure, W., Morita, H., Asao, T., and 
Kuwano, H. (2009). Phosphoglucose isomerase enhances colorectal cancer metastasis. Int J 
Oncol 35, 1117-1121. 
Tung, C.H. (2004). Fluorescent peptide probes for in vivo diagnostic imaging. Biopolymers 76, 
391-403. 
Uhrbom, L., Nerio, E., and Holland, E.C. (2004). Dissecting tumor maintenance requirements 
using bioluminescence imaging of cell proliferation in a mouse glioma model. Nat Med 10, 
1257-1260. 
van der Veldt, A.A., Haanen, J.B., van den Eertwegh, A.J., and Boven, E. (2010). Targeted 
therapy for renal cell cancer: current perspectives. Discov Med 10, 394-405. 
Vangestel, C., Peeters, M., Oltenfreiter, R., D'Asseler, Y., Staelens, S., Van Steenkiste, M., 
Philippe, J., Kusters, D., Reutelingsperger, C., Van Damme, N., et al. (2010). In vitro and in vivo 
evaluation of [99mTc]-labeled tricarbonyl His-annexin A5 as an imaging agent for the detection 
of phosphatidylserine-expressing cells. Nucl Med Biol 37, 965-975. 
Vantyghem, S.A., Wilson, S.M., Postenka, C.O., Al-Katib, W., Tuck, A.B., and Chambers, A.F. 
(2005). Dietary genistein reduces metastasis in a postsurgical orthotopic breast cancer model. 
Cancer Res 65, 3396-3403. 
Vassilev, L.T., Vu, B.T., Graves, B., Carvajal, D., Podlaski, F., Filipovic, Z., Kong, N., Kammlott, 
U., Lukacs, C., Klein, C., et al. (2004). In vivo activation of the p53 pathway by small-molecule 
antagonists of MDM2. Science 303, 844-848. 
Vigneswaran, N., Wu, J., Song, A., Annapragada, A., and Zacharias, W. (2011). Hypoxia-
induced autophagic response is associated with aggressive phenotype and elevated incidence 
277 
 
of metastasis in orthotopic immunocompetent murine models of head and neck squamous cell 
carcinomas (HNSCC). Exp Mol Pathol 90, 215-225. 
Vikhanskaya, F., D'Incalci, M., and Broggini, M. (1995). Decreased cytotoxic effects of 
doxorubicin in a human ovarian cancer-cell line expressing wild-type p53 and WAF1/CIP1 
genes. Int J Cancer 61, 397-401. 
Villalobos, V., Naik, S., and Piwnica-Worms, D. (2007). Current state of imaging protein-protein 
interactions in vivo with genetically encoded reporters. Annu Rev Biomed Eng 9, 321-349. 
Viola, R.J., Provenzale, J.M., Li, F., Li, C.Y., Yuan, H., Tashjian, J., and Dewhirst, M.W. (2008). 
In vivo bioluminescence imaging monitoring of hypoxia-inducible factor 1alpha, a promoter that 
protects cells, in response to chemotherapy. AJR Am J Roentgenol 191, 1779-1784. 
Visvader, J.E., and Lindeman, G.J. (2008). Cancer stem cells in solid tumours: accumulating 
evidence and unresolved questions. Nat Rev Cancer 8, 755-768. 
Vogel, C.L., Cobleigh, M.A., Tripathy, D., Gutheil, J.C., Harris, L.N., Fehrenbacher, L., Slamon, 
D.J., Murphy, M., Novotny, W.F., Burchmore, M., et al. (2002). Efficacy and safety of 
trastuzumab as a single agent in first-line treatment of HER2-overexpressing metastatic breast 
cancer. J Clin Oncol 20, 719-726. 
Wang, H., Cao, F., De, A., Cao, Y., Contag, C., Gambhir, S.S., Wu, J.C., and Chen, X. (2009a). 
Trafficking mesenchymal stem cell engraftment and differentiation in tumor-bearing mice by 
bioluminescence imaging. Stem cells (Dayton, Ohio) 27, 1548-1558. 
Wang, H., Marchal, G., and Ni, Y. (2011). Multiparametric MRI biomarkers for measuring 
vascular disrupting effect on cancer. World J Radiol 3, 1-16. 
Wang, H., Nan, L., Yu, D., Lindsey, J.R., Agrawal, S., and Zhang, R. (2002). Anti-tumor efficacy 
of a novel antisense anti-MDM2 mixed-backbone oligonucleotide in human colon cancer 
models: p53-dependent and p53-independent mechanisms. Mol Med 8, 185-199. 
Wang, H., and Yan, C. (2011). A Small-Molecule p53 Activator Induces Apoptosis through 
Inhibiting MDMX Expression in Breast Cancer Cells. Neoplasia (New York, NY 13, 611-619. 
Wang, J., Rajput, A., Kan, J.L., Rose, R., Liu, X.Q., Kuropatwinski, K., Hauser, J., Beko, A., 
Dominquez, I., Sharratt, E.A., et al. (2009b). Knockdown of Ron kinase inhibits mutant 
phosphatidylinositol 3-kinase and reduces metastasis in human colon carcinoma. J Biol Chem 
284, 10912-10922. 
Wang, S., Ren, W., Liu, J., Lahat, G., Torres, K., Lopez, G., Lazar, A.J., Hayes-Jordan, A., Liu, 
K., Bankson, J., et al. (2010). TRAIL and doxorubicin combination induces proapoptotic and 
antiangiogenic effects in soft tissue sarcoma in vivo. Clin Cancer Res 16, 2591-2604. 
Wang, S.Q., and Hashemi, P. (2010). Noninvasive imaging technologies in the diagnosis of 
melanoma. Semin Cutan Med Surg 29, 174-184. 
Wang, W., and El-Deiry, W.S. (2003). Bioluminescent molecular imaging of endogenous and 
exogenous p53-mediated transcription in vitro and in vivo using an HCT116 human colon 
carcinoma xenograft model. Cancer Biol Ther 2, 196-202. 
Wang, W., Kim, S.H., and El-Deiry, W.S. (2006). Small-molecule modulators of p53 family 
signaling and antitumor effects in p53-deficient human colon tumor xenografts. Proc Natl Acad 
Sci USA 103, 11003-11008. 
Wang, W., Rastinejad, F., and El-Deiry, W.S. (2003). Restoring p53-dependent tumor 
suppression. Cancer Biol Ther 2, S55-63. 
278 
 
Wankhede, M., Dedeugd, C., Siemann, D.W., and Sorg, B.S. (2010). In vivo functional 
differences in microvascular response of 4T1 and Caki-1 tumors after treatment with OXi4503. 
Oncol Rep 23, 685-692. 
Warburg, and Christian (1942). Isolierung und Kristallisation des Gärungsferments Enolase. 
Biochem Z, 384-421. 
Watanabe, J., Natsume, T., Fujio, N., Miyasaka, K., and Kobayashi, M. (2000). Induction of 
apoptosis in human cancer cells by TZT-1027, an antimicrotubule agent. Apoptosis 5, 345-353. 
Watkins, G.A., Jones, E.F., Scott Shell, M., VanBrocklin, H.F., Pan, M.H., Hanrahan, S.M., 
Feng, J.J., He, J., Sounni, N.E., Dill, K.A., et al. (2009). Development of an optimized 
activatable MMP-14 targeted SPECT imaging probe. Bioorg Med Chem 17, 653-659. 
Weisheng, Z., Min, C., West, D.B., and Purchio, A.F. (2005). Visualizing drug efficacy in vivo. 
Mol imaging 4, 88-90. 
Weiss, M.S., Penalver Bernabe, B., Bellis, A.D., Broadbelt, L.J., Jeruss, J.S., and Shea, L.D. 
(2010). Dynamic, large-scale profiling of transcription factor activity from live cells in 3D culture. 
PLoS One 5, e14026. 
Weissleder, R., and Pittet, M.J. (2008). Imaging in the era of molecular oncology. Nature 452, 
580-589. 
Wender, P.A., Goun, E.A., Jones, L.R., Pillow, T.H., Rothbard, J.B., Shinde, R., and Contag, 
C.H. (2007). Real-time analysis of uptake and bioactivatable cleavage of luciferin-transporter 
conjugates in transgenic reporter mice. Proc Natl Acad Sci U S A 104, 10340-10345. 
Wessels, J.T., Busse, A.C., Mahrt, J., Dullin, C., Grabbe, E., and Mueller, G.A. (2007). In vivo 
imaging in experimental preclinical tumor research--a review. Cytometry A 71, 542-549. 
Wilson, W.R., and Hay, M.P. (2011). Targeting hypoxia in cancer therapy. Nat Rev Cancer 11, 
393-410. 
Winnard, P.T., Jr., Kluth, J.B., Kato, Y., Artemov, D., and Raman, V. (2007). Development of 
novel chimeric transmembrane proteins for multimodality imaging of cancer cells. Cancer Biol 
Ther 6, 1889-1899. 
Woo, J., and von Arnim, A.G. (2008). Mutational optimization of the coelenterazine-dependent 
luciferase from Renilla. Plant Methods 4, 23. 
Workman, P., Aboagye, E.O., Balkwill, F., Balmain, A., Bruder, G., Chaplin, D.J., Double, J.A., 
Everitt, J., Farningham, D.A., Glennie, M.J., et al. (2010). Guidelines for the welfare and use of 
animals in cancer research. Br J Cancer 102, 1555-1577. 
Wu, J.T., Archer, S.Y., Hinnebusch, B., Meng, S., and Hodin, R.A. (2001). Transient vs. 
prolonged histone hyperacetylation: effects on colon cancer cell growth, differentiation, and 
apoptosis. Am J Physiol 280, G482-490. 
Yamaguchi, T., Kakefuda, R., Tajima, N., Sowa, Y., and Sakai, T. (2011). Antitumor activities of 
JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and 
in vivo. Int J Oncol 39, 23-31. 
Yang, M., Jiang, P., and Hoffman, R.M. (2007). Whole-body subcellular multicolor imaging of 
tumor-host interaction and drug response in real time. Cancer Res 67, 5195-5200. 
Yoon, A.R., Gao, R., Kaul, Z., Choi, I.K., Ryu, J., Noble, J.R., Kato, Y., Saito, S., Hirano, T., 
Ishii, T., et al. (2011). MicroRNA-296 is enriched in cancer cells and downregulates p21WAF1 
279 
 
mRNA expression via interaction with its 3' untranslated region. Nucleic acids research 39, 
8078-8091. 
Yurek, D.M., Fletcher, A.M., McShane, M., Kowalczyk, T.H., Padegimas, L., Weatherspoon, 
M.R., Kaytor, M.D., Cooper, M.J., and Ziady, A.G. (2011). DNA Nanoparticles: Detection Of 
Long-term Transgene Activity In Brain Using Bioluminescence Imaging. Mol Imaging 10, 327-
339. 
Zabala, M., Alzuguren, P., Benavides, C., Crettaz, J., Gonzalez-Aseguinolaza, G., Ortiz de 
Solorzano, C., Gonzalez-Aparicio, M., Kramer, M.G., Prieto, J., and Hernandez-Alcoceba, R. 
(2009). Evaluation of bioluminescent imaging for noninvasive monitoring of colorectal cancer 
progression in the liver and its response to immunogene therapy. Mol Cancer 8, 2. 
Zaidi, H., and Prasad, R. (2009). Advances in multimodality molecular imaging. J Med Phys 34, 
122-128. 
Zamble, D.B., and Lippard, S.J. (1995). Cisplatin and DNA repair in cancer chemotherapy. 
Trends Biochem Sci 20, 435-439. 
Zeng, Q., Yang, Z., Gao, Y.J., Yuan, H., Cui, K., Shi, Y., Wang, H., Huang, X., Wong, S.T., 
Wang, Y., et al. (2010). Treating triple-negative breast cancer by a combination of rapamycin 
and cyclophosphamide: an in vivo bioluminescence imaging study. Eur J Cancer 46, 1132-
1143. 
Zetter, B.R. (1998). Angiogenesis and tumor metastasis. Annu Rev Med 49, 407-424. 
Zhang, C., Yan, Z., Arango, M.E., Painter, C.L., and Anderes, K. (2009). Advancing 
bioluminescence imaging technology for the evaluation of anticancer agents in the MDA-MB-
435-HAL-Luc mammary fat pad and subrenal capsule tumor models. Clin Cancer Res 15, 238-
246. 
Zhang, C.C., Yan, Z., Zhang, Q., Kuszpit, K., Zasadny, K., Qiu, M., Painter, C.L., Wong, A., 
Kraynov, E., Arango, M.E., et al. (2010). PF-03732010: a fully human monoclonal antibody 
against P-cadherin with antitumor and antimetastatic activity. Clin Cancer Res 16, 5177-5188. 
Zhang, G.J., Chen, T.B., Bednar, B., Connolly, B.M., Hargreaves, R., Sur, C., and Williams, D.L. 
(2007a). Optical imaging of tumor cells in hollow fibers: evaluation of the antitumor activities of 
anticancer drugs and target validation. Neoplasia 9, 652-661. 
Zhang, Y., Bressler, J.P., Neal, J., Lal, B., Bhang, H.E., Laterra, J., and Pomper, M.G. (2007b). 
ABCG2/BCRP expression modulates D-Luciferin based bioluminescence imaging. Cancer Res 
67, 9389-9397. 
Zhao, D., Richer, E., Antich, P.P., and Mason, R.P. (2008). Antivascular effects of 
combretastatin A4 phosphate in breast cancer xenograft assessed using dynamic 
bioluminescence imaging and confirmed by MRI. FASEB J 22, 2445-2451. 
Zhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J., Yu, Y., Zhou, W., Zheng, Q., et 
al. (2006). Acetylation of p53 at lysine 373/382 by the histone deacetylase inhibitor depsipeptide 
induces expression of p21(Waf1/Cip1). Mol Cell Biol 26, 2782-2790. 
Zinn, K.R., Chaudhuri, T.R., Szafran, A.A., O'Quinn, D., Weaver, C., Dugger, K., Lamar, D., 
Kesterson, R.A., Wang, X., and Frank, S.J. (2008). Noninvasive bioluminescence imaging in 
small animals. ILAR J 49, 103-115. 
 
 
 
